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Abstract
Chapter 1.  Introduction:  Electron Transfer in Biological Systems
In many biological processes, including oxidative phosphorylation and
photosynthesis, electron transfer reactions play vital roles.  Electrons must be
transported at catalytically relevant rates and with specificity to prevent indiscriminate
electron transfer that would quickly bring cells to equilibrium.  To meet these
requirements, biological systems employ a panoply of organic and inorganic redox
centers, most of which are sequestered within proteins.  In addition to protecting a
cofactor from undesirable reactions, the surrounding protein environment tunes its
redox properties and mediates specific contacts with other molecules.  This brief
overview describes the types of redox centers used in biology, the application of
electron transfer theory to physiological systems, the kinetic complexity introduced by
interprotein interactions, and general mechanisms for regulating biological electron
transfer.
Chapter 2.  Expression and Site-Directed Mutagenesis of the Reductase Component
of Soluble Methane Monooxygenase from Methylococcus capsulatus (Bath)
The soluble methane monooxygenase (sMMO) system comprises three
components, a hydroxylase (MMOH), a reductase (MMOR), and a regulatory protein
(MMOB), all of which are required for conversion of methane to methanol by this
system in methanotrophic bacteria.  The reductase protein employs flavin adenine
dinucleotide (FAD) and [2Fe-2S] cofactors to facilitate electron transfer from NADH to
MMOH.  MMOR from Methylococcus capsulatus (Bath) was overexpressed in Escherichia
coli, affording high yields of pure reductase after a two-step purification procedure.
Recombinant MMOR was indistinguishable from native MMOR isolated from M.
capsulatus (Bath) in every respect examined, including mass, amino acid composition,
cofactor content, activity, and spectroscopic (optical and EPR) properties.  Seven site-
directed MMOR mutants, D26A, R43A, E72A, E73A, E74A, E75A, and E76A, were
prepared in order to investigate MMOH–MMOR binding interactions.  Iron depletion
in the mutant reductases was largely overcome by slightly modifying the purification
protocol, but MMOR(R43A) could not be obtained with full [2Fe-2S] complementation.
4Steady-state sMMO activity assays indicated reduced MMOH–MMOR binding affinity
and/or frequency for the E73A, E75A, and D26A mutants.  In single-turnover reactions
with NADH, the electron transfer steps in all six reductase mutants proceeded at rates
similar to those observed for wild-type MMOR (MMOR-wt).  MMOR(E73A), which
displayed the same distribution of electrons after reduction with NADH as MMOR-wt,
was selected for further study.  A K d of ~50 µM was determined for the
MMOH–MMOR(E73A) interaction at pH 7.0 and 25 °C by isothermal titration
calorimetry.  Roles for the mutated reductase residues in complex formation with
MMOH are discussed, and an evaluation of the MMOH–MMOR docking model used
for mutant selection is presented.
Chapter 3.  Expression and Characterization of Ferredoxin and Flavin Adenine
Dinucleotide-Binding Domains of the Reductase Component of Soluble Methane
Monooxygenase from Methylococcus capsulatus (Bath)
Soluble methane monooxygenase (sMMO) from Methylococcus capsulatus (Bath)
catalyzes the selective oxidation of methane to methanol, the first step in the primary
catabolic pathway of methanotrophic bacteria.  A reductase (MMOR) mediates electron
transfer from NADH through its FAD and [2Fe-2S] cofactors to the dinuclear non-heme
iron sites housed in a hydroxylase (MMOH).  The structurally distinct [2Fe-2S], FAD,
and NADH binding domains of MMOR facilitated division of the protein into its
functional ferredoxin (MMOR-Fd) and FAD/NADH (MMOR-FAD) component
domains.  The 10.9-kDa MMOR-Fd (MMOR residues 1-98) and 27.6-kDa MMOR-FAD
(MMOR residues 99-348) were expressed and purified from recombinant Escherichia coli
systems.  The Fd and FAD domains have optical features identical to those of the
[2Fe-2S] and flavin components, respectively, of MMOR.  Redox potentials, determined
by reductive titrations including indicator dyes, for the [2Fe-2S] and FAD cofactors in
the domains are [2Fe-2S]ox/red, –205 ± 1 mV; FADox/sq, –172 ± 2 mV; and FADsq/hq, –266 ±
4 mV.  Kinetic and spectral properties of intermediates observed in the reaction of
oxidized MMOR-FAD (FADox) with NADH at 4 °C were established with stopped-flow
UV-visible spectroscopy.  Analysis of the influence of pH on MMOR-FAD optical
spectra, redox potentials, and NADH reaction kinetics afforded pKa values for the
semiquinone (FADsq) and hydroquinone (FADhq) MMOR-FAD species and two
protonatable groups near the flavin cofactor.  Electron transfer from MMOR-FADhq to
oxidized MMOR-Fd is extremely slow (k = 1500 M-1 s-1 at 25 °C, compared to 90 s-1 at 4
°C for internal electron transfer between cofactors in MMOR), indicating that cofactor
proximity is essential for efficient interdomain electron transfer.
Chapter 4.  Intermolecular Electron Transfer Reactions in Soluble Methane
Monooxygenase from Methylococcus capsulatus (Bath):  A Role for Hysteresis in
Protein Function
Electron transfer from NADH to the hydroxylase component (MMOH) of
soluble methane monooxygenase (sMMO) primes its non-heme diiron centers for
reaction with dioxygen to generate high-valent iron intermediates that convert
5methane to methanol.  This intermolecular electron transfer step is facilitated by a
reductase (MMOR), which contains [2Fe-2S] and flavin adenine dinucleotide (FAD)
prosthetic groups.  In order to investigate interprotein electron transfer, chemically
reduced MMOR was mixed rapidly with oxidized MMOH in a stopped-flow
apparatus, and optical changes associated with reductase oxidation were recorded.
The reaction proceeds via four discrete kinetic phases corresponding to the transfer of
four electrons into the two dinuclear iron sites of MMOH.  Pre-equilibrating the
hydroxylase with sMMO auxiliary proteins MMOB or MMOD severely diminishes
electron transfer throughput from MMOR, primarily by shifting the bulk of electron
transfer to the slowest pathway.  The biphasic reactions for electron transfer to MMOH
from several MMOR ferredoxin analogs are also inhibited by MMOB.  These results
contrast sharply with the previous finding that MMOB enhances interprotein electron
transfer when pre-formed MMOR–MMOH–MMOB complexes are reacted with
NADH.  To account for the extremely slow electron transfer rates observed for the
ternary pre-complex in this work, a model in which conformational changes imparted
to the hydroxylase by MMOR are retained throughout the catalytic cycle is proposed.
Several electron transfer schemes are discussed with emphasis on those that invoke
multiple interconverting MMOH populations.  Applying electron transfer theory
expressions to the temperature dependence of electron transfer rate constants provides
an estimate of 11 Å for the distance between the reductase [2Fe-2S] and hydroxylase
diiron centers in the MMOH–MMOR complex.
Chapter 5.  Domain Engineering of the Reductase Component of Soluble Methane
Monooxygenase from Methylococcus capsulatus (Bath)
Upon separation of the soluble methane monooxygenase reductase (MMOR)
ferredoxin (MMOR-Fd, MMOR residues 1-98) and FAD/NADH (MMOR-FAD, MMOR
residues 99-348) domains, nearly all biochemical properties of full-length MMOR are
retained, except for interdomain electron transfer rates.  In order to investigate the
extent to which rapid electron transfer between domains might be restored and further
to explore the modularity of MMOR, the MMOR-Fd and MMOR-FAD proteins were
connected in a non-native fashion.  Four different linker sequences were employed to
create reversed-domains MMOR (MMOR-RD) constructs, MMOR(99-
342)–linker–MMOR(2-98), with a domain connectivity observed in other homologous
oxidoreductases.  The optical, redox, and electron transfer properties of the four
MMOR-RD proteins were characterized and compared to those of wild-type MMOR.
The linker sequence plays a key role in controlling solvent accessibility to the FAD
cofactor, as evidenced by perturbed flavin optical spectra, decreased FADox/FADsq
redox potentials, and increased steady-state oxidase activities in three of the constructs.
Stopped-flow optical spectroscopy revealed slow interdomain electron transfer (k <
0.04 s-1 at 4 °C, compared to 90 s-1 for wild-type MMOR) for all three MMOR-RD
proteins with 7-residue linkers.  A long (14-residue), flexible linker afforded much
faster electron transfer between the FAD and [2Fe-2S] cofactors (k = 0.9 s-1 at 4 °C).
6Chapter 6.  Expression in Escherichia coli of the Hydroxylase Component of Soluble
Methane Monooxygenase from Methylococcus capsulatus (Bath)
Soluble methane monooxygenase from Methylococcus capsulatus (Bath) is a three-
component enzyme system that catalyzes the selective conversion of methane to
methanol.  Reductive activation of dioxygen and substrate oxidation occur at non-heme
diiron sites in MMOH, a 251-kDa a2b2g2 hydroxylase.  Site-directed mutagenesis affords
the opportunity to probe specifically the contributions of individual amino acid
residues to catalysis or binding, but to employ this method, the protein of interest must
be expressed from controllable genes.  Several strategies, including stringent regulation
of expression, placing all six sMMO genes on the expression vector, and constructing
artificial mmo operons, were undertaken to facilitate production of active recombinant
M. capsulatus (Bath) MMOH in Escherichia coli.  For the first time, all three hydroxylase
subunits were expressed in the soluble fraction of E. coli hosts, but the subunits did not
assemble to produce the native a2b2g2 configuration.  A second series of expression
plasmids yielded a very small quantity of properly folded recombinant MMOH
(rMMOH), which was detected by native PAGE Western blot analysis of soluble cell
extracts.  Attempts to purify this material were hampered by contamination from
native MMOH at some stage in the purification procedure.  Despite varying many
expression conditions, the amounts of soluble, folded rMMOH produced by the E. coli
systems were not increased substantially.  In an effort to find factors required for
MMOH folding and assembly, genes flanking the mmo operon of M. capsulatus (Bath)
were identified by examining open reading frames for homology with other known
proteins.  Of particular note is a GroEL homolog located immediately downstream of
the mmo  operon.  Suggestions for developing high-yield heterologous MMOH
expression systems are presented.
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Chapter 1
Introduction:  Electron Transfer in Biological Systems
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Introduction
Electron transfer (ET) reactions are fundamental steps in many biological
processes, including respiration, photosynthesis, nitrogen fixation, neurotransmitter
metabolism, and the immune response.1,2  Aerobic respiration and photosynthesis
produce most of the energy required to support life and largely maintain the global
carbon, hydrogen, and oxygen cycles.  This chapter describes the various redox centers
employed for ET in biology, the application of ET theory to physiological electron
transfer reactions, and several regulatory mechanisms for achieving rapid and specific
biological electron transfer.
Redox Centers in Biology
Oxidation-reduction (redox) centers employed by biological systems fall into
three broad categories:  protein side chains, small molecules, and inorganic cofactors.
Although the redox-active properties of amino acids in proteins have sometimes been
overlooked, this class comprises many unique prosthetic groups that effect a wide
range of chemical transformations.  Cysteine sulfhydryl functionalities are readily
oxidized to form a dimer, cystine (eq 1), where R-SH represents the cysteine side chain.
2 R-SH  ›  R-S–S-R + 2 H+ + 2 e– (1)
Interconversion between the cysteine and cystine oxidation states occurs in several
redox enzymes, including xanthine oxidase, thioredoxin, and mercuric ion reductase.2
Electron paramagnetic resonance (EPR) spectroscopy of proteins with specific isotopic
labels has identified amino acid radicals localized on tyrosine (class I ribonucleotide
reductase (RNR) and photosystem II),3,4 tryptophan (cytochrome c peroxidase),5
cysteine (class II RNR),6 and glycine (class III RNR and pyruvate formate lyase)7,8
residues.  Formation of these transient radical species, which subsequently interact
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directly with substrates, usually requires metal cofactors.9  Modified tyrosine and
tryptophan amino acids, including topaquinone (TPQ), lysine tyrosylquinone (LTQ),
tryptophan tryptophylquinone (TTQ), and cysteine tryptophylquinone (CTQ) (Figure
1.1), represent a still-expanding class of biological redox centers.10,11  After oxidation of
primary amine substrates, electrons are transferred from the reduced quinone cofactor
to dioxygen or other exogenous acceptors to complete the catalytic cycle.
Three types of small organic molecules, pyridine nucleotides, flavins, and
quinones, function as carriers of reducing equivalents in cells.  Nicotinamide adenine
dinucleotide (NAD+, Figure 1.2A) and flavin adenine dinucleotide (FAD, Figure 1.2B)
transmit electrons derived from the oxidation of fuel molecules to the terminal electron
acceptor in energy-generating processes.  In reductive biosynthesis, the reduced form
of nicotinamide adenine dinucleotide phosphate (NADPH) is the major electron donor.
The most common quinone, coenzyme Q or ubiquinone (Figure 1.2C), has a long
isoprenoid tail that allows it to diffuse through membranes; this quinone cofactor exists
in both free and protein-bound forms.2  Flavins and pyrroloquinoline quinone (PQQ,
Figure 1.1), which is functionally similar to TPQ, LTQ, TTQ, and CTQ,10 are usually
attached noncovalently to proteins.  Whereas the pyridine nucleotides are two-electron
carriers, flavins and quinones can be reduced by either one or two electrons.  Therefore,
these cofactors can facilitate ET between two-electron redox reagents and one-electron
carriers (e.g. many metal centers).
The biological functions of metalloproteins include electron transfer, the binding
and activation of substrates, and atom- and group-transfer chemistry.12  Electron-
carrying metalloproteins typically employ iron or copper, metals that can be tuned by
the surrounding protein environment to access a wide range of biologically relevant
redox potentials.  For inorganic redox centers, one-electron transfer is generally
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favored.  Upon electron transfer, metal-ligand bonds are retained in order to minimize
structural reorganization.  Some complex metalloenzymes such as cytochrome c
oxidase and nitrogenase contain redox cofactors that shuttle electrons between other
metal sites in the same protein.
Classes of Electron Transferases
Electron transfer proteins, or electron transferases, possess several common
characteristics.13  They must, of course, contain a suitable cofactor for accepting
electrons.  For intermolecular electron transfer at biologically useful rates, the cofactor
must be positioned relatively close to the protein surface.  A hydrophobic cavity
adjacent to, but not necessarily completely surrounding, the cofactor is a typical
feature.  Electron transfer is accompanied by only small structural changes at the redox
center.  Finally, a flexible architecture that permits slight expansion or contraction upon
electron transfer is employed.  A key feature of electron transferases is their ability to
modulate cofactor redox potentials by hydrogen bonding, electrostatic, and other
interactions between the polypeptide and the redox center.
There are four classes of electron transferases, which are defined by their redox
cofactors:  flavoproteins, iron-sulfur proteins, blue copper proteins, and cytochromes.2
As their name implies, flavoproteins contain an FAD or flavin mononucleotide (FMN)
cofactor (Figure 1.2B), which is bound, in most cases noncovalently, to the protein.
Examples include the flavodoxins of bacteria and algae14 and ferredoxin:NADP+
reductase, which produces NADPH during photosynthesis.15  For free flavins, the
formal reduction potential of the second redox couple is higher than the first, such that
only the oxidized and two-electron reduced (hydroquinone) species are
thermodynamically accessible.  In flavoproteins, however, both flavin potentials are
26
substantially altered by the protein environment, thereby stabilizing the one-electron
reduced (semiquinone) oxidation state.  Thus, flavoproteins can interact with both one-
and two-electron carriers.
Virtually all living organisms utilize iron-sulfur proteins as electron carriers in
processes such as oxidative phosphorylation, photosynthesis, and nitrogen fixation.2,12
Iron-sulfur clusters comprising varying numbers of iron and sulfide ions are ligated to
these proteins via cysteine side chains (Figure 1.3A).  The simplest iron-sulfur protein,
rubredoxin, has a single iron atom tetrahedrally coordinated by four cysteines.  This
cofactor cycles between the Fe3+ and Fe2+ oxidation states with a redox potential
between –50 and +50 mV.  The [2Fe-2S] ferredoxins have [Fe2S2(S-Cys)4]2– clusters in
which the tetrahedrally coordinated iron atoms are bridged by two sulfide ligands.
The biologically relevant redox couple interconverts the [Fe2S2]2+ (two Fe3+ ions) and
[Fe2S2]+ (formally one Fe2+ ion and one Fe3+ ion) forms and exhibits a reduction potential
between –280 and –490 mV.  In [3Fe-4S] ferredoxins, the three iron and four sulfide
ions are arranged at seven corners of a distorted cube with a cysteine ligated to each
iron atom.  One-electron reduction of the [Fe3S4]+ cluster occurs with a midpoint
potential of ca. –120 mV.  The fourth type of iron-sulfur proteins, which contain
[4Fe-4S] clusters, is the most common in biological systems.  The core cluster contains
four iron ions and four sulfides at alternate corners of a distorted cube.  Four cysteine
thiolates coordinate the iron atoms, anchoring the cube to the protein.  Each [4Fe-4S]
cofactor uses a single redox couple, but two classes of ferredoxins access different
oxidation states.  Thus, redox potentials for proteins that use the [Fe4S4]2+/[Fe4S4]+
couple range from –650 to –280 mV, whereas ferredoxins operating between the
[Fe4S4]3+ and [Fe4S4]2+ states have potentials near +350 mV.  Taken as a whole, the most
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striking feature of iron-sulfur proteins is the wide range of redox potentials (ca. 850
mV) achieved primarily by rearranging iron, sulfide, and cysteine building blocks.
Blue copper proteins are characterized by intense thiolate-to-copper charge-
transfer bands near 600 nm.  These sites are found in relatively small proteins like
azurin (from bacteria) and plastocyanin (from plants), which have a single copper ion,
as well as multicopper oxidases that contain four or more copper ions arranged in
multiple, distinguishable centers.16,17  The copper ion in plastocyanin is coordinated in a
distorted tetrahedron by one cysteine, two histidines, and one methionine.  The copper
site exhibits a quite short Cu–S(Cys) bond (2.1 Å) and a very long Cu–S(Met) bond (2.9
Å), as shown in Figure 1.3B.  The structure of azurin from Alcaligenes denitrificans is
quite similar to that of plastocyanin, but the copper is five-coordinate, with the cysteine
and two histidine ligands arranged in a trigonal plane.  Long axial bonds to the copper
ion (ca. 3 Å) are formed between a methionine sulfur and a backbone amide oxygen.18,19
The five-coordinate copper site of azurin gives rise to a significantly lower redox
potential (+230 to +280 mV) than that determined for plastocyanin (+360 mV).19
Cytochromes contain one or more heme cofactors, three types of which are
depicted in Figure 1.4.  Heme a, which has a long phytyl tail, is found in cytochrome c
oxidase, b-type cytochromes and globins possess heme b, and heme c is covalently
attached via two thioether linkages to c-type cytochromes.2  The prosthetic groups are
coordinated to cytochromes by one histidine and one methionine or by two histidines.
Different cofactor environments yield a very wide range of redox potentials (–350 to
+350 mV) for cytochromes.  Chlorophylls, the principal photoreceptors in
photosynthetic light-harvesting complexes, have Mg2+ ions coordinated by cyclic
tetrapyrroles similar to those of hemes.  In photosynthetic organisms, these cofactors
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absorb photons and participate in electron transport chains that generate proton
gradients used to generate chemical energy.
Biological Electron Transfer:  ET Theory
With the repertoire of biological redox centers outlined above, electron transport
over long distances, often > 10 Å, can be achieved by arranging redox cofactors in
pathways such that ET is thermodynamically favorable.  Individual steps may be
endergonic, as long as the flux through the pathway is maintained by other exergonic
processes.20  Two important conditions must be fulfilled for functional electron transfer
in biological systems.  First, ET reactions must occur at rates that are metabolically
useful.  Second, in order to prevent rapid cellular equilibration (and death), electrons
must be transferred between specific redox partners.  Sequestering redox cofactors
within proteins solves the problem of short circuits and affords specificity via
molecular recognition in protein–protein complexes.21  The dynamics of protein
complex formation should yield a complex with a lifetime long enough to allow the
electron transfer reaction but not so long that steady-state turnover rates are
substantially compromised.
A key distinction between adiabatic chemical reactions which involve making
and breaking bonds and nonadiabatic electron transfer reactions is the probability of
forming products when the activation energy is reached.1  For adiabatic processes, this
probability is approximately unity, allowing analysis by classical transition state
theory.  On the other hand, the probability of nonadiabatic reactions occurring when
the reactants reach the transition state is much less than unity.  Therefore, a modified
form of transition state theory is required to describe these reactions (eqs 2 and 3),1
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† 
kET = k0e
-b (r-r0 )e[-(DG°+l)
2 / 4lRT ]
† 
kET =
4p 2HAB
2
h 4plRT
e[-(DG°+l)
2 / 4lRT ] (2)
(3)
where h is Planck’s constant, R is the universal gas constant, and k0 is the characteristic
frequency of the nuclei, generally taken as 1013 s-1.  At a given temperature (T), the rate
of electron transfer between two redox centers (kET) is controlled primarily by donor-
acceptor distance (r), driving force (∆G°), and reorganizational energy (l ).  The
activation free energy is given by (∆G° + l)2/4l, where ∆G° is determined from the
difference in redox potentials between the donor and acceptor molecules.  The
reorganizational energy is defined as the energy required for deforming the nuclear
configuration of the reactants to that of the product as well as inducing charge-
dependent changes in the surrounding medium.  For biological electron transfer, this
term includes not only solvent repolarization, but also repolarization of the protein
surrounding the redox centers and perhaps even the protein–protein interface.21  The
degree of nonadiabaticity is described by HAB, the electronic coupling matrix element.
Reactions with very little wave function overlap between donor and acceptor sites have
small values of HAB; adiabatic reactions have large HAB values (> 80 cm-1) and are better
treated by transition state theory.22  In eq 3, this probability term is expressed instead in
terms of the distance between redox centers (r – r0), where r0 is the close contact
distance (3.0 Å), and b, which is related to the nature of the intervening medium.  For
proteins, b values ranging from 0.7 to 1.4 Å-1 are typically used.23,24
A systematic investigation of optimal intramolecular electron transfer rates
suggested that proteins exhibit a nearly uniform electronic barrier to electron tunneling
that is well described by a b value of 1.4 ± 0.2 Å-1.23  This value is intermediate between
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Kd klim
k–lim
Aox + Bred Aox/Bred [Aox/Bred]*
Kd kX
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Ared/Box
kET
k–ET
that determined for electron tunneling through covalent bonds in synthetic systems (b
= 0.9 Å-1)25 and through a vacuum (b = 2.8 Å-1).23  Because the interiors of proteins are
chemically heterogeneous, it is remarkable that these varied protein matrices present
similar environments for electron transfer.  One possibility is that the large size of
biological redox centers affords multiple competing electron transfer pathways,
thereby producing uniform b values.23  Theoretical approaches that define specific
pathways by assigning different b values to electron transfer through covalent bonds,
hydrogen bonds, and through-space jumps have also been proposed.26,27  This so-called
pathways model has been used successfully to describe electron transfer in chemically
modified cytochrome c.28,29  Expansion of the model to group multiple similar pathways
into a tube or central path for electron transfer has yielded more accurate descriptions
of systems for which the original single pathway model was insufficient.30
Kinetic Complexity of Interprotein Electron Transfer Reactions
Electron transfer between proteins is facilitated by formation of a specific
protein–protein complex prior to electron transfer.  For a simple kinetic model of
intermolecular electron transfer (eq 4), the observed first-order rate constant for
(4)
(5)
electron transfer is given by klim.  Interprotein redox reactions often include additional
adiabatic steps such as conformational rearrangements or proton transfers before
electron transfer occurs, necessitating a more complex kinetic model (eq 5).  These
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preceding steps may influence the observed rate constant for electron transfer, kobs, so
this value must be interpreted carefully.
For interprotein electron transfer events that are preceded by a reversible
prerequisite non-electron transfer process, three situations are possible.24,31  True
electron transfer is observed when kET is the slowest step in the redox reaction, such
that kobs = kET.  Reasonable values for l, HAB, and r may be determined when electron
transfer is rate-limiting.  When the adiabatic step preceding electron transfer is fast but
very unfavorable (KX = kX/k–X << 1), the observed rate constant for electron transfer will
be influenced by the equilibrium constant for the non-ET step (kobs = kETKX), resulting in
coupled electron transfer.  For this type of reaction, l will contain contributions for
both the preceding adiabatic step and the electron transfer event; HAB may also be an
apparent value.  Gated electron transfer occurs when the reaction step prior to electron
transfer is rate-limiting (kobs = kX).  Analysis by ET theory will yield unreasonably large
l and HAB values that are unrelated to the electron transfer event and, in some cases,
negative values for the donor–acceptor distance.
Applying ET theory to biological electron transfer reactions has been performed
primarily by measuring the dependence of reaction rates on ∆G°.  Modulation of ∆G°
values can be accomplished by covalently attaching ruthenium complexes with varying
redox potentials to the surface of a protein of interest and monitoring intramolecular
electron transfer between the ruthenium and the native redox center.22  Another
methodology involves changing the metal or organic prosthetic groups of redox
cofactors to achieve different redox potentials.21,23  Finally, site-directed mutagenesis of
amino acids near a redox center has been employed to alter ∆G°.32,33  The approach of
varying ∆G° is not always possible or convenient for interprotein electron transfer
systems.  If the redox center or the surrounding protein matrix is perturbed by the
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modifications to ∆G°, parameters determined by analysis with ET theory will not be
valid.  Moreover, in many biological electron transfer reactions –∆G° is much smaller
than l, so that producing sufficiently large –∆G° values may not be feasible.
An alternative experimental approach involves analyzing the temperature
dependence of electron transfer rates by ET theory.24,31  There are several important
caveats for applying this method to interprotein electron transfer.  First, ∆G° may vary
with temperature.  Determining the redox potentials of the proteins at varying
temperatures can verify the assumption that ∆G° is constant.  Even if ∆G° changes with
temperature (or is not precisely known), the effect on most biological electron transfer
reactions, in which –∆G° is small compared to l, is often not important for determining
accurate electron transfer parameters.31  A change in the rate-limiting step with
temperature could complicate analysis by ET theory.  In ideal cases, it might be
possible to obtain electron transfer parameters for the ET event and activation
parameters for the preceding adiabatic step.  Temperature-dependent changes in
protein conformation may alter HAB or l.  This effect is minimized by the requirement
for performing experiments within a relatively narrow range of temperatures within
which the proteins are stable.  This method has yielded accurate values for the
donor–acceptor distance in several proteins for which structures are known.34-36  In
addition, the characteristic HAB, l, and r values obtained when analyzing gated electron
transfer reactions by ET theory are useful for proper classification.
Regulation of Biological Electron Transfer
Several mechanisms exist for regulating the rates of electron transfer in
biological systems.  First, variation of the ∆G°, b, l, and r parameters affords control of
electron transfer rates over many orders of magnitude.  Robust electron transfer in
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proteins is maintained by positioning redox cofactors within 14 Å of each other.20  By
employing limited donor–acceptor distances, optimal electron transfer rates are far
faster than typical catalytic rates.  Therefore, ∆G°, b, and l can be varied substantially
before electron transfer becomes the rate-limiting step in a reaction.  Beyond the 14-Å
limit, rates of electron transfer are much more susceptible to changes in other ET
parameters; therefore, natural selection appears to favor shorter distances between
redox centers.
By placing redox cofactors in separate proteins, an exquisite level of control over
electron transfer rates can be achieved via complex protein–protein interactions.  For
example, many monooxygenase and dioxygenase enzyme systems employ separate
reductase components.37  Protein conformational changes or rearrangement of proteins
within an ET complex may occur prior to electron transfer in order to optimize the
positions and geometries of the redox centers.38  In this manner, electron transfer can be
closely coupled with enzyme turnover, a feat that would be more difficult if both
functions resided in the same protein.  In addition, the timing of electron transfer with
respect to other steps in the catalytic cycle is controlled by carefully orchestrated
changes in properties such as affinity or redox potentials.
In several biological electron transfer systems, a chemical activation step is
employed to transform a slow, unfavorable process into a much faster, favorable
reaction.39  Chemical gating may represent a common metabolic strategy that allows
control of electron transfer rates by the concentration of specific metabolites, effector
molecules, or pH.  The flux of electrons through such a system may be regulated
effectively provided that the ET rates for the unactivated and activated forms are
sufficiently different.  Thus, this regulatory mechanism can prevent metabolically
unnecessary electron transfer when, for instance, a suitable electron acceptor is
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unavailable or the reaction products are already present in sufficient concentrations.
Further studies will reveal whether chemically gated electron transfer plays an
important role in metabolic regulation.
Thesis Overview:  ET Reactions in sMMO
Much of this thesis details the exploration of electron transfer reactions
involving the reductase component (MMOR) of soluble methane monooxygenase
(sMMO) from Methylococcus capsulatus (Bath).  Site-directed mutagenesis was
employed to probe the contributions of surface MMOR residues in binding the sMMO
hydroxylase component (MMOH), its physiological redox partner (Chapter 2).
Characterization of the individual [2Fe-2S] and FAD/NADH domains of MMOR
demonstrated the modular nature of the reductase and facilitated experiments not
possible for the full-length protein (Chapter 3).  Examination of intermolecular ET
reactions between MMOR and MMOH revealed a complex system regulated by
protein–protein binding interactions (Chapter 4).  Finally, Chapter 5 documents the
effect on interdomain ET rates when the MMOR domains are attached in a non-native
configuration.
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Figure 1.1.  Quinoprotein cofactors. PQQ, pyrroloquinoline quinone; TPQ,
topaquinone; LTQ, lysine tyrosylquinone; CTQ, cysteine tryptophylquinone; TTQ,
tryptophan tryptophylquinone.
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Figure 1.2.  Redox states of (A) pyridine nucleotides, (B) flavins, and (C) ubiquinone.
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Figure 1.3.  Active site structures for (A) iron-sulfur proteins and (B) plastocyanin, a
blue copper protein.
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Figure 1.4.  Structures of hemes a, b, and c.
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Chapter 2
Expression and Site-Directed Mutagenesis of the Reductase Component of Soluble
Methane Monooxygenase from Methylococcus capsulatus (Bath)*
43
INTRODUCTION
The first step in the primary catabolic pathway of methanotrophic bacteria is the
selective oxidation of methane to methanol by methane monooxygenases (MMOs) (eq
1).1,2  After this remarkable chemical transformation, methanol dehydrogenase oxidizes
CH4 + O2 + NADH + H+   ›   CH3OH + NAD+ + H2O (1)
the methanol product to formaldehyde, which is assimilated into cellular biomass or
further oxidized to generate reducing equivalents necessary for biosynthesis.3  These
organisms play an important role in regulating atmospheric levels of methane, a potent
greenhouse gas,4 and in environmental bioremediation applications.5,6
Virtually all methanotrophs can produce a membrane-bound, particulate MMO
(pMMO),7 which contains 4-5 copper atoms associated with two types of active sites.8,9
Due largely to difficulties in purification and instability of pMMO, the soluble form of
MMO (sMMO), expressed under low copper-to-biomass conditions in a few
methanotrophic bacteria,10 has received considerable attention.  The sMMO enzyme
systems from Methylococcus capsulatus (Bath) and Methylosinus trichosporium OB3b have
been characterized extensively by a wide range of biochemical and spectroscopic
methods.11-16  Both systems comprise three components:  a dimeric (abg)2 hydroxylase
(MMOH, 251 kDa) containing carboxylate-bridged diiron centers where dioxygen
activation and methane hydroxylation occur, a [2Fe-2S]- and FAD-containing reductase
(MMOR, 38.5 kDa), and a regulatory protein (MMOB, 15.9 kDa), all of which are
required for catalysis (Figure 2.1).17,18  In addition, a fourth protein (MMOD, 11.9 kDa)
was identified recently in the sMMO from M. capsulatus (Bath), although its function
has not yet been determined.19
The sMMO catalytic cycle is illustrated in Scheme 2.1.  To prime MMOH for
dioxygen activation, two electrons are transferred from NADH through the FAD and
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[2Fe-2S] cofactors of MMOR to the hydroxylase active sites housed in the a subunit,
yielding the reduced diiron(II) state.  In the presence of MMOB, reduced MMOH reacts
with O2 to generate a series of transient intermediate species.20-23  Upon substrate
hydroxylation, the MMOH active sites return to the resting diiron(III) oxidation state.
Until recently,18,24,25 the intra- and intermolecular electron transfer reactions required for
catalysis received little attention relative to the dioxygen and methane activation steps
of the sMMO reaction.
MMOR has been assigned to a class of modular flavoprotein electron
transferases on the basis of function and sequence homology.26-28  Members of this
protein family include ferredoxin (Fd), ferredoxin:NADP+ oxidoreductase (FNR),
phthalate dioxygenase reductase (PDR), cytidine diphosphate-6-deoxy-∆3,4-glucoseen
reductase (E3), nitrate reductase, cytochrome b5 reductase, and cytochrome P450
reductase.  In addition, other bacterial mono- and dioxygenases, including phenol
hydroxylase and alkene monooxygenase, employ similar reductase systems.29-32  All of
these proteins use flavins to facilitate electron transfer between NAD(P)H, a two-
electron redox reagent, and metal centers, which often function as single-electron
conduits.
Despite the detailed biochemical characterization of interactions between the
sMMO component proteins,18,33-36 there is little structural information available about
the complexes.  By covalently cross-linking M. trichosporium OB3b sMMO proteins, the
polypeptides involved in component binding were identified.37  At the time the work
presented here was begun, the only existing high-resolution structural description of
inter-protein interactions was an MMOH–MMOR docking model generated by
analyzing packing contacts in MMOH crystals.38  In this model, the [2Fe-2S] domain of
MMOR was postulated to bind to a domain of the MMOH a subunit that does not
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contain the catalytic diiron core (Figure 2.2).  A low-resolution model for the ternary
MMOH–MMOB–MMOR complex, in which MMOH undergoes a large structural
rearrangement, has also been proposed based on small-angle X-ray scattering studies.39
In recent years, several methods have been employed to investigate complexes
of the sMMO proteins.  NMR titrations of MMOB and the ferredoxin domain of
MMOR (MMOR-Fd)25 revealed specific residues that interact with MMOH.40-42  The
binding faces of MMOB and MMOR were clearly delineated in these NMR
experiments.  A mass spectrometric study of MMOR-Fd covalently cross-linked to
MMOH identified two specific cross-links between residues on the non-binding face of
MMOR-Fd with the N-terminus of the MMOH a subunit.43  Modifying positively
charged surface residues of MMOH inhibited MMOB binding and electron transfer
from MMOR.44
In the absence of crystal structures of the MMOH–MMOB or MMOH–MMOR
complexes, site-directed mutagenesis provides a means of probing the inter-protein
contacts necessary for complex formation and catalysis.  Here we report a high-yield
Escherichia coli expression system for MMOR, which was required for making site-
specific mutations.  This strategy was pursued to investigate the roles of several
MMOR residues in promoting MMOH–MMOR interactions.  In addition, we evaluate
the docking model38 used to select MMOR mutants.  This work provides a framework
for learning how individual MMOR residues might facilitate the binding and transfer
of electrons to the hydroxylase.
MATERIALS AND METHODS
Purification of MMOH from M. capsulatus (Bath).  The sMMO hydroxylase
protein was purified from M. capsulatus (Bath) cells by following a published protocol
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with minor modifications.18  Frozen M. capsulatus (Bath) cell paste (70-100 g) was
thawed on ice in a large stainless steel beaker and suspended in about 125 mL of cold
cracking buffer [25 mM 3-[N-morpholino]-propanesulfonic acid (MOPS; pH 7.0), 200
µM Fe(NH4)2(SO4)2·6H2O, 8 mM sodium thioglycolate (NaTG), 2 mM cysteine, and 5
mM MgCl2] containing DNase (1.5 units/mL) and Pefabloc SC (Roche Molecular
Biochemicals, Indianapolis, IN).  The cell suspension was sonicated on ice at 40%
maximum output (Branson Sonifier Model 450 equipped with a 3/4-inch horn) with
three 5-min pulses, which were separated by 5 min to prevent overheating.  To prevent
proteolysis during sonication, additional Pefabloc SC (ca. 10 mg) was added after the
second pulse.  The lysed cells were centrifuged at 98,000g for 30 min in order to
separate the soluble and insoluble materials.  The supernatant was transferred to clean
ultracentrifuge tubes, which were spun again for 30 min.  The soluble portion was
decanted immediately and filtered through 0.45 µm membranes then through 0.2 µm
membranes.
The soluble cell extract (ca. 150 mL) was loaded onto a DEAE Sepharose Fast
Flow (Amersham Pharmacia Biotech, Piscataway, NJ) column (5.0 cm ¥ 30 cm)
equilibrated with buffer A [25 mM MOPS (pH 7.0), 200 µM Fe(NH4)2(SO4)2·6H2O, 8 mM
NaTG, and 2 mM cysteine].  Proteins were eluted with a 4.3-L linear gradient from
buffer A to buffer B [buffer A plus 400 mM NaCl].  Under these conditions, MMOH
and MMOR eluted around 130 and 350 mM NaCl, respectively.  MMOH fractions were
identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
pooled in two batches, and concentrated by ultrafiltration.  To obtain pure MMOH,
small quantities (35-60 mg) of this crude MMOH solution were resolved with a
Superdex 200 (Amersham Pharmacia) size-exclusion column (2.6 cm ¥  80 cm)
equilibrated in 25 mM MOPS (pH 7.0), 120 mM NaCl, 1 mM 1,4-dithiothreitol (DTT),
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and 5% glycerol.  Alternatively, crude MMOH (500-800 mg) was purified further with a
Sephacryl S300 (Amersham Pharmacia) size-exclusion column (5.0 cm ¥ 95 cm).
Fractions containing MMOH were pooled based on purity as determined by SDS-
PAGE then drop-frozen in liquid nitrogen and stored at –80 °C.  The iron content of
pure hydroxylase was determined with a standard ferrozine iron assay.45,46  Typical
preparations yielded 10-12 mg of pure MMOH (e280 = 665,000 M-1 cm-1) per gram of M.
capsulatus (Bath) cell paste.  The pure hydroxylase contained 3.9-4.0 mol Fe per mol
protein; specific activity for the conversion of propylene to propylene oxide at 45 °C
was 250-300 nmol min-1 mg-1 MMOH.
Purification of MMOR from M. capsulatus (Bath).  The MMOR fractions from
the DEAE Fast Flow column were identified by SDS-PAGE and 2,6-
dichlorophenolindophenol (DCPIP; Sigma, St. Louis, MO) activity assays and then
pooled and concentrated by ultrafiltration.  To reduce the salt concentration, the crude
MMOR solution was diluted 8-fold with 25 mM MOPS (pH 7.0), 8 mM NaTG before
loading onto a DEAE Sepharose CL-6B (Amersham Pharmacia) column (2.6 cm ¥ 15
cm) equilibrated with buffer A [20 mM Tris (pH 7.0), 8 mM NaTG, and 50 mM NaCl].
Proteins were resolved with a 630-mL linear gradient from 85% buffer A (117 mM
NaCl solution) to buffer B [20 mM Tris (pH 7.0), 8 mM NaTG, and 500 mM NaCl].
Fractions containing MMOR were pooled based on their optical spectra in the 320-650
nm region, concentrated to 10 mL, and diluted to 80 mL with NaCl-free buffer to
reduce the salt concentration.  This solution was loaded onto a Sepharose 5’-AMP
(Sigma) column (2.6 cm ¥ 10 cm) equilibrated with buffer A.  The column was washed
with 20 mM Tris (pH 7.0), 8 mM NaTG containing 95 mM NaCl (55 mL), 410 mM NaCl
(40 mL), and then 50 mM NaCl (120 mL) to remove protein contaminants.  The
reductase was eluted with buffer B containing 1 mM NADH.  Fractions were pooled
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according to their A280 values, concentrated to ca. 2 mL by ultrafiltration over a YM3
membrane, and exchanged into 20 mM Tris (pH 7.0), 8 mM NaTG with a Biogel P6
desalting column (Bio-Rad, Hercules, CA).  The concentration and yield were
determined from A458 measurements (e458 = 20,800 M-1 cm-1), and the protein was drop-
frozen in liquid nitrogen.  By SDS-PAGE analysis of the pure MMOR, a high-molecular
weight contaminant was identified.  To remove this protein, the reductase was run
over a Superdex 200 size-exclusion column, as described above for MMOH.  Iron
content of the pure MMOR protein was analyzed with a ferrozine assay.
Expression and Purification of MMOB.  A 50-mL Luria-Bertani medium (LB)-
ampicillin (Ap, 100 µg/mL) solution was inoculated with Escherichia coli
JM105/pWWBg cells from a frozen stock.47  The flask was transferred to a 37 °C
incubator set to rotate at 200 rpm for overnight growth.  Six 1-L quantities of LB-Ap
(100 µg/mL) medium were inoculated with 5-mL aliquots of the saturated
JM105/pWWBg culture and transferred to a 37 °C incubator (200 rpm).  When the
OD600 of the cultures reached ca. 0.7, MMOB expression was induced by adding
isopropyl b-D-thiogalactopyranoside (IPTG) to a final concentration of 1.0 mM.  Two
hours after induction was started, cells from the JM105 cultures were collected by
centrifugation for 10 min at 2700g.  The cell pellets were drained briefly then
transferred to ice and suspended in 100 mL of cracking buffer [25 mM MOPS (pH 7.0),
8 mM NaTG, and 5 mM MgCl2] containing DNase (1.5 units/mL), 1 mM Pefabloc SC,
and 1 mM phenylmethylsulfonyl fluoride (PMSF).  The cells were sonicated on ice with
three 2-min pulses at 40% maximum output (Branson Sonifier Model 450 equipped
with a 3/4-inch horn), allowing for adequate sample cooling between pulses.  The
soluble cell extract was separated from insoluble material by centrifugation for 40 min
at 98,000g, then filtered through 0.2 µm membranes.
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The filtered cell extract was loaded onto a Q-Sepharose (Amersham Pharmacia)
column (2.6 cm ¥ 12 cm) equilibrated with buffer A [25 mM MOPS (pH 7.0), 1 mM
DTT, and 150 mM NaCl].  A 2-L gradient from buffer A to buffer B [25 mM MOPS (pH
7.0), 1 mM DTT, and 350 mM NaCl] was performed.  Fractions containing MMOB were
identified by SDS-PAGE analysis, pooled, and concentrated by ultrafiltration over a
YM3 membrane.  The concentrated protein was drop-frozen in liquid nitrogen and
stored as crude MMOB.  A Sephadex G-50 (Amersham Pharmacia) size-exclusion
column (2.6 cm ¥ 85 cm) was equilibrated with buffer A.  About half of the crude
MMOB solution was thawed and applied to the column with a superloop.  Proteins
were eluted by washing with buffer A’ [buffer A plus 1 mM ethylenediaminetetraacetic
acid (EDTA)].  MMOB-containing fractions were identified by SDS-PAGE and pooled;
the concentration was determined by UV-visible absorbance measurements (e280 =
19,300 M-1 cm-1), and the protein was drop-frozen in liquid nitrogen.
DNA Primer Synthesis and Purification.   All of the primers used for cloning
and DNA sequencing were designed manually and synthesized on an Applied
Biosystems Model 392 DNA/RNA synthesizer.  Each primer was purified by
polyacrylamide gel electrophoresis on a 12% denaturing polyacrylamide gel, extracted
from the gel slices by using a crush and soak method, then precipitated to remove most
of the salt added during extraction.  The DNA pellets were suspended in appropriate
quantities of deionized distilled water and stored at –20 °C.
Construction of Expression Vectors for MMOR Expression.  The mmoC gene,
which codes for the MMO reductase protein, was amplified from pCH4 by polymerase
chain reaction (PCR) using the primers RFE10 (5’-CGGAATTCAACATTAAGGAGGT-
AAATTTATGCAGCGAG) and RRH10 (5’-TCACAGTACTTAAGCTTTTCAGGCCGC-
CCCGGAC).  RFE10 and RRH10 introduced the restriction sites EcoRI and HindIII,
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respectively, into the ends of the resulting 1093-bp amplified gene (boldface font).  PCR
was performed with Taq DNA polymerase (Gibco BRL, Gaithersburg, MD) with the
following thermal cycler conditions:  2 min at 96 °C; 1 min at 96 °C, 1 min at 60 °C, and
2 min at 72 °C for 22 cycles, followed by extension for 10 min at 72 °C.  The resulting
PCR product was digested with the restriction enzymes EcoRI and HindIII (New
England Biolabs, Inc., Beverly, MA) by following the provided instructions.  pKK223-3,
a relatively high-copy-number expression plasmid with a tac promoter (Amersham
Pharmacia), was digested with the same enzymes to remove the EcoRI–HindIII
multiple cloning site fragment.  The restriction enzymes in both the PCR product and
plasmid digests were inactivated by incubation at 65 °C for 20 min.  The pKK223-3
digest was treated with alkaline phosphatase (AP; Boehringer Mannheim, Indianapolis,
IN) to prevent recircularization in the subsequent ligation reaction.  After inactivating
the AP by adding 20 mM ethylene glycol-bis[b-aminoethyl ether]-N,N,N’,N’-tetraacetic
acid (EGTA) and heating at 65 °C for 10 min, the DNA was extracted with an equal
volume of phenol:chloroform:isoamyl alcohol (25:24:1) and precipitated with ethanol.
The AP-treated pKK223-3 digest and mmoC PCR digest were ligated by using T4 DNA
ligase (New England Biolabs), and the ligation products were transformed into E. coli
XL1-Blue cells for selection on LB-Ap (94 µg/mL) plates.  By restriction digest analysis
of plasmid DNA isolated from minipreps, five positive clones (Figure 2.3A) were
identified.
DNA sequencing (MIT Biopolymers Laboratory) of two positive clones,
pRED(AP5) and pRED(AP14), revealed point mutations in mmoC, which would result
in T123I and T6A mutations, respectively, in the expressed MMOR.  Site-directed
mutagenesis using the QuikChange kit (Stratagene, La Jolla, CA) was performed on
pRED(AP14) with the primers 5’-GCAGCGAGTTCACACTATCACGGCGGTG and 5’-
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CACCGCCGTGATAGTGTGAACTCGCTGC.  Isolation and sequencing of the
resulting plasmid, pRED-K2, revealed that it contained the native mmoC sequence.
Redesign of mmoC Ribosome Binding Site.  The sequence AAGGA is one of
the most common E. coli ribosome binding sites, although much variation exists, and
the selection of a Shine-Dalgarno sequence for maximum expression is still not fully
understood.48-50  The native mmoC gene has a rather unconventional ribosome binding
site (RBS), CAGGTA, and a short 5-nucleotide translational spacer between the RBS
and start codon of the gene.51  Although this sequence may function well in the native
M. capsulatus (Bath), it was altered to the longer Shine-Dalgarno sequence
UAAGGAGG, which affords at least threefold better translation in E. coli than the
consensus sequence AAGGA,52 to ensure translational recognition in the foreign host.
In addition, the translational spacer (TS) was lengthened to 7 nucleotides, since
efficient translation occurs when 5 < TS < 13.52  Figure 2.3B depicts the changes
introduced in this region by the PCR primer RFE10.
Expression and Purification of Recombinant MMOR.  The pRED-K2
expression plasmid was transformed into E. coli JM105 cells.  A 100-mL Terrific Broth
(TB)-Ap (100 µg/mL) culture was inoculated with cells from a single colony of
JM105/pRED-K2 and grown overnight at 37 °C with 200 rpm shaking.  To each of six
1-L quantities of TB-Ap (100 µg/mL) medium were added 10 mL of freshly prepared
filter-sterilized 10 mM Fe(NH4)2(SO4)2·6H2O in 100 mM sodium citrate (pH 7.0) and 10
mL of the unsaturated JM105/pRED-K2 starter culture.  When the OD660 reached 0.6,
the cultures were supplemented with 80 µM Fe2+, added as 2 mL of a 40 mM
FeSO4·7H2O solution in 12.5 mM H2SO4 per liter of cell culture, and induction of
MMOR expression was started by adding IPTG to a final concentration of 1.0 mM.
After 3.5 h, the cells were collected by centrifugation and then suspended in 100 mL of
52
cracking buffer [20 mM Tris (pH 7.0), 8 mM NaTG, 5 mM MgCl2, and 200 µM
Fe(NH4)2(SO4)2·6H2O] containing DNase (1.5 units/mL) and 1 mM Pefabloc SC.  The
cells were sonicated on ice with three well-separated 2-min pulses at 40% maximum
output (Branson Sonifier model 450 equipped with a 3/4-inch horn).  The soluble cell
extract was isolated by centrifugation for 40 min at 98,000g and then filtered through
0.2 µm membranes.
This solution was loaded onto a DEAE Sepharose CL-6B column (2.6 cm ¥ 15
cm) equilibrated with buffer A [20 mM Tris (pH 7.0), 8 mM NaTG, and 50 mM NaCl].
After a 120-mL wash with buffer A, proteins were eluted with a 740-mL linear gradient
from buffer A to buffer B [20 mM Tris (pH 7.0), 8 mM NaTG, and 500 mM NaCl].
Under these conditions, MMOR eluted at approximately 350 mM NaCl.  Fractions were
pooled as crude MMOR based on SDS-PAGE analysis and UV-visible absorbance
spectra.  The crude protein was concentrated by ultrafiltration over a YM10 membrane
and then diluted to a NaCl concentration of ca. 50 mM with 20 mM Tris (pH 7.0), 8 mM
NaTG.  This material was applied to a Sepharose 5’-AMP column (2.6 cm ¥ 18 cm)
equilibrated in buffer A.  The column was washed with 20 mM Tris (pH 7.0), 8 mM
NaTG containing 95 mM NaCl (70 mL), 410 mM NaCl (50 mL), and then 50 mM NaCl
(175 mM) to remove protein contaminants.  Elution with buffer B containing 1 mM
NADH afforded >95% pure MMOR, as judged by SDS-PAGE.  Pure protein was
concentrated over a YM10 membrane, exchanged into 20 mM Tris (pH 7.0), 8 mM
NaTG with a Biogel P6 desalting column, drop-frozen in liquid nitrogen, and stored at
–80 °C.
General Characterization of Recombinant MMOR.  UV-visible spectra were
obtained with an HP 8452A diode array spectrophotometer.  The ferrozine method was
used to determine the iron content of recombinant MMOR.  FAD determinations were
53
performed by boiling a sample of MMOR for 3 min, centrifuging for 5 min at 10,000g to
pellet the denatured protein, and quantifying FAD in the supernatant (e450 = 11,300 M-1
cm-1).
Mass Spectrometric Analysis of Native and Recombinant MMOR.  Native and
recombinant MMOR were exchanged into distilled deionized water with Quick Spin
Sephadex G-50 columns (Boehringer Mannheim).  Methanol and acetic acid were
added to the desalted MMOR solutions to yield 15 pmol/µL protein in 50% methanol,
0.1% acetic acid, and the samples were submitted to the MIT Biopolymers Laboratory
for analysis by electrospray ionization mass spectrometry (ESI-MS).  To remove
cofactors that had separated from the reductase peptides during sample preparation,
high performance liquid chromatography (HPLC) purification was necessary.  The
protein components were analyzed with a Sciex model API 365 triple stage mass
spectrometer.
Total Amino Acid Analysis of Native and Recombinant MMOR.  Samples of
native and recombinant MMOR were exchanged into 10 mM potassium phosphate
buffer (pH 7.0) with a Biogel P6 desalting column.  A sample of each protein (50 µg)
and a buffer blank were submitted to the Harvard Medical School Biopolymers
Laboratory (Boston, MA) for total amino acid analysis.  Each sample was examined in
triplicate.
EPR Spectroscopy.  Recombinant MMOR in 25 mM potassium phosphate buffer
(pH 7.0) was made anaerobic by vacuum gas exchange with O2-free N2.  In an
anaerobic chamber, protein, anaerobic buffer, and sodium dithionite were combined to
yield a 258 µM MMOR solution containing 1.5 mM dithionite.  After equilibration for
several minutes, an aliquot of the fully reduced protein, MMOR3e–, was transferred to
an EPR tube and frozen in liquid nitrogen.  EPR spectra of the MMOR3e– sample were
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recorded with a Bruker EMX X-band spectrometer fitted with an Oxford ESR 900 liquid
helium cryostat set to 10 K.  The power saturation behavior of the sample was
examined, and a high-quality spectrum was collected at a power at which the signal
was not saturated.
Steady-State sMMO Activity Assays.  Reductase concentration-dependence
studies were performed for steady-state sMMO propylene assays in order to
characterize the binding and electron transfer abilities of recombinant MMOR.  In a 1-
mL masked cuvette, 1.0 µM MMOH, 1.0 µM MMOB, 0.8 mM propylene, and buffer [25
mM MOPS (pH 7.0) and 1 mM DTT] were mixed.  The MMOR concentration was
varied from 0 to 3.2 µM; 13 different concentrations were assayed in duplicate.  NADH
(0.16 mM) was added to initiate the propylene epoxidation reaction.  The contents were
mixed thoroughly, and NADH consumption was monitored at 340 nm (e340 = 6220 M-1
cm-1) for 110 s.  The temperature was held constant at 25 °C with a circulating water
bath.  The kinetic traces were fit with lines in KaleidaGraph v. 3.0 (Synergy Software,
Reading, PA).  Plots of activity vs [MMOR] were constructed and fit with a hyperbolic
function describing hydroxylase activity added to a line representing MMOR oxidase
activity.  From the fit parameters, Vmax,app and pseudo KM values were determined and
compared to those of native MMOR.
Construction of MMOR Site-Directed Mutants.  Seven amino acids, Asp26,
Arg43, Glu72, Glu73, Glu74, Glu75, and Glu76, which are all located in the ferredoxin
domain of MMOR (Figure 2.4), were selected for mutagenesis based on a proposed
MMOH–MMOR docking model (Figure 2.2) and homology to similar ferredoxins and
reductases.  Site-directed mutagenesis was performed to introduce mutations into the
pRED-K2 plasmid by using a QuikChange kit.  The primers in Table 2.2 were designed
and purified for use in the Pfu DNA polymerase-catalyzed PCR mutagenesis reactions.
55
Subsequent isolation and sequencing (MIT Biopolymers Laboratory) of pRED(D26A),
pRED(E74A), and pRED(E75A) showed all three had sequence errors.  Upon observing
that cells containing the pRED plasmid with an intact mmoC gene (no frame-shift
deletions) grow rather poorly, clones were selected for this quality before plasmid
purification.  By using this approach, the mutant plasmids pRED(D26A), pRED(R43A),
pRED(E72A), pRED(E73A), pRED(E74A), pRED(E75A), and pRED(E76A) were
isolated; DNA sequencing verified the gene sequences contained only the desired
mutations.
Expression and Purification of MMOR Mutants.   The MMOR mutant proteins
were expressed and purified by following the same protocol for wild-type MMOR
(MMOR-wt) outlined above.  The D26A and R43A mutants purified in this manner
were significantly iron-depleted, as determined spectroscopically and by performing
iron assays.  To avoid cofactor depletion, a shallower gradient was used on the CL-6B
column, and CL-6B column fractions were analyzed more rigorously before pooling.
Based on spectroscopic observations, iron-depleted MMOR elutes slightly earlier from
the CL-6B column than fully complemented reductase.  Thus, each MMOR fraction was
characterized spectrophotometrically, and plots of relevant absorbance values (A332,
A458, and A 550/A458) were produced to determine quantitatively appropriate pooling
cutoffs.  The [2Fe-2S] cluster of MMOR contributes significantly to absorbances at 332
and 550 nm, whereas the peak at 458 nm is due to both the [2Fe-2S] and FAD cofactors.
Fractions with low A550/A458 or A332 values were discarded.  Because the D26A mutant
was expressed only in low quantities, larger expression volumes (10-12 L) were
required to yield adequate amounts of this protein.
Characterization of MMOR Mutants.  The iron content of each MMOR mutant
was determined with the standard ferrozine assay.  Steady-state sMMO assays
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(described above) were performed to evaluate the effect of the mutations on sMMO
activity, MMOH–MMOR binding, and MMOR oxidase activity.  In each set of steady-
state assays, wild-type MMOR was included as a control.
Stopped-Flow Analysis of MMOR Mutant Reduction with NADH.  To
examine whether the MMOR mutations altered intramolecular electron transfer rates
in the reductase, a stopped-flow experiment was performed.  A Hi-Tech Scientific SF-
61 DX2 double-mixing stopped-flow spectrophotometer was configured in single
wavelength photomultiplier tube mode.  Prior to use, the stopped-flow apparatus was
made anaerobic by scrubbing with glucose/glucose oxidase and then washed with
anaerobic buffer.  Each MMOR sample was exchanged into 25 mM MOPS (pH 7.0), 1
mM DTT and made anaerobic by 12 cycles of vacuum gas exchange with O2-free N2.
An anaerobic solution of NADH in 25 mM MOPS (pH 7.0), 1 mM DTT was prepared
by bubbling nitrogen through the solution.  Concentrations of MMOR and NADH
were 20 µM and 200 µM, respectively, after mixing.  The MMOR–NADH reaction was
monitored at 458, 625, and 725 nm, and data points (512) were collected in 2-s or 200-s
shots on a log time scale.  The temperature was maintained at 4 °C with a constant
temperature circulating water bath.  Five or more shots were collected per wavelength.
The experiment was repeated for MMOR-wt, MMOR(D26A), MMOR(E72A),
MMOR(E73A), MMOR(E74A), MMOR(E75A), and MMOR(E76A).  KinetAsyst 2, v. 2.0
was used to fit each kinetic trace with sums of four or five exponentials.
Isothermal Titration Calorimetry.  A VP-ITC isothermal titration calorimeter
(MicroCal, Inc., Northampton, MA) was used to measure the binding affinity of the
MMOH–MMOR(E73A) complex.  All titrations were performed at 25 °C in 25 mM
MOPS (pH 7.0), 1 mM DTT.  Titrant (371 µM MMOR(E73A)) was injected in 10-µL
aliquots from a 250-µL stirred titration syringe into the 1.430-mL sample cell containing
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9.76 µM MMOH.  Stirring was maintained at 310 rpm throughout the titration.  To
measure the heat of dilution for MMOR(E73A), the experiment was repeated with
buffer in the sample cell.  For comparison, data were collected for wild-type MMOR
(150-400 µM in the titrating syringe) binding to MMOH (9.5-10.0 µM).  Data were
integrated and fit with the MicroCal Origin version 5.0 software package.
RESULTS
DNA Sequencing and Correction of mmoC  in pRED Plasmids.  DNA
sequencing of mmoC in pCH4 revealed a two-base inversion (CAC › ACC) in the
original published sequence,51 resulting in a change from V252WHEP to V252WTEP in
MMOR.  A native reductase mass of 38,545.6 Da was obtained by ESI-MS, which is
consistent with the sequence change.  With the N-terminal methionine intact and the
H254T sequence correction, the expected mass is 38,542.6, less than a 0.01% difference
from the observed value and within the accuracy range of the mass spectrometer.  On
the other hand, the published sequence would yield a mass of 38,578.7 Da, a difference
of 33 Da (0.09%), which is well outside the expected accuracy of the instrument.
Two of the pRED plasmids constructed by insertion of a Taq DNA polymerase-
generated mmoC gene into pKK223-3 had single point mutations in the coding region.
Several attempts at site-directed mutagenesis were required before a pRED expression
plasmid with the native mmoC sequence was prepared.  In order to isolate pRED
without base deletions, it was routinely necessary to select colonies that did not grow
to saturation in overnight cultures.  Thus, there must be a low level of read-through
transcription and MMOR production, which appears to interfere with normal E. coli
growth.  Colony selection based on the poor-growth criterion proved highly successful
for obtaining mmoC sequences without deletions.
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Characterization of Recombinant MMOR.  MMOR was prepared in good yield
from a recombinant expression system.  A purification protocol, which includes the
DEAE Sepharose CL-6B and Sepharose 5’-AMP columns used in the purification of
native MMOR, was developed for recombinant MMOR.  The expression conditions
were later altered slightly by substituting LB medium for TB medium, which is more
expensive and time-consuming to prepare.  In addition, 25 mM MOPS (pH 7.0), 1 mM
DTT was frequently used in place of 20 mM Tris (pH 7.0), 8 mM NaTG throughout the
chromatographic steps.  A typical preparation yielded ca. 15 mg of pure MMOR per
liter of E. coli culture.
Cofactor analysis indicated that recombinant MMOR contained 1.99 ± 0.05 mol
Fe and 1.0 ± 0.1 mol FAD per mol of protein, in agreement with literature values (Table
2.2).53  The optical spectra of the native and recombinant proteins were
indistinguishable.  The EPR spectrum of fully reduced MMOR exhibits a rhombic
signal characteristic of a mixed-valent [2Fe-2S]+ center with g values very similar to
those reported for native MMOR.54  Molecular weights within experimental error of the
calculated values for the apoproteins (N-terminal Met intact and the H254T alteration
to the published sequence51) were obtained by mass spectrometry.  Total amino acid
analysis of native and recombinant MMOR demonstrated that the proteins contained
essentially the same ratio of component amino acids.  Substituting recombinant MMOR
for native MMOR in sMMO activity assays afforded identical results.
Expression and Purification of MMOR Site-Directed Mutants.  Isolating
MMOR mutants with full iron content proved somewhat difficult.  Purification of
MMOR(D26A) and MMOR(E74A) by following the protocol used successfully for wild-
type MMOR resulted in protein that was significantly iron-depleted.  The DEAE
Sepharose CL-6B column was able to resolve to some extent iron-depleted MMOR
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† 
v = Vmax[R]
KM + [R]
+ koxidase[R]
from fully complemented reductase, so careful analysis and pooling of the CL-6B
fractions afforded MMOR(E73A), MMOR(E74A), and MMOR(E75A) proteins with 2.0
Fe/protein.  The MMOR(E72A) and MMOR(E76A) mutants were purified with 1.8 and
1.7 Fe/protein, respectively.  The JM105/MMOR(D26A) expression system produced
large amounts of inclusion bodies; the yield from the initial 4-L expression was only 5
mg of iron-depleted reductase.  In subsequent expressions, larger culture volumes, a
shallower NaCl gradient on the CL-6B column, and rigorous CL-6B fraction pooling
yielded 24 mg of MMOR(D26A) with full iron content.  Despite multiple purification
attempts, MMOR(R43A) was obtained with only 1.2-1.4 Fe/protein.  Arg43 is located
immediately next to one of the cysteine ligands of the [2Fe-2S] cluster; the cofactor may
be inherently unstable in this mutant.  Therefore, this mutant was not included in any
of the subsequent studies.
Steady-State sMMO Activity Assays for MMOR Mutants.   Reductase
concentration dependence for the steady-state sMMO propylene reaction was
investigated for the MMOR-wt, MMOR(D26A), MMOR(E72A), MMOR(E73A),
MMOR(E74A), MMOR(E75A), and MMOR(E76A) proteins.  Plots of NADH
consumption rate vs MMOR concentration obtained from one experiment are shown in
Figure 2.5.  By treating MMOR as a substrate of MMOH, the data were fit with a
function (eq 2) representing both sMMO activity (hyperbola) and MMOR oxidase
(2)
activity (line), yielding Vmax,app and pseudo KM values for MMOR and the mutant
proteins (Table 2.3).  The Vmax,app/KM value, a measurement of specificity, was markedly
lower for three of the mutants (mutant, % of wild-type):  MMOR(E73A), 31%;
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MMOR(D26A), 42%; and MMOR(E75A), 49%.  The D26A, E73A, and E75A mutations
caused significant increases in the KM value, which correspond to decreases in either
the binding affinity or binding frequency of the hydroxylase and reductase.  The
oxidase activities of four mutants, E73A, E74A, E75A, and E76A, were slightly lower
than that of the wild-type reductase.
Kinetics of MMOR Mutant Reduction with NADH.   The reactions of oxidized
MMOR mutants with NADH at 4 °C were monitored at 458, 625, and 725 nm in a
stopped-flow experiment.  The kinetic steps for the reduction of wild-type MMOR with
NADH have been determined previously18,24,25 and are depicted in Scheme 2.2.  Upon
NADH binding to MMOR, intermediate CT1, which is characterized by a charge
transfer interaction between the NADH nicotinamide ring and flavin isoalloxazine
group (lmax ≈ 575 nm), is formed.  Hydride transfer from NADH to the oxidized FAD
produces intermediate CT2, which exhibits a lower-energy charge transfer band (lmax ≈
740 nm) between the NAD+ and reduced flavin (FADhq) groups.  Release of NAD+
occurs simultaneously with intramolecular electron transfer between the MMOR
cofactors, forming intermediate SQ1 with FADsq/hq and [2Fe-2S]red/ox cofactors.
Additional electron transfer (35% of total) from FADhq to [2Fe-2S]ox yields the final
species, SQ2.
The most obvious difference between wild-type MMOR and the mutants was
the varying shapes of the kinetic traces at 625 nm, corresponding to formation of
charge transfer complexes and flavin semiquinone (Figure 2.6A).  Each kinetic trace
was fit with sums of four or five exponentials.  Nearly every data set could be fit well
by fixing the rate constants at 400 s-1, 180 s-1, 106 s-1, 30 s-1, and 1 s-1.24,55  By starting with
all of the rates fixed and then allowing some or all of the rates to vary in subsequent
fitting iterations, rate constants were obtained for the NADH reduction of for
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MMOR-wt, MMOR(D26A), MMOR(E72A), MMOR(E73A), MMOR(E74A),
MMOR(E75A), and MMOR(E76A).  There were not enough data to establish any
statistical differences between the rate constants for the reductases.  The multiple rates,
which are not very different from one another, made the fitting process difficult; many
sets of rate constants could be used to fit the data adequately.
Comparison of the 625-nm traces (Figure 2.6A) leads to a few generalizations.
The D26A, E72A, E74A, E75A, and E76A mutants formed only about 60% as much
FAD semiquinone, as judged by the total increase in absorbance at 625 nm, as the wild-
type protein.  The E73A mutant forms approximately the same amount of semiquinone
as wild-type reductase, but the corresponding 625-nm traces do not have the same
shape (Figure 2.6B).  Thus, the kinetics for intramolecular electron transfer are slightly
perturbed in the mutant.  Comparing traces of mutants which performed poorly in the
steady-state assays (D26A, E73A, and E75A; Figure 2.6C) with traces of mutants which
exhibited unaltered steady-state kinetic parameters (E72A, E74A, and E76A; Figure
2.6D) does not allow any correlation to be made between pre-steady-state
intramolecular and steady-state intermolecular electron transfer results.
Measurement of the MMOR(E73A)–MMOH Binding Constant.
MMOR(E73A), which exhibited a significantly increased KM value in steady-state
sMMO assays but relatively unaltered pre-steady-state intramolecular electron transfer,
was selected for further analysis.  The binding affinity of the E73A mutant for MMOH
was examined by isothermal titration calorimetry.  Figure 2.7A shows the power
required to compensate for the exothermic binding reaction after each addition of
titrant to the sample cell.  Data for wild-type MMOR binding to MMOH are also
displayed for comparison.  The incremental heat change for each injection was
calculated by integrating the heat pulses with respect to time.  A plot of these data as a
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function of the MMOR/MMOH molar ratio is presented in Figure 2.7B.  The data could
be fit with either the two-site (noninteracting sites) or sequential (interacting sites)
binding model resident in the Origin software.  Sequential fitting was performed with
both uncorrected and corrected MMOH concentrations, as described for sMMO
component interactions in ref 1 8 .  Because the heat pulses for the
MMOH–MMOR(E73A) binding interaction were very small and the binding affinity
fairly weak, the calorimetry data could be fit reasonably well with several different
models.  Thermodynamic parameters obtained from two fits to a sequential binding
model (uncorrected and corrected [MMOH]), as well as values for the MMOH–MMOR
interaction determined previously,18 are included in Table 2.4.  Depending on the
fitting model employed, the E73A mutation decreases MMOH–MMOR binding affinity
by a factor of 20-120 (average of 50-fold) at 25 °C.
In this study, the MMOH–MMOR binding reaction was complete after only a
few additions (Figure 2.7A), but approximate Kd values of 1 µM were determined.
Furthermore, the heat changes observed for MMOH–MMOR binding in 25 mM MOPS
(pH 7.0), 1 mM DTT have a smaller absolute value than for the same interaction
measured in 20 mM Tris (pH 7.0), 1 mM DTT.18  Although the buffer composition
appears to affect the ∆H and ∆S parameters for MMOH–MMOR binding, the Kd values
are relatively unchanged.
DISCUSSION
Recombinant MMOR.  The first high-yield recombinant system for MMOR
expression was developed, affording good yields of pure reductase with a full
complement of [2Fe-2S] and FAD cofactors.  In Methylosinus trichosporium OB3b cells,
MMOR is present at only ~10% of the MMOH level.56  Therefore, only small quantities
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of reductase can be isolated from sMMO-expressing methanotrophs; for instance, 100 g
of M. capsulatus (Bath) cell paste yields only 5-10 mg of pure MMOR in a typical
preparation.  A previous account of M. capsulatus (Bath) MMOR expression in E. coli
demonstrated MMOR activity in cell extracts, but expression levels were similar to
those in the native organism and purification was not reported.57  With the
recombinant system reported here, however, the 100-mg quantities of MMOR required
for extensive characterization are easily obtained.
In every respect that has been examined, purified recombinant MMOR is
identical to native MMOR isolated from M. capsulatus (Bath) (Table 2.2).  As judged by
optical and EPR spectroscopy, the reductase cofactors and surrounding protein
environments are the same.  Total amino acid and mass spectrometric analysis
establish the identity of the recombinant and native apoproteins.  Steady-state sMMO
activity and pre-steady-state reduction with NADH are unchanged.  Finally, the redox
potentials of recombinant MMOR24 are nearly identical to those reported previously for
the native reductase.54  We conclude that the recombinant and native MMOR proteins
are fully interchangeable.
Selection of MMOR Residues for Site-Directed Mutagenesis.  The expression
system described here not only produces sufficient reductase for detailed biochemical
studies of the wild-type protein,18,24 but also enables preparation of site-directed
MMOR mutants.  At the time this work was undertaken, no structural information was
available for MMOR or the MMOH–MMOR complex.  A novel, semi-empirical analysis
of packing contacts in MMOH crystals had just been employed to locate potential
binding sites for MMOB or MMOR on MMOH.38  Assuming that MMOH–MMOH
crystal contacts mimic MMOH–MMOB or MMOH–MMOR interactions, sequences
involved in helix-helix contacts between two MMOH molecules were examined for
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homology with MMOB and MMOR.  From this analysis, an 11-residue peptide of
MMOR (D24EDVITAALRQ34) was identified with a putative binding site on the second
domain of the MMOH a subunit.  Superimposing a homologous [2Fe-2S] ferredoxin
(PDB entry 1FRD) onto the peptide generated a docking model for MMOR with
MMOH which appeared to feature compatible binding interactions (Figure 2.2).  By
using this docking model, several MMOR residues were identified as potentially
involved in MMOH–MMOR binding interactions:  Asp26, Arg43, Glu72, Glu73, Glu74,
Glu75, and Glu76.58  Criteria for selection included residency in the ferredoxin domain,
location near the protein-protein interface (with minor adjustments for the glutamate
loop), and conservation between the M. capsulatus (Bath) and M. trichosporium OB3b
MMOR proteins.  The docking model predicted no hydrophobic contacts for the
MMOH–MMOR interface.
Activity of MMOR Mutants.  All seven MMOR mutants were obtained by site-
directed mutagenesis of the pRED-K2 expression plasmid.  Except for R43A, which
could not be prepared with full [2Fe-2S] complementation, difficulties with iron
depletion in the mutant reductases were largely overcome by slightly modifying the
purification protocol.  To evaluate the effects of these site-specific mutations on
MMOH–MMOR interactions, steady-state sMMO propylene activity assays were
performed with the D26A, E72A, E73A, E74A, E75A, and E76A mutants.  All of these
MMOR mutants are capable of transferring electrons to MMOH, which suggests that
the mutations did not cause gross changes in the wild-type reductase structure or
redox potentials.  The Vmax,app parameter for hydroxylase activity (propylene
epoxidation) is relatively unaffected for the MMOR mutants compared to MMOR-wt
(Table 2.3), in accord with the notion that the electron transfer step is not rate-limiting
in the sMMO reaction.18  In the E73A, D26A, E75A, and, to a much lesser extent, E76A
65
mutants, KM, a measure of MMOH–MMOR binding affinity and/or frequency is
significantly increased.  Because the MMOR binding and electron transfer reactions are
quite fast with respect to substrate oxidation at the MMOH active site, a single
reductase molecule can service many hydroxylase molecules during one turnover.18
Therefore, the differences in pseudo KM values determined in this study probably
underestimate the actual changes in MMOH–MMOR binding constants by a factor of
at least 10.
Stopped-flow studies of the reduction of MMOR mutants with NADH were
undertaken to investigate electron transfer in the reductive half reaction.  For all of the
mutants, the absorbance traces could be fit with the same kinetic model and rate
constants determined for wild-type MMOR (Scheme 2.2), demonstrating that the
intramolecular electron transfer steps are not severely perturbed by mutagenesis of
amino acids in the ferredoxin domain.  Of the six MMOR mutants examined, only
E73A formed the same amount of FADsq as MMOR-wt, judging by the total absorbance
increase at 625 nm (Figure 2.6).  Flavin semiquinone generation in the D26A, E72A,
E74A, E75A, and E76A mutants appeared to be only ca. 60% that of the wild-type
reductase.  Traces similar to those observed for these five mutants have been noted for
iron-depleted MMOR-wt,55 which leads to the obvious suggestion that these proteins
were not fully complemented with iron.  It is curious that all five generated essentially
equivalent amounts of semiquinone, regardless of somewhat varying iron contents
after purification.  Other explanations for decreased semiquinone formation in the
reaction with NADH include altered redox potentials of the [2Fe-2S] centers, decreased
extinction coefficients of the [2Fe-2S]red or FADsq species, diminished stability of the
reduced protein, or even a large structural perturbation.  Without further experiments,
we cannot distinguish between these possibilities with a high degree of confidence.
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Considering the difficulty encountered in isolating MMOR mutants with full [2Fe-2S]
complementation, however, iron depletion probably occurs.
The E72A and E74A mutants, which show decreased FADsq formation in the
single-turnover reaction with NADH, have sMMO steady-state kinetic parameters that
are nearly the same as those measured for wild-type MMOR (Table 2.3).  Therefore,
diminished semiquinone production under pre-steady-state conditions does not
preclude normal steady-state intermolecular electron transfer.  By extension of this
argument, the increased KM values observed for E73A, D26A, and E75A in steady-state
assays are probably due at least in part to reduced binding affinity and/or frequency
between MMOH and MMOR, rather than solely to altered [2Fe-2S] potentials.
Involvement of Glu73 in MMOH–MMOR Interaction.  Intrinsic differences in
the mutants, such as altered redox potentials or protein structure, make it difficult to
make valid comparisons to MMOR-wt regarding MMOH–MMOR binding interactions.
Therefore, the MMOR(E73A) protein, which has an increased KM (300% of wild-type
value) in steady-state sMMO reactions with propylene but also forms wild-type levels
of FADsq when reduced with NADH, was selected for further study.  Isothermal
titration calorimetry yielded a Kd of ~50 µM for the interaction of MMOR(E73A) with
MMOH at pH 7.0 and 25 °C.  By comparing the relative binding constants determined
in this study, it is apparent that the full effect of decreased MMOH–MMOR affinity (20-
to 120-fold difference for the E73A mutant compared to wild-type MMOR18) is masked
in the steady-state sMMO propylene assays (3-fold difference), in which intermolecular
electron transfer is not the rate-limiting step.
A recent parallel mutagenesis study on the M. trichosporium OB3b MMOR
protein complements the results reported here.59  Five MMOR mutants, D10A/E12A,
K48A, D69A/E70A, E71A, and R80A, were prepared and examined in steady-state
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sMMO assays at a single MMOR concentration.  Only MMOR(D69A/E70A) exhibited
significantly reduced hydroxylase activity with nitrobenzene (5-fold decrease
compared to wild-type MMOR; [MMOR] not described).  The E72A and E73A mutants
of M. capsulatus (Bath) MMOR, which correspond directly with the M. trichosporium
OB3b D69A and E70A mutations, were studied separately in this work.  In steady-state
activity assays and calorimetry experiments, MMOR(E73A) but not MMOR(E72A)
displayed decreased affinity to MMOH.  Therefore, the diminished activity observed
for the M. trichosporium MMOR double mutant is likely due to the E70A rather than the
D69A mutation, although synergistic effects cannot be ruled out.
Insights from NMR Spectroscopy.  Subsequent to this work, the ferredoxin
domain of MMOR was expressed as a separate protein,25 and its NMR solution
structure was solved.42  Figure 2.4 displays the amino acid residues mutated in this
study mapped onto the MMOR-Fd structure.  All are located on the protein surface
except for Glu74, which is somewhat buried.  The E74A reductase mutant displayed
essentially unaltered kinetic parameters in sMMO steady-state assays, a result that
correlates well with its buried position.  Of the glutamate helix (a3, Glu72-Glu76)
surface residues, only Glu73 and Glu75 are strongly implicated in binding MMOH in
this mutagenesis study.  It is interesting to note that Glu73, Glu74, and Glu75 are
absolutely conserved in all sMMO reductases, while some have aspartate rather than
glutamate at positions 72 and 76.  The inability to isolate MMOR(R43A) with full
cofactor complementation suggests a structural role for this residue.  In the ten lowest
energy MMOR-Fd structures, the location of the Arg43 side chain varies greatly.  This
amino acid is within the paramagnetic region of the [2Fe-2S]+ cofactor, however, so
proper constraints could not be determined.  Therefore, it is possible that Arg43 makes
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a specific contact with another structural element, perhaps helix a1, that is vital for
stability of the [2Fe-2S] cluster.
Amino acids involved in intermolecular contacts between MMOR-Fd and
MMOH were also identified in the NMR spectroscopic study.42  With this method, the
binding interface was determined to comprise mostly hydrophobic but also uncharged
polar and charged residues.  The MMOR-Fd surface residues most affected by the
addition of MMOH include Thr29 (helix a1), Met39 (loop), Lys51 (beta strand b3),
Gln67 (a2), Ala68 (a2), Leu69 (a2), and Glu73 (a3).  This result confirms the
involvement of Glu73 in binding MMOH first identified by site-directed mutagenesis.
In addition, Asp26 is located on the MMOR-Fd binding face and immediately precedes
helix a1, which was implicated in binding MMOH.42  This information, coupled with
the increased KM for MMOR(D26A) in steady-state sMMO reactions, may indicate a
role for this residue in the MMOH–MMOR binding interaction.
Evaluation of MMOH–MMOR Docking Model.  The MMOH–MMOR docking
model38 used to select MMOR residues for mutagenesis can be evaluated, at least in
part, by comparison with the NMR solution structure of MMOR-Fd and associated
MMOH binding experiments.42  In terms of the MMOR binding interface, the docking
prediction is quite accurate, identifying the correct binding face of the MMOR
ferredoxin domain as well as specific a helices, Asp24–Gln34 and Glu72–Glu76,
involved in the MMOH–MMOR interface.  The NMR structure verifies that the
Val27–Gln34 sequence forms an a helix and that the first half of the helix is close to the
binding interface with MMOH.  The Asp26 and Arg43 residues mutated in this study
are indeed located close to the MMOR-Fd contact surface.  Although the docking
model failed to identify an a helix deemed absolutely necessary for binding to MMOH
(a2, Val66–Leu69),42 the possibility of deviations from the template structure were
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noted specifically for the P70PEEEEEG77 helix and the V66QAL insertion immediately
preceding this structural element.58  The prediction that hydrophobic contacts are
absent from the MMOH–MMOR interface is incorrect; the NMR titration experiments
show clearly that the interface comprises both electrostatic and hydrophobic
interactions.
According to the MMOH–MMOR docking model, MMOR contacts Lys385 of
the MMOH a  subunit, which would position the [2Fe-2S] and non-heme diiron
cofactors 40 Å from each other.  For MMOR to transfer electrons efficiently to MMOH,
the cofactors are likely to be separated by 10-15 Å,60 ruling out this proposed MMOH
binding site in the absence of a large structural change upon MMOH–MMOR complex
formation or a special long-range electron transfer system.  A recent mass
spectrometric analysis of MMOR-Fd cross-linking to MMOH found specific cross-links
between both Glu56 and Glu91 of MMOR-Fd and the N-terminus of the MMOH a
subunit.43  Because these Glu residues are located on the side of the Fd domain farthest
from the [2Fe-2S] center and least affected by MMOH binding,42 it is unclear whether
these cross-links represent physiologically important binding interactions.  In contrast
to these results, MMOR from M. trichosporium OB3b cross-links to the MMOH b
subunit.37  It is possible that MMOR binds near the a/b interface in both systems, and
the disparate cross-linking behavior simply reflects different positioning of reactive
residues on the protein surfaces.  Definitive identification of the MMOH binding site
awaits determination of the MMOH–MMOR complex structure.
Conclusions.  The MMOR mutagenesis studies reported here, coupled with the
MMOR-Fd NMR solution structure,42 provide the groundwork for probing the contacts
in the MMOH–MMOR binding interface.  The identification of the same reductase
residues involved in binding MMOH (Glu73 and Asp26) by site-directed mutagenesis
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of MMOR and NMR titrations of MMOR-Fd demonstrates that full-length MMOR and
the Fd domain contact MMOH with similar geometry.  By using the MMOR-Fd
structure to guide future MMOR mutagenesis experiments, the roles of specific
reductase residues in the MMOH binding and intermolecular electron transfer steps
may be delineated.
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Table 2.1:  Primers for Site-Directed Mutagenesis of MMOR
Mutant Forward Primer a
D26A 5’-CCGTTCGGACGAGGCCGTCATCACC
R43A 5’-ATGTCGTCCTGCGCGGAGGGCGGCTG
E72A 5’-TGCCGCCGGCAGAGGAGGAGGAAG
E73A 5’-TGCCGCCGGAAGCGGAGGAGGAAG
E74A 5’-GCCGGAAGAGGCGGAGGAAGGGTTG
E75A 5’-CGGAAGAGGAGGCGGAAGGGTTGGTG
E76A 5’-CGGAAGAGGAGGAGGCAGGGTTGGTG
a  Forward primers are depicted; reverse primers are the reverse complements.  The
altered codon is shown in bold with the changed base(s) underlined.
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Table 2.2:  Properties of Recombinant and Native MMOR
Recombinant MMOR Native MMOR
MW measured a (Da) 38,546.9 ± 3.9 38,545.6 ± 3.9
Fe content (mol/mol protein) 1.99 ± 0.05 1.92 b
FAD content (mol/mol protein) 1.0 ± 0.1 1.00 b
lmax (nm), pH 7.0, 25 °C 334, 394, 458 334, 394, 458
g values (fully reduced) 2.047, 1.958, 1.871 c 2.047, 1.960, 1.864 b
FADox/sq (mV), pH 7.0, 25 °C –176 ± 7 d –150 ± 20 e
[2Fe-2S]ox/red (mV), pH 7.0, 25 °C –209 ± 14 d –220 ± 20 e
FADsq/hq (mV), pH 7.0, 25 °C –266 ± 15 d –260 ± 5 e
a  Expected 38,542.6 Da for apoprotein with H254T sequence correction and N-terminal methionine
intact.  b  As reported in ref 5 3 .  c  EPR recorded at 10 K, 500 µW at 9.478 GHz, 10.0-G modulation
amplitude.  d As reported in ref 24.  e As reported in ref 54.
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Table 2.3:  sMMO Steady-State Propylene Reaction Parameters for MMOR Mutants
Mutant Vmax,app (% of wt) a KM (% of wt) Vmax/KM (% of wt) koxidase (% of wt)
D26A 85 202 42 107
E72A 92 107 86 100
E73A 92 301 31 77
E74A 97 114 86 89
E75A 94 191 49 90
E76A 100 139 72 90
a  Kinetic parameters reported as percentage of wild-type MMOR parameters.  Bold values deviate
significantly from those of MMOR-wt.
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Table 2.4:  Thermodynamic Parameters for MMOH–MMOR Binding at 25 °C
MMOR
Kd1
(µM)
∆G1
(kcal mol-1)
∆H1
(kcal mol-1)
T∆S1
(kcal mol-1)
Kd2
(µM)
∆G2
(kcal mol-1)
∆H2
(kcal mol-1)
T∆S2
(kcal mol-1)
E73A a 22 –6.4 –3.9 2.5 65 –5.7 –20.8 –15.1
E73A b 56 –5.8 –13.5 –7.7 52 –5.8 –23.8 –18.0
wt c 0.9 –8.3 8.1 16.4 2.6 –7.6 6.5 14.1
a  Sequential fitting model.  b  Sequential fitting model with [MMOH] correction; see ref 18 for details.
c#From ref 18.
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Scheme 2.1
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Scheme 2.2
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Figure 2.1.  Schematic view of the four protein components that comprise the soluble
methane monooxygenase enzyme system.  The role of each protein in catalysis is
indicated, except for MMOD, for which a function is currently unknown.  Only one of
the two non-heme diiron centers in the MMOH dimer is depicted.
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Figure 2.2.  MMOH–MMOR docking model developed by analyzing packing contacts
in MMOH crystals (ref 38).  The MMOH backbone is shown in blue, and the putative
MMOR binding helix, D24EDVITAALRQ34, is highlighted in red.  The MMOR model
(green backbone) was generated by aligning a homologous ferredoxin protein (PDB
entry 1FRD) with the MMOR contact helix.  The FAD/NADH portion of MMOR was
added by mapping the corresponding portion of PDR (PDB entry 2PIA) onto the
docked ferredoxin protein.  The irons in the MMOH active sites and MMOR [2Fe-2S]
sites are depicted as red spheres, and the organic cofactors of MMOR are outlined in
yellow.
83
Figure 2.3.  pRED plasmid for recombinant MMOR expression.  (A) Plasmid map for
pRED, showing mmoC  inserted into the multiple cloning site of the pKK223-3
expression vector.  (B) Redesign of the mmoC ribosome binding site by altering the
DNA sequence of the forward primer used to amplify the gene from pCH4.
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Figure 2.4.  Mutated MMOR residues mapped onto the MMOR-Fd structure (PDB code
1JQ4).  b strands and a helices are colored blue and red, respectively.  Residues Asp26,
Arg43, Glu72, Glu73, Glu74, Glu75, and Glu76 are shown as balls and sticks and the
[2Fe-2S] cluster as black (iron), yellow (cysteine sulfur), and orange (inorganic sulfur)
spheres.  (A) Direct view of the MMOR-Fd face that binds MMOH, as determined by
NMR titration experiments.  (B) View A rotated by 90° about the vertical axis.
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Figure 2.5.  MMOR concentration dependence for NADH consumption in steady-state
sMMO propylene assays.  (A) Curves for MMOR-wt (circles), MMOR(E73A)
(triangles), and MMOR(E75A) (squares) fit with an expression representing
hydroxylase and MMOR oxidase activity (eq 2; solid lines).  (B) Expanded region of (A)
for MMOR concentrations between 0 and 0.2 µM.  Error bars show one standard
deviation.
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Figure 2.6.  (A) Comparison of the kinetic traces monitored at 625 nm for the reaction
of MMOR site-directed mutants with NADH at 4 °C.  (B) Traces for duplicate samples
of MMOR-wt (red and orange) and MMOR(E73A) (green and blue).  (C) Overlay of
stopped-flow data for the MMOR mutants that performed poorly in steady-state
sMMO assays (D26A, E73A, and E75A).  (D) Kinetic traces for MMOR mutants that
showed relatively unaltered kinetic parameters in steady-state assays (E72A, E74A, and
E76A).  For panels A, C, and D, the coloring scheme is:  MMOR-wt, red; D26A, orange;
E72A, gold; E73A, green; E74A, blue; E75A, violet; E76A, pink.
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Figure 2.7.  Determination of MMOH–MMOR(E73A) binding constants by isothermal
titration calorimetry.  (A) Data recorded for the formation of the complex between
MMOR-wt (upper trace, offset by 0.1 µcal s-1 for clarity) or MMOR(E73A) (lower trace)
and MMOH at 25 °C.  (B) Integrated enthalpy data for the MMOH–MMOR (squares)
and MMOH–MMOR(E73A) (circles) binding interactions fit with sequential binding
models (solid lines).
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Chapter 3
Expression and Characterization of Ferredoxin and Flavin Adenine
Dinucleotide-Binding Domains of the Reductase Component of Soluble Methane
Monooxygenase from Methylococcus capsulatus (Bath)*
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INTRODUCTION
Methanotrophic bacteria serve an important role in the carbon cycle by
consuming methane produced in anaerobic sediments and thereby limiting the flux of
this greenhouse gas into the atmosphere.1  The first step of the process, which is
catalyzed by the enzyme methane monooxygenase (MMO), involves the conversion of
methane to methanol (eq 1).  All methanotrophs express a membrane-bound
CH4 + NADH + H+ + O2  ›  CH3OH + NAD+ + H2O (1)
particulate MMO (pMMO), which contains copper.2  In the few species of
methanotrophic bacteria capable of producing a second, soluble form of MMO
(sMMO), differential expression of the two enzyme systems is regulated by the
availability of copper ions.  When the copper-to-biomass ratio is low, sMMO activity is
observed, whereas pMMO is expressed at high copper-to-biomass ratios.3
The sMMO complex from Methylococcus capsulatus (Bath) has been characterized
extensively by a wide range of reactivity, spectroscopic, crystallographic, and kinetic
methods.4-9  It comprises three proteins, a hydroxylase (MMOH, 251 kDa), a reductase
(MMOR, 38.5 kDa), and a regulatory protein (MMOB, 15.9 kDa), all of which are
required for catalytic function.10,11  Recent work demonstrates that a fourth protein,
MMOD, is also involved in the sMMO system.12  The hydroxylase, a dimer of three
subunits4 in an a 2b2g2 configuration, contains two dinuclear carboxylate-bridged iron
centers where dioxygen activation and methane hydroxylation occur.  MMOR is an
iron-sulfur flavoprotein that shuttles electrons from NADH to the hydroxylase to
prime the enzyme system for reaction with dioxygen.13,14  The MMOR [2Fe-2S] center is
located in the N-terminal portion of the protein and exhibits significant homology with
ferredoxins of plants, cyanobacteria, and archaebacteria.15  The C-terminal domain
binds a single flavin adenine dinucleotide (FAD) molecule, which accepts two electrons
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from NADH.  Electrons are then delivered one at a time to the [2Fe-2S] center for
transfer to the hydroxylase diiron site.11,14,16
MMOR belongs to a class of modular flavoprotein electron transferases (Figure
3.1), also called the ferredoxin:NADP+ oxidoreductase (FNR) family.  These proteins
contain a flavin domain capable of accepting two electrons from a nicotinamide
dinucleotide and a one-electron carrier domain, which may be linked or dissociable.17-19
The ability to attach the electron carrier domain to either the N- or C-terminal end of
the core flavin/NAD(P) protein implies that this domain is an independent modular
unit.  In accord with this notion, the crystal structure of Burkholderia cepacia phthalate
dioxygenase reductase (PDR), a member of the FNR family, reveals distinct flavin
mononucleotide (FMN), NADH binding, and [2Fe-2S] domains.19  Removal of the PDR
[2Fe-2S] domain by fortuitous proteolytic cleavage produces a stable, truncated form
amenable to biochemical characterization.20
The highly modular nature of FNR family proteins suggested that dividing
MMOR into its component ferredoxin (MMOR-Fd) and flavin/pyridine nucleotide
(MMOR-FAD) domains should be feasible.  The separate domain proteins were
predicted to serve as useful models for studying the intra- and intermolecular electron
transfer reactions of MMOR.  In this paper, we report recombinant Escherichia coli
systems for the high-yield expression of the individual MMOR domains.  For both
MMOR-Fd and MMOR-FAD, spectroscopic properties and redox potentials are
examined and compared to those of MMOR.  The kinetics of MMOR-FAD reduction
with NADH and interdomain electron transfer reactions are described.  An
examination of the influence of pH on MMOR-FAD optical spectra, redox potentials,
and NADH reaction kinetics is also presented.  Ultimately, characterization of the
individual electron transfer steps in the sMMO system, combined with the structures of
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MMOR and MMOH, will provide the means for tracing the electron transfer pathway
from NADH through the flavin and [2Fe-2S] cofactors of MMOR into the carboxylate-
bridged diiron active sites of MMOH.
MATERIALS AND METHODS
General Methods.  The ferrozine method21,22 was used to determine the iron
content of MMOR-Fd; FAD determinations were performed as described in ref 16.  UV-
visible spectra were obtained with an HP 8453 diode array spectrophotometer.
Fluorescence excitation and emission scans were recorded with a Hitachi F-3010
fluorescence spectrophotometer.
MMOR Domain Selection.  To define the Fd and FAD/NADH domain
boundaries of M. capsulatus (Bath) MMOR, sections of MMOR were aligned with the
full-length B. cepacia PDR protein sequence (PDB code 2PIA) by using ClustalW.23  In
addition, the approximate MMOR domain sequences (residues 1-114, Fd domain;
residues 89-348, FAD/NADH domain) were compared to and aligned with other
protein sequences in the non-redundant National Center for Biotechnology
Information protein databases with the PSI-BLAST program.  The C-terminal end of the
MMOR-Fd domain was selected as residue 98, and the MMOR-FAD domain was
designed to start at residue 99 after an obligatory methionine residue.
MMOR Domain Cloning.  The Fd portion of the mmoC gene, which codes for
MMOR,15 was amplified with Pfu DNA polymerase (Stratagene, La Jolla, CA) from
pCH4,24 obtained from J. C. Murrell (University of Warwick, UK), by using the
following primers:  5’-CGGAATTCAACATTAAGGAGGTAAATTTATGCAGCGAG
and 5’-CCTCTCCAAAGCTTATGCGTCAATGGGTATAG.  The primers, 5’-CGAAGA-
CCGACCTGGAATTCTAAGGAGGTTATAATATGTGCCGCATCAGTTTTGGTGAG
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and 5’-TCACAGTACTTAAGCTTTTCAGGCCGCCCCGGAC, were used to amplify
the region of mmoC corresponding to the MMOR-FAD domain.  The resulting 344-bp
(Fd) and 809-bp (FAD) fragments were flanked by EcoRI and HindIII sites (boldface
font), which were introduced by the forward and reverse primers, respectively.  The
amplified DNA was purified from the PCR reactions by using the QIAquick PCR
purification kit (Qiagen Inc., Valencia, CA).  Both PCR products were digested with the
restriction enzymes EcoRI and HindIII (New England Biolabs, Beverly, MA) by
following the provided instructions.  The high-copy-number plasmid pKK223-3
(Amersham Pharmacia Biotech, Piscataway, NJ) was digested with the same restriction
enzymes, and then treated with alkaline phosphatase (AP; Boehringer Mannheim,
Indianapolis, IN) to prevent recircularization in the subsequent ligation reaction.  After
inactivating the AP by adding 20 mM ethylene glycol-bis[b-aminoethyl ether]-
N,N,N’,N’-tetraacetic acid (EGTA) and heating at 65 °C for 10 min, the DNA was
isolated with the QIAquick PCR purification kit.  The AP-treated pKK223-3 digest and
mmoC-Fd or mmoC-FAD digest were ligated with T4 DNA ligase (New England
Biolabs); the resulting plasmid solutions were transformed into E. coli XL1-Blue cells
and plated on Luria-Bertani (LB)-ampicillin (Ap; 100 µg/mL) agar plates.  Colonies
with ampicillin resistance were analyzed further by restriction mapping of DNA
obtained from plasmid minipreps.  DNA sequencing (MIT Biopolymers Laboratory) of
positive pRED-Fd and pRED-FAD clones confirmed that the inserted genes contained
no errors.
Expression and Purification of MMOR-Fd.  The pRED-Fd(2) expression
plasmid was transformed into E. coli JM105 cells.  Cells were grown to saturation in 100
mL of LB-Ap (100 µg/mL) medium at 37 °C with 200 rpm shaking.  To each of six 1-L
quantities of LB-Ap (100 µg/mL) medium were added 10 mL of freshly prepared filter-
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sterilized 10 mM Fe(NH4)2(SO4)2·6H2O in 100 mM sodium citrate (pH 7.0) and 10 mL of
the saturated JM105/pRED-Fd(2) starter culture.  When the OD660 values reached 0.6,
the cultures were supplemented with 80 µM Fe2+, added as 2 mL of 40 mM FeSO4·7H2O
in 12.5 mM H2SO4 per L of cell culture, and induction was started by adding isopropyl
thio-b-D-galactopyranoside (IPTG) to a final concentration of 1.0 mM.  After 3.5 h, the
cells were collected by centrifugation, then suspended in 100 mL of cold cracking
buffer [25 mM 3-(N-morpholino)propanesulfonic acid (MOPS; pH 7.0), 1 mM 1,4-
dithiothreitol (DTT), 5 mM MgCl2, and 200 µM Fe(NH4)2(SO4)2·6H2O] containing DNase
(1.5 units/mL) and 1 mM Pefabloc SC.  The cells were sonicated on ice with three 2-
min pulses at 40% output (Branson Sonifier Model 450 equipped with a 3/4-inch horn)
and then centrifuged for 40 min at 98,000g to separate the soluble and insoluble
materials.  The soluble cell extract was filtered through a 0.2 µm membrane and loaded
onto a DEAE Sepharose CL-6B (Amersham Pharmacia) column (2.6 ¥ 15 cm)
equilibrated with buffer A [25 mM MOPS (pH 7.0), 1 mM DTT, and 50 mM NaCl].
After a 120-mL wash with buffer A, proteins were eluted with a 740-mL linear gradient
from buffer A to buffer B [25 mM MOPS (pH 7.0), 1 mM DTT, and 500 mM NaCl].
MMOR-Fd eluted at approximately 370 mM NaCl.  Fractions containing MMOR-Fd
were identified by optical spectroscopy and SDS-PAGE, then pooled and concentrated
by ultrafiltration.  This crude Fd protein solution was filtered through a 0.2 µm
membrane and applied to a Superdex 75 (Amersham Pharmacia) size-exclusion
column (2.6 ¥ 60 cm) equilibrated with 25 mM MOPS (pH 7.0) containing 1 mM DTT
and 150 mM NaCl.  Fractions were pooled based on color and SDS-PAGE analysis.
Typical preparations yielded 12-14 mg of >98% pure MMOR-Fd (98 residues, MW
10,931) per L of E. coli expression culture.
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Expression and Purification of MMOR-FAD.  A 100-mL JM105/pRED-FAD(1)
culture in LB-Ap (100 µg/mL) was grown to saturation at 37 °C with shaking at 200
rpm.  Each of six 1-L quantities of LB-Ap (100 µg/mL) medium was inoculated with 10
mL of the saturated starter culture and transferred to a 37 °C incubator set to rotate at
200 rpm.  When the OD660 reached ca. 0.6, expression of the MMOR-FAD domain was
induced with 1.0 mM IPTG.  After 3.5 h, the cells were collected by centrifugation,
suspended in 100 mL of cracking buffer, and sonicated as described above.  The soluble
cell extract was obtained by centrifugation for 40 min at 98,000g followed by filtration
through a 0.2 µm membrane.  The first chromatographic step, resolution on a DEAE
Sepharose CL-6B anion-exchange column, was performed exactly as described for
MMOR-Fd.  Fractions containing the FAD domain, which eluted at approximately 240
mM NaCl, were identified by SDS-PAGE and pooled.  Half of this crude material was
loaded onto a 5’-AMP Sepharose (Sigma, St. Louis, MO) column (2.6 ¥ 18 cm)
equilibrated with buffer A.  The column was washed with 25 mM MOPS (pH 7.0), 1
mM DTT containing 95 mM NaCl (70 mL), 410 mM NaCl (50 mL), and then 50 mM
NaCl (175 mL) to remove protein contaminants.   The FAD domain was eluted with
buffer B containing 1 mM NADH.  All of the fractions collected in the NADH wash
were combined as pure MMOR-FAD domain and concentrated over a YM10 Amicon
membrane.  The FAD domain was exchanged into 25 mM MOPS (pH 7.0), 2 mM DTT
with a Biogel P6 desalting column (Bio-Rad, Hercules, CA).  This procedure typically
afforded 25 mg of >95% pure MMOR-FAD (250 residues, MW 27,629) per L of
expression culture.
Expression and Purification of MMOR.  Full-length MMOR was prepared from
a recombinant E. coli expression system exactly as published,16 except that iron was
added to the media as described for MMOR-Fd domain expression.
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Mass Spectrometric Analysis.  Pure MMOR-Fd and MMOR-FAD proteins in 25
mM MOPS (pH 7.0) were submitted to the MIT Biopolymers Laboratory for analysis by
electrospray ionization mass spectrometry (ESI-MS)  To remove cofactors which
separated from the proteins upon treatment with ammonium acetate, formic acid, and
acetonitrile, HPLC purification was necessary.  The protein component was analyzed
with a Sciex Model API 365 triple stage mass spectrometer.
EXAFS Spectroscopy.  MMOR-Fd and MMOR in 25 mM MOPS (pH 7.0), 1 mM
DTT were made anaerobic by vacuum gas exchange with O2-free N2.  To reduce the
proteins completely, protein, anaerobic buffer, and excess sodium dithionite were
mixed in an anaerobic chamber to produce 1.75 mM MMOR-Fd and 0.92 mM MMOR
solutions in 25 mM MOPS (pH 7.0), 1 mM DTT, 10 mM Na2S2O4, and 39% (v/v)
glycerol.  After the samples had equilibrated for ca. 20 min, 100-µL aliquots were
loaded into lucite EXAFS cells (1 mm thick) with Kapton tape windows, the cells were
capped, and the samples were immediately frozen in liquid nitrogen.
The X-ray absorption spectra for MMOR-Fd and MMOR were measured at the
Stanford Synchrotron Radiation Laboratory (SSRL) on unfocussed 8-pole wiggler beam
line 7-3, with the ring operating at 3 GeV and 50-100 mA.  A Si(220) monochromator
was utilized for energy selection at the Fe K-edge.  To minimize higher harmonic
components in the X-ray beam, the monochromator was detuned 50% at 7987 eV.  The
sample was maintained at 10 K during data collection by using a continuous flow
liquid helium cryostat (Oxford Instruments model CF1208).  Data were measured to k =
17 Å-1 in fluorescence mode with a Canberra Ge 30-element array detector.  Internal
energy calibration was performed by simultaneous measurement of the absorption of a
Fe foil placed between two ionization chambers located after the sample.  The first
inflection point of the foil was assigned to 7111.2 eV.
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No evidence of photoreduction was observed for either MMOR-Fd or MMOR.
The final averages included 20 and 25 scans for MMOR-Fd and MMOR, respectively.
The averaged data were processed by fitting a second-order polynomial to the post-
edge region and subtracting this background from the entire spectrum.  A three-
segment spline (polynomial curves of orders 2, 3, and 3) was used to model the smooth
background above the edge.  Normalization of the data was achieved by subtracting
the spline and setting the edge jump to 1.0 at 7150 eV.  To enhance the impact of high-k
data, the resultant EXAFS data were k3-weighted, where the photoelectron wave vector
k = [2me(E – E0)/(h/2p)2]1/2, E is energy, E0 is the energy of onset of the EXAFS, and me is
the mass of an electron.  Because of the signal-to-noise level, the EXAFS data were
truncated at k = 15 Å-1 during the analysis.  Simulated EXAFS spectra were calculated
with FEFF 6.025,26 using phase and amplitude parameters derived from the crystal
structure of a [2Fe-2S] ferredoxin from Aquifex aeolicus27 then adjusted by a least-
squares fitting process to match the data (using the EXAFSPAK programs by G. N.
George, SSRL).  The experimental energy threshold, E0, was fixed at 7130 eV.  The
structural parameters that were varied during the refinement include the bond distance
(R) and the bond variance (s2).  The s2 parameter is related to the Debye-Waller factor,
which is a measure of thermal vibration and static disorder of the absorbers and
scatterers.  Coordination numbers were varied systematically during the course of the
analysis, but were not allowed to vary within a given fit.
EPR Spectroscopy.  MMOR-Fd and MMOR in 25 mM potassium phosphate
buffer (pH 7.0) were made anaerobic by vacuum gas exchange with O2-free N2.  In an
anaerobic chamber, protein, anaerobic buffer, and sodium dithionite were combined to
yield 258 µM protein solutions containing a two-fold molar excess of dithionite (i.e. 500
µM for MMOR-Fd and 1.5 mM for MMOR).  After equilibration for several minutes,
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aliquots of the reduced protein samples were transferred to EPR tubes and frozen in
liquid nitrogen.
By estimating the MMOR (and MMOR-FAD) midpoint potentials as –174 mV,
–206 mV (MMOR only), and –265 mV (vide infra), the maximum amount of
semiquinone species that can be stabilized was calculated.  Plots of species
concentration (FADox, FADsq, and FADhq for MMOR-FAD; also Fdox and Fdred for
MMOR) vs solution potential were constructed with KaleidaGraph, v. 3.0 or 3.51
(Synergy Software, Reading, PA).  Wavelengths (590 nm for MMOR-FAD; 640 nm for
MMOR) for monitoring the titrations were selected such that maximum absorbance
and maximum fraction of semiquinone species (0.75) coincided.  A 900-µL quantity of
MMOR-FAD (159 µM in 25 mM potassium phosphate, pH 7.0) was made anaerobic in
a sealed quartz cuvette by vacuum gas exchange and titrated with sodium dithionite
(ca. 4 mM) to maximize the FADsq species; this objective was achieved by reducing the
sample until A590 reached a maximum.  In a similar fashion, the MMOR protein (900 µL
of 170 µM protein in 25 mM potassium phosphate, pH 7.0) was reduced to the point of
maximum FADsq species by maximizing A 640.  After dithionite additions, the
MMOR-FAD and MMOR concentrations were calculated as 148 µM and 153 µM,
respectively, of which about 75% of the FAD cofactor (ca. 110 µM) was expected to be
in the semiquinone oxidation state.  In an anaerobic chamber aliquots of the
semiquinone samples were transferred to EPR tubes.
EPR spectra of the four samples, MMOR-Fdred, MMOR3e-, MMOR-FADsq,max, and
MMORsq,max, were recorded with a Bruker EMX X-band spectrometer fitted with an
Oxford ESR 900 liquid helium cryostat.  The temperature was maintained at 10 K for
the first two samples (reduced [2Fe-2S]) and 100 K for the latter two samples (FADsq).
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The power saturation behavior of each protein sample was examined, and a high-
quality spectrum was collected at a power at which the signal was not saturated.
Determination of FADsq Optical Spectrum by Evolving Factor Analysis.  To
examine the optical spectra of MMOR-FAD in various oxidation states, anaerobic
reductive titrations were performed.  A 1.00-mL aliquot of 90 µM MMOR-FAD in 25
mM potassium phosphate (pH 7.0) was transferred to a sealed quartz cuvette and
made anaerobic by 10-12 cycles of vacuum gas exchange with O2-free N2.  Aliquots of
1-2 mM sodium dithionite were added with a gas-tight Hamilton titrating syringe.
After each addition, optical spectra were collected until no further changes were
observed (usually less than 5 min), and the final spectrum was saved for data analysis.
The temperature for the titration experiments was held constant at 25 °C with a
circulating water bath.
After subtracting the average absorbance between 800 and 900 nm from each
spectrum, dilution corrections were applied.  The evolving factor analysis (EFA)
function resident in the Specfit Global Analysis software suite (v. 2.10U or 3.0.16;
Spectrum Software Associates, Chapel Hill, NC) was used to extract component
spectra for the MMOR-FAD domain, corresponding to the oxidized (FADox),
semiquinone (FADsq), and hydroquinone (FADhq) forms of the protein.  Non-iterative
EFA was performed for each data set to generate extinction coefficient profiles for the
three spectroscopically distinct MMOR-FAD oxidation states.  The extinction
coefficients were scaled such that e458 = 11,000 M-1 cm-1 for FADox.  To test the validity of
this method, the individual spectra collected during the reductive titrations were fit
with linear combinations of the oxidized, semiquinone, and hydroquinone component
spectra (KaleidaGraph).
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pH Effects on MMOR Domains Optical Spectra.  In order to investigate the
effects of pH on the optical spectra of the MMOR-Fd and MMOR-FAD proteins,
samples of the oxidized and reduced domains were examined at varying pH values.
Fourteen buffers were prepared for these experiments:  100 mM sodium citrate (pH
4.92, 5.06, 5.21, 5.47, and 5.81), 100 mM potassium phosphate (pH 6.00, 6.49, 6.98, 7.50,
and 8.02), and 100 mM TAPS (pH 8.07, 8.50, 8.98, and 9.10).  MMOR-FADox (214 µM) in
1 mM potassium phosphate (pH 7.0) was combined with each of these buffers to yield
~40 µM protein solutions.  Each solution was allowed to equilibrate for about 2 min,
and an optical spectrum (300-900 nm) was recorded.  The temperature was maintained
at 25 °C with a circulating water bath.  To determine the pKa for the observed optical
change, plots of A450 or A500 vs pH were fit with the expressions shown in eqs 2 and 3,
(2)
(3)
respectively, by using the program KaleidaGraph.  To yield ~45 µM MMOR-Fdox
solutions, MMOR-Fd in 1 mM potassium phosphate (pH 7.0) was mixed with 100 mM
sodium citrate (pH 5.47), 100 mM potassium phosphate (pH 6.00, 6.98, or 8.02), or 100
mM TAPS (pH 8.98).  After brief equilibration, optical spectra (300-900 nm) were
collected at room temperature.
Fdred and FADhq samples were prepared at varying pH values by reducing the
proteins with sodium dithionite in an anaerobic chamber, dialyzing away excess
dithionite, and combining aliquots of the reduced proteins with strong buffers (same
used for Fdox experiment described above).  Sealed MMOR-Fdred and MMOR-FADhq
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samples were removed from the box, and optical spectra (300-900 nm) were recorded.
For all samples, the temperature was held constant at 25 °C with a circulating water
bath.
To examine the effects of pH on the MMOR-FADsq optical spectrum, anaerobic
reductive titrations of MMOR-FAD were performed at varying pH.  The following
buffers were used in these experiments:  80 mM potassium phosphate (pH 6.00), 60
mM potassium phosphate (pH 6.49), 75 mM potassium phosphate (pH 6.98), 70 mM
potassium phosphate (pH 8.02), and 75 mM TAPS (pH 8.50, 8.98, or 9.31).  The
MMOR-FAD domain (ca. 50 µM) in a total volume of 1.00 mL was reduced with
dithionite exactly as described above.  After each addition of reductant, equilibrium
was usually achieved in 5-10 min, but took as long as 40 min at high pH values.  Data
were processed as described, and EFA afforded FADox, FADsq, and FADhq component
spectra for each titration data set.
Redox Potential Determinations for the MMOR Domains.  The equilibrium
midpoint potentials of the MMOR-Fd and MMOR-FAD domains were determined by
using a series of reductive titrations.  All of the titrations were performed in 25 mM
potassium phosphate (pH 7.0) buffer because MOPS, the standard buffer used in
sMMO studies, interferes with electron equilibration.  Each titration included one or
more redox-active indicator dyes with known midpoint potentials to permit calculation
of the solution potential throughout the titration.  Dyes used for MMOR-Fd potential
determination included anthraquinone-2-sulfonate (AQ2S; E °’ = –226 mV),
phenosafranine (E°’ = –252 mV), and anthraquinone-2,6-disulfonate (AQ2,6S; E°’ =
–184 mV) in combination with phenosafranine (15-20% relative to AQ2,6S).
The MMOR-Fd domain (ca. 40 µM) and dye(s) (ca. 35 µM for AQ2S and AQ2,6S;
ca. 12 µM for phenosafranine) in a total volume of 1.00 mL were placed in a sealed
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quartz cuvette and made anaerobic by twelve cycles of vacuum gas exchange with O2-
free N2.  A gas-tight Hamilton titrating syringe was filled with a solution of sodium
dithionite (1-2 mM) in phosphate buffer and then transferred to the cuvette under
positive pressure.  After the solution had equilibrated to 25 °C, an initial visible
spectrum (300-900 nm) of the oxidized material was collected.  Dithionite was added to
the protein-dye solution in 5-µL aliquots, the solution was mixed thoroughly, and a
spectrum was recorded.  Multiple scans were taken after each dithionite addition until
the system had reached equilibrium (usually 5-10 min, but as long as 40 min).  The final
spectrum was saved for data analysis.  This process was repeated until the protein and
dye(s) were reduced completely.  In addition, the MMOR-Fd potential was measured
in the presence of MMOH (0.5 equiv) and/or MMOB (1 equiv) with AQ2S as the
solution potential indicator.
The equilibrium midpoint potentials of the MMOR-FAD domain were
determined by using the same method.  The indicator dyes AQ2S, anthraquinone-1,5-
disulfonate (AQ1,5S; E°’ = –172 mV), phenosafranine, safranine O (E°’ = –289 mV), and
AQ2,6S in combination with phenosafranine (15-20% relative to AQ2,6S) were used for
the MMOR-FAD domain reductive titrations.  The MMOR-FAD protein (ca. 30 µM)
and dye(s) (ca. 35 µM for AQ2S, AQ1,5S, and AQ2,6S; ca. 12 µM for phenosafranine
and safranine O) were titrated at 25 °C with sodium dithionite.
To obtain dye component spectra, an anaerobic solution of each dye (1.00 mL;
65-70 µM for the anthraquinone dyes, 20 µM for phenosafranine and safranine O) was
titrated with 1-2 mM sodium dithionite.  The initial spectrum was taken as the oxidized
dye component spectrum.  After performing baseline and dilution corrections, the first
spectrum for which no optical changes were observed upon dithionite addition was
selected as the fully reduced dye spectrum.  The MMOR-Fd component spectra, Fdox
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DA(l ) = SDe i(l )(Dci)
and Fdred, were also determined by titration with dithionite; the MMOR-FAD
component spectra, FADox, FADsq, and FADhq, were obtained by EFA as described
above.  For each redox couple (dyeox/dyered, Fdox/Fdred, FADox/FADsq, and
FADsq/FADhq), a difference spectrum, ∆ei(l), was calculated by subtracting the
extinction coefficients of the oxidized species from those of the reduced species.
Dilution corrections were applied to each spectrum in a titration data set.  To
eliminate any errors due to inaccurate extinction coefficients, the initial species
concentrations were determined by fitting the initial oxidized spectrum with a linear
combination of oxidized protein and oxidized indicator spectra (KaleidaGraph).  A
difference spectrum for each titration point was generated by subtracting the starting
oxidized spectrum from each spectrum in the data set.  These difference spectra (350
nm ≤ l ≤ 800 nm) were then fit with linear combinations of component difference
spectra, as shown in eq 4.
(4)
The concentration differences, ∆ci, returned by fitting with eq 4 were readily
converted to species concentrations by comparison with the total concentrations of
protein and dye(s).  The solution potential and MMOR domain midpoint potentials
were computed for each titration point with modified Nernst equations.16  Average
MMOR-Fd and MMOR-FAD midpoint potentials were calculated by including only
those data for which the solution potential was within 40 mV of both the approximate
MMOR-Fd or MMOR-FAD domain potential and the indicator potential.
Relative redox potentials were determined for the FAD domain at varying pH
values.  For each MMOR-FAD reductive titration (vide supra), a species fraction
(FADox, FADsq, or FADhq) vs percent reduction plot was constructed, where the latter
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was computed according to eq 5.  The FADsq vs % reduction plots were fit manually by
(5)
generating a series of curves representing different ∆E° values (difference between the
FADox/sq and FADsq/hq redox potentials).  First, given various ∆E° values, theoretical
fractions of FADox, FADsq, and FADhq were calculated over a range of solution
potentials (Eh; –500 mV to +100 mV) with eqs 6-8, respectively.  For each Eh value, the
(6)
(7)
(8)
percent reduction (eq 5) was calculated.  Finally, the theoretical mole fraction vs %
reduction curves were compared to the experimental data in KaleidaGraph; the ∆E°
value used to generate the best-fitting curve was taken as the difference in redox
potentials at that pH.
Isothermal Titration Calorimetry.  A VP-ITC isothermal titration calorimeter
(MicroCal, Inc., Northampton, MA) was used to measure the binding affinity of the
FADox–NAD+ complex.  All titrations were performed at 4.2 °C in 25 mM MOPS (pH
7.0).  Titrant (1.89 mM NAD+) was injected in 10-µL aliquots from a 250-µL stirred
titration syringe into the 1.430-mL sample cell containing 43 µM MMOR-FAD.  Stirring
% reduction = 100 ¥
0.5[FADsq] + [FADhq]
[FAD]T
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104
was maintained at 310 rpm throughout the titrations.  In order to measure the heat of
dilution for NAD+, the experiment was repeated with buffer in the sample cell.  Data
were integrated and fit with the MicroCal Origin v. 5.0 software package.
MMOR-FAD Reaction with NADH.  To examine intramolecular electron
transfer for the reduction of MMOR-FAD with NADH, several stopped-flow
experiments were performed.  A Hi-Tech Scientific SF-61 DX2 double-mixing stopped-
flow spectrophotometer configured for either single-wavelength photomultiplier or
multi-wavelength diode-array collection was used for all experiments.  Prior to use, the
stopped-flow apparatus was made anaerobic by flushing the syringes and flow cell
with a solution of ca. 5 mM sodium dithionite.  The dithionite was then flushed from
the system with anaerobic buffer.  Oxidized MMOR-FAD protein in 25 mM MOPS (pH
7.0) was made anaerobic by 12-15 cycles of vacuum gas exchange with O2-free N2.
Anaerobic NADH solutions were prepared by bubbling with nitrogen for at least 15
min.  Concentrations of MMOR-FAD were 20-40 µM after mixing; NADH
concentrations were ~10 times that of MMOR-FAD, except where noted.  The
MMOR-FAD reaction with NADH was monitored at 458, 625, and 725 nm in single-
wavelength photomultiplier mode.  Data points (512) were collected in 1-s shots on a
log time scale.  The experiment was repeated with the stopped-flow apparatus in
multi-wavelength diode array mode.  For each 1.4- or 2-s shot, 160 spectra (295-705 nm
or 370-740 nm) were recorded with a logarithmic time base.  The temperature was
maintained at 4 °C with a constant temperature circulating water bath for all
experiments.  Single-wavelength absorbance data were fit to a sum of two or three
exponential decays with the program KinetAsyst 2, v. 2.2 (Hi-Tech Limited, Salisbury,
England).  The Specfit program was used to analyze diode array data and second-order
reaction data.
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MMOR-FAD reduction with NADH was also investigated over a range of pH
values.  For these experiments, the FAD domain was prepared in 1 mM MOPS (pH
7.0), 49 mM NaCl and mixed with strongly buffered NADH solutions at the desired
pH.  Buffers included were 50 mM MES (pH 5.47, 5.93, and 6.29), 50 mM MOPS (pH
6.70, 7.00, and 7.40), and 50 mM TAPS (pH 7.77, 8.21, and 8.47).  Ionic strength was
maintained at 50 mM by addition of appropriate quantities of NaCl to each buffer.  pKa
values for pH-dependent effects were calculated by using eqs 2 and 3.
Interdomain Electron Transfer Reactions.  Electron transfer reactions between
a) MMOR-FADhq and MMOR-Fdox; b) MMOR-FADhq and MMOR-FADox; and c)
MMOR-Fdox/MMOR-FADox and NADH were investigated by stopped-flow optical
spectroscopy.  All experiments were performed in 25 mM MOPS (pH 7.0) or 25 mM
potassium phosphate (pH 7.0) at 4 °C and/or 25 °C.  Single-wavelength
photomultiplier data collection was used for reactions b) and c); multi-wavelength
diode array mode was employed for reactions a) and b).  Protein concentrations after
mixing were 20-30 µM, except where noted.
RESULTS
General Characterization of MMOR Domains.  Both MMOR-Fd (MMOR
residues 1-98) and MMOR-FAD (MMOR residues 99-348) were prepared in good yield
from recombinant expression systems.  Protein purity and cofactor content were
monitored effectively by examining absorbance ratios.  For MMOR-Fd, an A276/A332
ratio of 1.05 indicates pure, fully complemented protein; pure MMOR-FAD has an
A270/A458 ratio of ~6.7.  Molecular weights within experimental error of the calculated
values for the apoproteins (N-terminal methionine intact for the Fd domain and
cleaved for the FAD domain) were obtained by mass spectrometric analysis (Table 3.1).
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Iron and FAD determinations were used to calculate extinction coefficients for the
domains, assuming 2.0 mol Fe/mol MMOR-Fd and 1.0 mol FAD/mol MMOR-FAD.
The Fe K-edge, EXAFS, and Fourier transform spectra of MMOR-Fd and MMOR show
only very small differences between the two samples (data not shown).  The Fe–Fe and
Fe–S distances determined for the fully reduced domain and full-length proteins, are
essentially identical (Table 3.1).  A second fit, with three long Fe–S distances (ca. 2.3 Å)
and one short Fe–S distance (ca. 2.2 Å) was also possible, but the Fe–S paths were just
within the resolution of the data for MMOR-Fd and not resolvable for MMOR.  It is
likely that there is one short Fe–S bond in the [2Fe-2S] cluster; however, the quality of
the data does not allow this statement to be made with assurance.  The EPR spectra of
fully reduced MMOR-Fd and full-length MMOR exhibit rhombic signals characteristic
of mixed-valent [2Fe-2S]+ centers with nearly identical g values.  Although the EPR
spectra of FADsq,max and MMORsq,max are essentially identical, the power saturation
behavior for these samples is somewhat different (Figure 3.2), presumably due to the
presence of EPR-active [2Fe-2S]+ (ca. 60% of total [2Fe-2S]) in the MMORsq,max sample.28
The UV-visible spectra for the MMOR domains can be added to yield a spectrum
identical to that of full-length MMOR (Figure 3.3).  Full-length MMOR is not very
fluorescent, a property that was previously believed29 to be due to quenching of the
FAD fluorescence by the nearby [2Fe-2S] center.  Fluorescence studies of MMOR-FAD
and free FMN demonstrated that the FAD domain is also a weak fluorophore;
therefore, the protein environment around the FAD cofactor must quench most of the
flavin fluorescence.
Evolving Factor Analysis for MMOR-FAD Component Spectra.  Selected
spectra from a reductive titration of MMOR-FAD at pH 7.0 are shown in Figure 3.4A.
The FADox, FADsq, and FADhq component spectra extracted by evolving factor analysis
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are displayed in Figure 3.4B.  The generated component spectra fit the original titration
data extremely well; in addition, the total calculated concentration of MMOR-FAD (the
sum of the FADox, FADsq, and FADhq concentrations) is constant for all of the titration
spectra, showing that the component spectra are correctly scaled with respect to each
other.
Effect of pH on MMOR Domains Optical Spectra.  Below pH 5.5, the Fd and
FAD domains precipitate from solution, so the effective range for the pH investigations
was 5.5 to 9.3.  Over this pH range, the oxidized and reduced MMOR-Fd spectra did
not exhibit pH-dependent optical changes.  The UV-visible spectra of all three
MMOR-FAD chromophores (FADox, FADsq, and FADhq) are altered by pH (Figure
3.5A).  Data corresponding to the wavelengths at which maximum absorbance changes
occur reflect processes having pKa values of 6.55 ± 0.05 (Figure 3.5B) and 7.1 ± 0.2
(Figure 3.5C) for FADox and FADhq, respectively.  Above pH 8.5, the FADsq spectra
provide evidence for deprotonation of the blue neutral semiquinone species to form a
red anionic semiquinone.30  There were not enough data to determine an accurate pKa
for this transition, but the value must be at least 9.
Redox Potentials of MMOR-Fd and MMOR-FAD.  Figure 3.6 shows selected
difference spectra from a reductive titration of MMOR-FAD in the presence of the
indicator phenosafranine.  To examine the accuracy of difference fitting, global fits to
both difference spectra and the original titration spectra were performed for a
reductive titration of MMOR-Fd and AQ2S.  The returned [2Fe-2S]ox/red E°’ values
(–205.1 ± 1.3 mV for difference fitting; –208.3 ± 3.8 mV for direct fitting) are essentially
identical, except that direct fitting results in a larger standard deviation.  Difference
spectra emphasize the changes in a sample, so that even small spectral differences can
be fit accurately when not obscured by much larger (and unchanged) features.  In
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addition, difference fitting in many cases reduces the number of independent variables
in a fit so that a unique solution may be calculated.  Therefore, fitting difference spectra
is the method used to calculate component concentrations for all of the redox potential
determinations.
Plots of MMOR domain potential versus solution potential were constructed to
aid in selecting the data range included in the overall midpoint potential averages.
Only those titration points that returned a relatively constant potential over a range of
solution potentials were selected.  In general, this linear range correlates well with the
arbitrary selection of data points with solution potentials within 40 mV of both the
estimated domain potential and indicator potential.  It was necessary to correct the
safranine O range from the calculated –250 to –304 mV to a range of –266 to –322 mV.
The calculated midpoint potentials for MMOR-Fd ([2Fe-2S]ox/red) and MMOR-FAD
(FADox/sq and FADsq/hq) are displayed in Table 3.1.  Within experimental error, addition
of 0.5 equiv MMOH and/or 1 equiv MMOB to MMOR-Fd does not alter the Fd domain
potential.  MMOH forms complexes with both MMOB11 and MMOR-Fd31; by analogy
to MMOR,11,16,32 MMOR-Fd is not expected to bind MMOB.
Relative MMOR-FAD redox potentials were determined by analyzing reductive
titrations of the FAD domain performed at varying pH values.  Because no indicator
dye was included in these titrations, the solution potential at each titration point is
unknown, and only the difference between the FADox/sq and FADsq/hq potentials may be
computed.  Fits to mole fraction vs % reduction plots generated ∆E° (FADox/sq –
FADsq/hq) values for each titration, as shown in Figure 3.7A.  The MMOR-FAD ∆E°
values increase from 80 mV at pH 6.0, the lowest pH examined, to a maximum of 94
mV at pH 7.0, and then decrease to 32 mV at pH 9.0, the highest pH examined (Figure
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3.7B).  Additional titrations to extend the pH range could not be performed due to
protein precipitation at low pH and extremely slow equilibration at high pH.
To analyze these data further, it was necessary to account for protons involved
in the redox equilibria.  For a reductive reaction including a single proton, the
measured midpoint potential varies linearly with pH, as shown in eq 9.  Therefore, the
(9)
redox potential for a one-electron (n = 1), one-proton process exhibits a pH dependence
of –59 mV/pH unit at 25 °C.  Scheme 3.1 depicts the relevant redox equilibria for
MMOR-FAD.  At pH values below the FADsq pK a (> 9), reduction of FADox to the
neutral semiquinone state requires a proton (eq 10); above this pKa value, formation of
anionic semiquinone is proton-independent (eq 11).  Thus, the FADox/sq redox potential
FAD + e– + H+  ›  FADH• (10)
FAD + e–  ›  FAD•– (11)
should vary by –59 mV/pH unit at low pH and not at all at high pH (Figure 3.7C,
dotted line).  For semiquinone reduction to hydroquinone, there are three possible
redox equilibria (eqs 12-14).  At low and high pH values (eqs 12 and 14, respectively),
FADH• + e– + H+  ›  FADH2 (12)
FADH• + e–  ›  FADH– (13)
FAD•– + e– + H+  ›  FADH– (14)
the redox reactions include protons.  Between the FADhq and FADsq pKa values (6.0 and
> 9, respectively; vide infra), reduction proceeds without protonation (eq 13).
Therefore, the FADsq/hq potential should be constant between pH 6 and ~9 and vary by
–59 mV/pH unit at low and high pH (Figure 3.7C, dashed line).  Combining these
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processes yields a ∆E value (FADox/sq – FADsq/hq) that is constant below pH 6, decreases
by 59 mV/pH unit between pH 6 and ~9, and increases by 59 mV/pH unit above pH
~9 (Figure 3.7C, solid line).
In order to identify pH-dependent changes in MMOR-FAD redox potentials due
to the protein environment, the contributions to ∆E° by the redox equilibria were
subtracted from the ∆E° vs pH data.  An appropriate ∆E  correction curve was
constructed with slopes of 0, –59, and +59 mV/pH unit at low, middle, and high pH,
respectively, with transitions corresponding to pKa values of 6.0 and ≥ 9 (Figure 3.7C).
Because the precise FADsq pK a value is unknown, this procedure was repeated for
thirteen pKa values between 9.0 and 11.4.  Subtracting the ∆E correction curves from the
MMOR-FAD ∆E° vs pH data yielded titration curves that reflect a process with a pKa of
6.8 ± 0.1 and redox potential change of 119 ± 4 mV (Figure 3.7D).
Measurement of the MMOR-FADox–NAD+ Binding Constant.  The binding
affinity of NAD+ for MMOR-FADox was determined by isothermal titration calorimetry.
Figure 3.8A shows the power required to compensate for the exothermic binding
reaction after each addition of titrant to the sample cell.  By integrating these heat
pulses with respect to time, the incremental heat change for each injection was
calculated.  A plot of these data as a function of the NAD+/MMOR-FAD molar ratio is
presented in Figure 3.8B.  Fitting with the one-site model resident in the Origin
software yielded the following thermodynamic parameters for the
MMOR-FADox–NAD+ binding reaction:  Kd = 43 ± 2 µM; N = 1.00 ± 0.05 binding sites
per FADox molecule; ∆G = –5.5 kcal mol-1; ∆H = –7.7 ± 0.4 kcal mol-1; T∆S = –2.2 kcal
mol-1 (solid line in Figure 3.8B).
Kinetics of MMOR-FAD Reduction with NADH.  Reduction of the
MMOR-FAD domain with NADH was studied by diode array stopped-flow UV-visible
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spectroscopy.  A typical data set collected for this reaction at pH 7.0 and 4 °C is shown
in Figure 3.9A.  Spectra corresponding to four intermediates were resolved with Specfit
software by using a sequential four-component model with a fixed FADox spectrum as
the initial species  (Figure 3.9B).  Upon NADH binding to the MMOR-FAD domain,
species CT1, which is characterized by a charge transfer interaction between the
NADH nicotinamide ring and flavin isoalloxazine group (lmax ≈ 570 nm), is formed.
Hydride transfer from NADH to the oxidized FAD produces intermediate CT2, which
exhibits a lower-energy charge transfer band (lmax > 700 nm) between the NAD+ and
reduced flavin (FADhq) groups.  The CT2 species decays as NAD+ is released from the
fully reduced MMOR-FAD protein.  The NADH reaction with the FAD domain is
summarized in Scheme 3.2.
Single-wavelength stopped-flow data collected at 458, 625, and 725 nm were fit
with sums of two or three exponential decays (Figure 3.9C).  CT1 formation is observed
as an increase in A625 at t < 7 ms; CT2 formation produces an increase in A725 at t < 10
ms.  Decreases in both A625 and A725 at t > 10 ms correspond to CT2 decay to FADhq.  All
three transitions are reflected as decreases in A458.  Rate constants of 350 ± 20 s-1 (vide
infra), 188 ± 7 s-1, and 89 ± 4 s-1 were determined for CT1 formation, CT1 decay/CT2
formation, and CT2 decay, respectively, at pH 7.0 and 4 °C.
To investigate NADH binding to MMOR-FAD, single-wavelength stopped-flow
experiments were performed with varying concentrations of NADH.  The rate of CT1
formation increases hyperbolically with NADH concentration (Figure 3.10), which
indicates that a spectroscopically silent intermediate, denoted MC1 for Michaelis
complex 1, must precede CT1, the first observed intermediate.  By fitting these data
with a hyperbolic expression, a Kd value of 25 ± 4 µM was calculated for the FAD
domain–NADH binding interaction at 4 °C.  Under saturating NADH conditions, the
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rate constant for CT1 formation, k1, approaches 350 s-1.  In addition, at low NADH
concentrations the rate of CT2 formation converges with the slower CT1 formation rate
(data not shown), further substantiating the kinetic model.
Effect of pH on the Reaction of MMOR-FAD with NADH.  Reduction of
MMOR-FAD with NADH was also investigated at nine pH values in the range 5.5-8.5.
Reaction rates were determined from single-wavelength stopped-flow data collected at
each pH value; these results are displayed in Figure 3.11A.  CT1 formation (k1) and CT2
formation (k2) are somewhat faster at low pH; in addition, k1, and possibly k2, may
increase slightly at high pH.  The variation of k1 with respect to pH reflects either two
processes having pKa values of 6.61 ± 0.07 and 7.09 ± 0.08 (solid line in Figure 3.11A) or
a single process with a pKa of 6.2 ± 0.1 (fit not shown).  The minimum k1 value, 230 s-1,
occurs near pH 7.0.  At low and high pH, k1 approaches 372 s-1 and 274 s-1, respectively.
The k2 data can also be fit fairly well with these pKa values, yielding maxima of 330 s-1
and 200 s-1 at low and high pH values, respectively.  The rate of CT2 decay, k3, is
unchanged throughout this pH range.
Diode array stopped-flow experiments were performed for this reaction at five
pH values between 5.5 and 8.5.  Spectra corresponding to the FADox, CT1, CT2, and
FADhq intermediates were resolved with Specfit software by using a sequential four-
component model with a fixed FADox spectrum (initial species) determined at the
appropriate pH.  CT1 spectra are essentially unchanged over this pH range; FADhq
spectra vary as determined above (Figures 3.5A and 3.5C).  The CT2 intermediate
spectrum, however, is significantly altered as a function of pH, as shown in Figure
3.11B.  Large increases in CT2 absorbance between 400 and 500 nm accompany pH
decreases.  Reducing the pH also converts the CT2 charge transfer band from one
characteristic of a FADH––NAD+ complex (lmax > 700 nm) to one very similar to the
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FAD–NADH charge transfer band (lmax ≈ 570 nm) of CT1.  In fact, the CT1 and CT2
intermediates determined for data sets collected at pH 5.47 have nearly identical charge
transfer bands; therefore, these data can be fit equally well with a sequential three-
component model.  The changes in CT2 e470 and e700 values with pH reflect a pKa of 6.0 ±
0.1 (Figure 3.11C).
Interdomain Electron Transfer Reactions.  Reduction of full-length MMOR
with NADH proceeds in exactly the same manner described for MMOR-FAD, except
that NAD+ release (CT2 decay) is accompanied by electron transfer from the FADhq
cofactor to the [2Fe-2S]2+ cluster, yielding the FADsq and [2Fe-2S]+ oxidation
states.11,14,16,33  Therefore, electron transfer between the MMOR domains was
investigated to determine the effects of separating the domains.  Electron transfer from
MMOR-FADhq to Fdox at 25 °C can be fit as a second-order reaction (A + B › C) with
observed rate constant k = 1500 ± 100 M-1 s-1 (Figure 3.12A).  Within a reasonable range
of Fdox concentrations (12.5-50 µM), the second-order rate constant for electron transfer
from 12.5 µM MMOR-FADhq is unchanged.  A pseudo-first-order rate constant could
not be determined for this reaction due to the high concentration of MMOR-Fd,
estimated to be greater than 0.2 M, required to saturate the MMOR-FAD binding site.
To examine the possibility that interdomain electron transfer is slow because
MMOR-FAD–MMOR-Fd binding is slow, the domains were pre-complexed and
allowed to react with NADH in a stopped-flow experiment.  Although the CT1 and
CT2 formation and decay rate constants are unchanged, electron transfer to the Fd
domain is still extremely slow, even at increased temperature.  For the
comproportionation reaction of MMOR-FADox and MMOR-FADhq to form
MMOR-FADsq at 4 °C, there is a single observed step, which was fit with a second-
order model (Figure 3.12B).  The observed rate constant for electron transfer, k = 100 ±
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15 M-1 s-1, describes a slow reaction that should not interfere with the NADH reaction
kinetics reported above for MMOR-FAD.
DISCUSSION
Recombinant MMOR Domains.  High-yield recombinant expression systems
were developed for both the ferredoxin and FAD/NADH domains of MMOR.  The
NMR solution structure of the MMOR-Fd domain shows that this protein adopts a
compact three-dimensional fold similar to that of other plant-type ferredoxins.34
Preliminary NMR studies of the MMOR-FAD protein demonstrate that it too forms a
well-defined structure in solution.35  In nearly every respect examined, MMOR-Fd and
MMOR-FAD are extremely good models for these domains in the full-length reductase.
As judged by optical, EXAFS, and EPR spectroscopy, the domain cofactors are in
protein environments nearly identical to those of MMOR.  By separating the MMOR
domains, the complexity of the full-length protein is reduced without compromising
the integrity of most biochemical properties.  For some experiments, the domains
afford more straightforward data interpretation when compared to the corresponding
MMOR study; for others, the MMOR domains provide data that could not have been
obtained with the full-length reductase.
For example, the domains have been instrumental in structurally characterizing
MMOR.  The solution structure of the 10.9-kDa Fd domain was completed recently,34 a
feat that would have been far more challenging for the 38.5-kDa MMOR.
Determination of high-quality Fdox, Fdred, FADox, FADsq, and FADhq component spectra
required separation of the [2Fe-2S] and flavin cofactors; these component spectra were
essential for accurate determinations of the MMOR redox potentials.16  Furthermore,
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pH-associated optical changes observed for MMOR could not be assigned to individual
chromophores without examining MMOR-Fd and MMOR-FAD separately.
Redox Potentials of MMOR-Fd and MMOR-FAD.  The redox potentials
measured for MMOR-Fd and MMOR-FAD match closely those reported previously for
full-length MMOR (Table 3.1).13,16  Therefore, it appears that the ferredoxin domain of
MMOR exerts no effect on the FAD midpoint potentials (or vice versa).  Because data
fitting for the MMOR domains required fewer independent parameters (two or three)
than for MMOR (four or five), the domain potentials are more precise, as reflected by
the significantly smaller standard deviations.  The FADox/sq potential for MMOR-FAD
(–172 ± 2 mV) agrees better with the value reported recently for MMOR, –176 ± 7 mV,16
than with a previous determination, –150 ± 20 mV,13 although all three potentials are
within experimental error of each other.  The method employed for the MMOR domain
and recent MMOR16 redox potential studies has several advantages, including the
avoidance of dyes that bind to the investigated proteins, simultaneous data fitting over
the entire visible region, the production of multiple potential measurements for each
experiment, and collection of all data at a single regulated temperature.  For these
reasons, the lower FADox/sq midpoint potential determined with this method is
probably more accurate.  Addition of MMOH or MMOB does not affect the MMOR-Fd
midpoint potential within experimental error.  A lag phase preceding Fd reduction was
observed in titrations including MMOH, presumably due to electron transfer to the
MMOH diiron sites mediated by the Fd domain.
Reaction of MMOR-FAD with NADH.  The following kinetic model, which
accounts for the results of stopped-flow optical experiments, is proposed for the
reduction of the FAD domain with NADH at pH 7.0 and 4 °C (Scheme 3.2).  The
chemistry for this reaction corresponds directly with the first steps of the
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MMOR–NADH reaction.11,16  In the first step, NADH binds rapidly to MMOR-FAD,
forming a Michaelis complex, MC1, with an optical spectrum identical to that of FADox.
The Kd value for this interaction is 25 ± 4 µM (Figure 3.10).  Isothermal titration
calorimetry experiments yielded a Kd of 43 ± 2 µM for NAD+ binding to FADox (Figure
3.8).  MMOR binds NADH significantly more tightly with a measured Kd value of 3.8
µM.16  This result suggests that the NADH binding site of MMOR-FAD differs from
that of the full-length MMOR.  Possibilities for this reduced NADH–FADox binding
affinity include structural or hydrogen bonding perturbations near the NADH binding
site.
A conformational change, which occurs with an observed rate constant of 350 s-1
at pH 7.0, gives rise to the FAD–NADH charge transfer interaction of intermediate
CT1.  Due to the relatively weak FADox–NADH binding (Kd = 25 µM), a 30-fold excess
of NADH is required to approach the 350 s-1 limit for CT1 formation.  Because many
experiments were performed with only a 10-fold excess of NADH, the observed rate
constant for this step was typically 290 ± 20 s-1 (Figure 3.9).  In the MMOR–NADH
reaction, CT1 formation proceeds at the same rate (k = 350 s-1 at 4 °C) with saturating
NADH.16
Hydride transfer from NADH to FAD produces the CT2 intermediate with a
rate constant of 188 s-1.  This species is characterized by a FADH––NAD+ charge transfer
band that is more intense and lower in energy than the FAD–NADH charge transfer
band of CT1.  Release of NAD+, yielding the hydroquinone form of MMOR-FAD,
occurs with a rate constant of 89 s-1.  The rate constants for the corresponding steps of
the MMOR–NADH reaction, 190 s-1 and 90 s-1, respectively, are nearly identical.16  It
appears that, once NADH binds to MMOR-FAD, the electron transfer steps proceed
exactly as reported for MMOR.  In full-length MMOR, CT2 decay is accompanied by
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electron transfer from the reduced flavin cofactor to the [2Fe-2S] cluster, generating a
species, SQ, comprising mainly FADsq and Fdred.11,16  Electron transfer between the two
MMOR cofactors occurs with a rate constant of 130 s-1, as measured in a pH jump
experiment.16  Based on this result, it was proposed that the slower electron transfer
rate constant (90 s-1) observed in the MMOR–NADH reaction is limited by the rate of
NAD+ release.  The CT2 decay rate constant reported here for the isolated NAD+
release step in MMOR-FAD (89 s-1) supports this theory.
Influence of pH on MMOR-FAD Spectral, Redox, and Kinetic Properties. The
UV-visible spectra of FADox, FADsq, and FADhq species all exhibit pH-dependent
changes, as depicted in Figure 3.5, with pKa values of 6.55 ± 0.05, > 9, and 7.1 ± 0.2,
respectively.  As observed by extinction coefficient increases around 300 nm and
decreases above 500 nm at high pH, the FADsq optical transition represents
deprotonation of the blue neutral semiquinone to form a red species characteristic of
anionic flavin semiquinone (Scheme 3.1).  The macroscopic pKa values observed for the
FADox and FADhq chromophores are most likely associated with protonatable groups
near or hydrogen bonded to the flavin isoalloxazine moiety rather than direct
protonation of the flavin itself.  Protonation of protein-bound flavins in the
hydroquinone oxidation state typically occurs with a pKa below 6,36 so the pKa of 7.1
noted for the FADhq optical spectrum probably corresponds to a different protonation
event.
Equilibrium reductive titrations of MMOR-FAD at varying pH show that ∆E°
(FADox/sq – FADsq/hq) is maximized near pH 7.0 (Figure 3.7B).  Above or below this pH,
the difference in potentials is diminished.  By correcting for the flavin redox equilibria-
linked ∆E contributions, a protein-dependent pKa of 6.8 ± 0.1 for the MMOR-FAD ∆E°
values is revealed (Figure 3.7D).  This pKa value may reflect the combined effects of the
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two protein-associated pKa values (6.6 and 7.1) determined for the MMOR-FAD optical
spectra and CT1 formation rate constant (vide infra).  Because the measured ∆E° values
reflect the difference between FADox/sq and FADsq/hq, either or both potentials may be
affected by protonation of the protein environment.  The corresponding MMOR ∆E°
values exhibit a similar trend, with reported pKa values of 6.6 ± 0.5 and 7.6 ± 0.9.16
Analyzing the MMOR ∆E° vs pH data (Figure 8 in ref 16) in the same manner
described here for MMOR-FAD yields a single pKa of 6.5 ± 0.2 for ∆E° variation.37
Kinetic studies of the MMOR-FAD reduction with NADH at varying pH values
revealed several interesting pH-dependent features of this reaction.  The CT1 formation
rate constant, k1 in Scheme 3.2, increases at low pH and possibly also at high pH.  In
addition, the CT1 decay/CT2 formation rate constant exhibits a similar, but less
pronounced, variation with pH.  The k1 data could be fit as either one (pKa = 6.2 ± 0.1)
or two (pKa = 6.61 ± 0.07 and 7.09 ± 0.08) pH-dependent processes (Figure 3.11A).
Compared to the single-pKa model, the two-pKa model generates a better fit to the k1
versus pH data and is therefore favored.  In support of this assignment, the pKa values
calculated for this fit exactly match those determined for pH-dependent changes in the
FADox (pKa = 6.55 ± 0.05) and FADhq (pKa = 7.1 ± 0.2) optical spectra.  Formation of the
CT1 intermediate is presumed to represent a conformational change that orients the
pyridine nucleotide and flavin isoalloxazine groups for efficient electron transfer, as
indicated by the appearance of a FAD–NADH charge transfer band.  Such a
conformational reorganization step could easily be influenced by protonatable amino
acid side chains hydrogen bonded to or in the vicinity of the prosthetic groups.  The
nature of these processes may be clarified when the structure of MMOR-FAD is
available.  At pH < 6, the k1 value for the MMOR-FAD reaction with NADH reaches the
value reported for this step (350 s-1) in the corresponding MMOR reaction.16  The amino
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acid side chain responsible for the k1 variation in MMOR-FAD may be protected from
deprotonation or have an altered pKa in MMOR.  Alternatively, a more extensive
hydrogen bonding network in MMOR, including contacts between the Fd and FAD
domains, may make this residue less relevant for orienting the cofactors in MMOR.
The weaker binding of NADH to MMOR-FAD compared to MMOR (25 µM vs 3.8 µM)
may also arise from a slightly perturbed hydrogen bonding network in the NADH
binding cavity, possibly due to the same side chain that affects the CT1 formation rate
constant.  In fact, the variation in k1 with pH may simply reflect differences in NADH
binding affinity such that the NADH binding site is saturated only at low pH.
Spectra corresponding to the kinetic intermediates observed in the MMOR-FAD
reaction with NADH were resolved by global analysis of diode array stopped-flow
data.  Over the pH range 5.5-8.5, the CT1 spectrum is unchanged; the CT2 intermediate,
however, undergoes significant optical changes that reflect a pKa of 6.0 ± 0.1 (Figures
3.11B and 3.11C).  At pH 5.5, the CT2 optical spectrum closely resembles the CT1
intermediate, particularly at l > 530 nm.  The charge transfer bands for these two
species are essentially indistinguishable.  This phenomenon arises from protonation at
flavin position N1 of anionic FADhq (FADH–) to form FADH2 (Scheme 3.1).  The charge
transfer interaction between neutral FADH2 and NAD+ is significantly weaker than that
between FADH– and NAD+ but quite similar to the FAD–NADH charge transfer
interaction of CT1.  The measured FADhq pKa for MMOR-FAD is within the range of
values determined by NMR for N1 protonation in other flavoproteins.36  A similar pKa
of 6.2 ± 0.1 was attributed to protonation of the flavin N1 site in MMOR.16
The pKa values of ~6.5 and 6.8 noted for the FADox optical spectrum and ∆E°
values, respectively, may correspond to one or more carboxylate groups near the N1
and/or N3 position(s) of the flavin isoalloxazine ring system.  Similar pKa values have
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been attributed to carboxylate moieties near the flavin cofactors of other
flavoproteins.38,39  Deprotonation of the carboxylate(s) would destabilize the anionic
FADhq, thereby decreasing the FADsq/hq potential and increasing ∆E° at high pH, as
observed for MMOR-FAD.  In flavodoxin, neutralization of individual acidic residues
via amide substitution does not eliminate the redox-linked pKa observed for the flavin
semiquinone/hydroquinone redox potential.40,41  Increasing numbers of acid-to-amide
flavodoxin mutations, however, increase this potential in an additive manner, with
average contributions of about 15 mV per substitution.42  Moreover, the pH
dependence of the semiquinone/hydroquinone potential decreases progressively with
the number of charge neutralizations.40  Thus, for flavodoxin, modulation of this redox
potential appears to be controlled by the collective effect of multiple acidic residues
surrounding the flavin cofactor.40,41  The pKa values determined for MMOR-FAD may
also be macroscopic quantities that reflect multiple protonation events with similar
microscopic pKa values.
The MMOR-FADhq pKa of 6.0 is higher than that observed in many
flavoproteins, most of which exhibit a pKa < 5 for the hydroquinone oxidation state.36
Placement of a negative electrostatic field near the flavin cofactor could contribute to
this phenomenon by destabilizing the anionic hydroquinone species (Scheme 3.1).  In
addition, removing a negative charge from this position in the flavodoxin E60Q mutant
produces an optical change for the oxidized protein39 very similar to that observed for
FADox at low pH, where the putative charge(s) would be neutralized by protonation.
The pKa of 7.1 observed for the FADhq optical spectrum might even correspond to the
same carboxylate group(s); the presence of a negative charge on the flavin would be
expected to increase the pKa of nearby carboxylate groups, as suggested for
flavodoxin.38
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By comparing the preliminary MMOR-FAD NMR structure and the structures
of homologous proteins, including PDR,19 Alcaligenes eutrophus flavohemoglobin,43 and
Azotobacter vinelandii NADPH:ferredoxin reductase,44 candidates for the negatively
charged MMOR-FAD residue(s) were identified as Asp52, Glu85, and Asp90.  In the
other flavoproteins, these non-conserved residues are in or near homologous sequences
having atoms ≤ 7 Å from the isoalloxazine N1, N3, or N5 positions.  Subsequent
analysis of the nearly completed MMOR-FAD NMR structure45 revealed three
carboxylate side chains within 10 Å of the FAD cofactor:  Glu243 (4.5-5.0 Å), Asp52
(5.0-5.5 Å), and Asp59 (7.5-10.0 Å).  The Glu243 and Asp52 residues are completely
conserved in sMMO reductases, whereas Asp59 is replaced by His or Thr in other
MMOR proteins.  Addition/removal of other charges near the flavin cofactor, or a
conformational change that alters hydrogen bonding or solvent accessibility to the
isoalloxazine ring system, may also contribute to the pH dependence observed for the
MMOR-FAD optical spectra and redox potentials.39,46-49  More definitive assignment of
the pKa effects to specific protein residues awaits completion of the MMOR-FAD
structure and site-directed mutagenesis studies.
Interdomain Electron Transfer.  Electron transfer from MMOR-FADhq to either
Fdox or MMOR-FADox occurs on a very slow time scale (k = 1500 M-1 s-1 at 25 °C and 100
M-1 s-1 at 4 °C, respectively).  It is particularly interesting to compare the interdomain
electron transfer rates for the separated domains with the corresponding step in
MMOR reduction with NADH (k = 90 s-1 at 4 °C).16  Presumably, the [2Fe-2S] and flavin
cofactors in MMOR are positioned in an orientation amenable to electron transfer with
minimal structural reorganization.  The large effective rate decrease (at 25 °C) for the
noncovalently linked domains suggests that cofactor proximity is extremely important
for efficient electron transfer in MMOR.
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In FNR (Figure 3.1), a flavoprotein electron transferase protein with a
dissociable one-electron carrier, ferredoxin, transient noncovalent complexes between
the flavin and [2Fe-2S] proteins afford relatively fast electron transfer (k ≈ 1500-7000
s-1)19 between cofactors.  The X-ray structure of a complex between maize leaf
ferredoxin and FNR reveals an intermolecular interface comprising mainly electrostatic
interactions in the form of salt bridges and a hydrophobic region between the
cofactors.50  Precomplexing MMOR-Fd and MMOR-FAD before reduction with NADH
did not significantly increase the observed interdomain electron transfer rates.  This
result implies that, unlike the ferredoxin:FNR system, the separated MMOR domains
do not form a specific complex or that the complex that forms is unsuitable for efficient
electron transfer.  For full-length MMOR, in which the Fd and FAD domains are
covalently tethered, high-affinity interdomain interactions are apparently unnecessary.
Therefore, it appears that proximity rather than affinity facilitates interdomain electron
transfer in MMOR.
Conclusions.  This work demonstrates that the modular structure of MMOR can
be exploited to simplify and extend characterization of a complex protein.  Except for
interdomain electron transfer, the separated MMOR-Fd and MMOR-FAD proteins
retain essentially identical biochemical properties to the corresponding domains in
MMOR.  In simplifying a complicated system, these domains have already proved
valuable for characterizing the structure and intramolecular electron transfer
properties of the full-length reductase.16,34  By examining electron transfer to MMOH
from both MMOR and MMOR-Fd, elucidation of the carefully orchestrated
intermolecular electron transfer steps in the sMMO catalytic cycle will be possible.
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Table 3.1:  Properties of MMOR-Fd, MMOR-FAD, and MMOR
MMOR-Fd MMOR-FAD MMOR
MW measured (Da) 10,929.0 a ± 1.1 27,629.0 b ± 2.4 38,546.9 ± 3.9 c
e458 (M-1 cm-1), pH 7.0, 25 °C 9550 ± 200 11,000 ± 500 20,800 ± 1000 d
lmax (nm), pH 7.0, 25 °C 332, 418, 467 394, 458 332, 394, 458 c
Fe–Fe (Å, fully reduced) 2.73 n/a 2.74
Fe–S (Å, fully reduced) 2.29 n/a 2.29
g values (fully reduced) e 2.049, 1.958, 1.888 n/a 2.047, 1.958, 1.871
g values (maximum FADsq) n/a 2.004 f 2.005 g
FADox/sq (mV), pH 7.0, 25 °C n/a –172.4 ± 2.0 –176 ± 7 c
[2Fe-2S]ox/red (mV), pH 7.0, 25 °C –205.2 ± 1.3 n/a –209 ± 14 c
FADsq/hq (mV), pH 7.0, 25 °C n/a –266.4 ± 3.5 –266 ± 15 c
a%Expected 10,931.3 Da for apoprotein with N-terminal methionine intact.  b%Expected 27,628.3 Da for
apoprotein with N-terminal methionine cleaved.  c%As reported in ref 16.  d%As reported in ref 11.  e%EPR
recorded at 10 K, 500 µW at 9.478 GHz, 10.0-G modulation amplitude.  f%EPR recorded at 100 K, 32 µW at
9.478 GHz, 2.0-G modulation amplitude.  g%EPR recorded at 100 K, 127 µW at 9.482 GHz, 2.0-G
modulation amplitude.
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Scheme 3.2
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Figure 3.1.  Examples of alternative connectivities between the one-electron carrier and
flavin/NAD(P) binding domains of flavoprotein electron transferases.
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Figure 3.2.  Microwave progressive power saturation data for MMOR-FADsq,max
(squares) and MMORsq,max (circles) collected at 100 K, 9.48 GHz, 2.0-G modulation
amplitude.  The dotted lines are least-squares fits to the equation, S’/P1/2 = K/[1 +
(P/P1/2)]b/2, where S’ is the EPR derivative signal amplitude, P is the microwave power,
K  is a constant, P 1/2 is the microwave power at half-saturation, and b  is the
inhomogeneity parameter, as described in ref 28.  Compared to MMOR-FADsq,max, the
MMORsq,max sample requires higher power to saturate the EPR signal.
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Figure 3.3.  Optical spectra at pH 7.0 of MMOR-Fd (circles) and MMOR-FAD (squares)
in the fully oxidized (closed symbols and solid lines) and fully reduced (open symbols
and dotted lines) oxidation states.  The sum of the two oxidized domain spectra
(dashed line) is superimposed on the MMOR optical spectrum (triangles).
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Figure 3.4.  Determination of the FADsq optical spectrum at pH 7.0.  (A) Selected
spectra from an anaerobic reductive titration of 91 µM MMOR-FAD with ~2 mM
dithionite at 25 °C.  (B) Component spectra, which correspond to the FADox (squares),
FADsq (triangles), and FADhq (circles) oxidation states, derived from evolving factor
analysis of the titration data.
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Figure 3.5.  Effect of pH on the MMOR-FAD optical spectra.  (A) FADox (squares),
FADsq (triangles), and FADhq (circles) component spectra determined at pH 6 (solid
lines) and pH 9 (dashed lines).  (B) FADox absorbance at 450 (circles) and 500 nm
(squares) as a function of pH.  (C) Variation of FADhq absorbance at 382 (circles) and
490 nm (squares) with pH.  Solid lines in panels B and C are fits to eqs 2 and 3.
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Figure 3.6.  Difference spectra for the reductive titration of a 1-mL mixture of 30 µM
MMOR-FAD and 11 µM phenosafranine by dithionite at pH 7.0 and 25 °C.  Spectra 1-7
correspond to the addition of 20, 30, 40, 50, 70, 90, and 110 µL of ~2 mM dithionite,
respectively.  Fits (dashed lines) are superimposed on the difference spectra.
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Figure 3.7.  pH dependence of the relative redox potentials of MMOR-FAD.  (A)
MMOR-FAD reductive titration data obtained at pH 8.5 with fits (solid lines)
determined by using eqs 5-8:  FADox (squares), FADsq (triangles), and FADhq (circles).
(B) Variation of the difference between the two MMOR-FAD redox potentials with pH.
(C) Theoretical curves reflecting the pH dependence of FADox/sq (dotted line), FADsq/hq
(dashed line), and ∆E (FADox/sq – FADsq/hq; solid line) due to the inclusion of protons in
some of the redox equilibria (Scheme 3.1).  FADhq and FADsq pKa values of 6.0 and 9.6,
respectively, are shown.  (D) pH dependence of ∆E° values after subtracting redox
equilibria-related effects (panel C).  The solid line represents a fit to eq 3.
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Figure 3.8.  Determination of MMOR-FADox–NAD+ binding constant by isothermal
titration calorimetry.  (A) Data recorded for the complex formation between
MMOR-FADox (43 µM in the calorimeter cell) and NAD+ (1.89 mM in a 250-µL injection
syringe) at 4.2 °C.  Each heat pulse corresponds to a 10-µL injection into the 1.430-mL
sample cell.  (B) Integrated enthalpy data (circles) fit with a one-site binding model
(solid line).
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Figure 3.9.  Kinetics of MMOR-FAD reduction with NADH.  (A) Spectra recorded at
~3-ms intervals by diode array stopped-flow spectroscopy in the first 67 ms after
mixing 25 µM FADox with 250 µM NADH at 4 °C and pH 7.0.  (B) Spectra of
intermediates resolved by global analysis of the diode array kinetic data:  FADox
(squares), CT1 (triangles), CT2 (circles), and FADhq (diamonds).  (C) Time-dependent
absorbance changes at 625 (lower trace) and 725 nm for this reaction.  For clarity, the
725-nm trace was offset by 0.02 AU.  Dashed lines represent fits to the data.
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Figure 3.10.  Dependence of the CT1 formation rate constant, k1, on NADH
concentration for the reduction of MMOR-FAD with NADH at 4 °C and pH 7.0.  The
solid line represents a hyperbolic fit to the data.
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Figure 3.11.  Influence of pH on the reaction of MMOR-FAD with NADH at 4 °C.  (A)
Variation of k1 (CT1 formation, circles) and k2 (CT2 formation, squares) with pH.  Solid
lines are fits of the type defined in eqs 2 and 3.  (B) CT2 spectra determined at pH
values of 7.77 (squares), 7.00 (triangles), 6.29 (circles), and 5.47 (diamonds).  (C) CT2
extinction coefficients at 470 (closed circles) and 700 nm (open squares) with respect to
pH.  Solid lines are fits to eqs 2 and 3.
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Figure 3.12.  Electron transfer from MMOR-FADhq to Fdox or MMOR-FADox.  (A) Diode
array spectra collected on a log time scale during the first 380 s after mixing 30 µM
MMOR-FADhq and 30 µM Fdox at 25 °C and pH 7.0.  (B) Diode array spectra collected
on a log time scale during the first 380 s after mixing 30 µM MMOR-FADhq and 30 µM
MMOR-FADox at 4 °C and pH 7.0.  Second-order rate constants were determined by
fitting the data with second-order kinetic models in Specfit.
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Chapter 4
Intermolecular Electron Transfer Reactions in Soluble Methane Monooxygenase
from Methylococcus capsulatus (Bath):  A Role for Hysteresis in Protein Function
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INTRODUCTION
Long-range electron transfer is an essential process in many physiological
pathways, including respiration, photosynthesis, and intermediary metabolism.1
Biological electron transfer reactions often proceed via bimolecular interactions
between donor and acceptor proteins containing redox-active prosthetic groups.  In
order to achieve efficient interprotein electron transfer, steps such as specific
protein–protein binding, conformational rearrangements, and chemical
transformations may be required.2,3  A common strategy in bacterial mono- and
dioxygenase systems is separation of the reductase and oxygenase functionalities into
individual protein components.4  In this manner, the rate of electron transfer to the
oxygenase active site can be finely controlled by intricate intermolecular interactions.
In addition, the reductant can be physically separated from being consumed by active
oxygen species generated in the oxygenase component.
Among the best-studied of these multicomponent oxygenase systems is soluble
methane monooxygenase (sMMO), which catalyzes the selective oxidation of methane
to methanol at ambient temperature and pressure (eq 1).5,6  By using methane as their
CH4 + NADH + H+ + O2  ›  CH3OH + NAD+ + H2O (1)
primary source of carbon and energy, methanotrophs significantly reduce the amount
of this potent greenhouse gas that reaches the atmosphere.7  All methanotrophic
bacteria can express a copper-containing membrane-bound MMO (pMMO),8-10 whereas
the sMMO system is used by only a few species under copper-limited conditions.11  The
relative ease of purifying and stabilizing the sMMO proteins has facilitated detailed
reactivity, spectroscopic, structural, kinetic, and theoretical studies of these enzymes
from Methylococcus capsulatus (Bath) and Methylosinus trichosporium OB3b.12-15
145
Both sMMO systems comprise three proteins that are required for optimal
catalysis,16-18 a hydroxylase (MMOH, 251 kDa), a reductase (MMOR, 38.5 kDa), and a
regulatory protein (MMOB, 15.9 kDa).  The inclusion of a fourth protein (MMOD) in
the M. capsulatus (Bath) sMMO system was demonstrated recently.19  MMOH, a
dimeric (abg)2 protein, houses in its a subunits carboxylate-bridged non-heme diiron
sites where dioxygen activation and substrate hydroxylation occur.  MMOR is an iron-
sulfur flavoprotein that shuttles electrons from NADH to the hydroxylase to prime the
enzyme system for reaction with dioxygen.  A [2Fe-2S] cluster is located in the N-
terminal reductase domain, which exhibits sequence homology with ferredoxins of
plants, cyanobacteria, and archaebacteria.20  To begin the series of electron transfer
reactions necessary for steady-state sMMO turnover (Scheme 4.1), the flavin adenine
dinucleotide (FAD) cofactor bound to the C-terminal portion of MMOR accepts two
electrons from NADH.  Electrons are then transmitted sequentially from the reduced
flavin through the one-electron carrier [2Fe-2S] center to the diiron(III) hydroxylase
active sites.18,21-23  After reduction by MMOR, a complex formed between the diiron(II)
state of MMOH, Hred, and MMOB reacts with dioxygen to generate a series of
oxygenated high-valent diiron intermediates.24-27  The final transient species
hydroxylates methane, producing methanol and water and returning the hydroxylase
to the resting, diiron(III) state.  To complete the cycle, the MMOH diiron centers are
reduced by MMOR and methanol is discharged from the active site.  Interactions
between the three sMMO components modulate the rates, efficiency, and substrate
regioselectivity of the reaction.18,25,28-30
MMOR is a member of a class of modular electron transferases, also called the
ferredoxin:NADP+ oxidoreductase (FNR) family.  These proteins are distinguished by a
core flavin domain that transports electrons between a nicotinamide dinucleotide and a
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one-electron carrier domain, which may be either linked or dissociable (Figure
4.1A).31-33  Distinct flavin mononucleotide (FMN), NADH binding, and [2Fe-2S]
domains are revealed in the crystal structure of Burkholderia cepacia phthalate
dioxygenase reductase (PDR), demonstrating the structural and functional modularity
of FNR proteins.33  In order to simplify and extend the characterization of MMOR, the
ferredoxin (MMOR-Fd, referred to hereafter as MMOR-Fd(1-98)) and FAD/NADH
(MMOR-FAD) domains were expressed as separate proteins.34  Except for interdomain
electron transfer, the reductase domain proteins exhibit redox, spectroscopic, and
kinetic properties nearly identical to those of full-length MMOR.34  In addition, NMR
studies of MMOR-Fd(1-98)35 and MMOR-FAD36 show that the separated domains
adopt compact structures in solution with folds similar to homologous FNR proteins.
Previous studies of intermolecular electron transfer in the sMMO system
allowed pre-formed MMOR–MMOH or MMOR–MMOH–MMOB complexes to react
with NADH and monitored absorbance changes associated with multiple intra- and
intermolecular kinetic steps.18  In the present work, reactions were conducted by
rapidly mixing chemically reduced MMOR with oxidized MMOH, thereby affording
direct observation of intermolecular electron transfer events while avoiding the
complicating kinetics of the reductive half reaction of MMOR.  Three MMOR-Fd
analogs (Figure 4.1B) were also investigated to explore the features that modulate the
inaugural electron transfer to the hydroxylase.  Mechanisms for the intermolecular
electron transfer reaction and roles for MMOB and MMOD in regulating the rate and
extent of electron transfer are presented.
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MATERIALS AND METHODS
Protein Purification.  MMOH was isolated from M. capsulatus (Bath) cell paste
by following a published protocol.18  Pure hydroxylase contained 3.8-4.0 mol Fe per
mol protein, as determined by ferrozine iron assays,37,38 and exhibited specific activities
of 250-350 nmol min-1 mg-1 of MMOH for the conversion of propylene to propylene
oxide at 45 °C.  MMOR,23 MMOR-Fd(1-98),34 and MMOD19 were expressed in
recombinant Escherichia coli systems and purified as previously reported.  FAD-
depleted reductase, MMOR(apoFAD), was separated from MMOR by Sepharose 5’-
AMP affinity chromatography.
Recombinant MMOB was expressed in E. coli as described39 and purified by
using a modified protocol.  Cells from eight 1-L JM105/pWWBg cultures were
suspended in 100 mL of cracking buffer [25 mM 3-(N-morpholino)propanesulfonic acid
(MOPS; pH 7.0), 1 mM 1,4-dithiothreitol (DTT), 75 mM NaCl, and 5 mM MgCl2]
containing DNase (1.5 units/mL), 1 mM Pefabloc SC (Roche Molecular Biochemicals,
Indianapolis, IN), and 1 mM phenylmethylsulfonyl fluoride (PMSF).  The cell
suspension was sonicated on ice at 40% maximum output (Branson Sonifier Model 450
equipped with a 3/4-inch horn) with three 2-min pulses, which were spaced at 5-min
intervals to prevent overheating.  The lysed cells were centrifuged at 98,000g for 40 min
in order to separate the soluble and insoluble materials.  The soluble portion was
decanted immediately, filtered through 0.2 µm membranes, and applied to a DEAE
Sepharose CL-6B (Amersham Pharmacia Biotech, Piscataway, NJ) column (2.6 ¥ 15 cm)
equilibrated in buffer A [25 mM MOPS (pH 7.0), 1 mM DTT, 1 mM
ethylenediaminetetraacetic acid (EDTA), and 75 mM NaCl].  Following a 100-mL wash
with buffer A, proteins were eluted with a 750-mL linear gradient from buffer A to
buffer B [25 mM MOPS (pH 7.0), 1 mM DTT, 1 mM EDTA, and 350 mM NaCl].
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Fractions containing MMOB were identified by SDS-PAGE, pooled with additional
Pefabloc SC (ca. 1 mM), and concentrated to 4 mL by ultrafiltration.  This crude MMOB
solution was resolved on a Superdex 75 (Amersham Pharmacia) size-exclusion column
(2.6 ¥ 60 cm) equilibrated in buffer A.  Pure MMOB was pooled based on SDS-PAGE
analysis, concentrated by ultrafiltration, and stored at –80 °C.
Construction and Purification of the MMOR-Fd(1-120+tail) Fragment.  In an
attempt to correct by site-directed mutagenesis a Taq DNA polymerase-introduced
mutation (T123I) in the original MMOR expression vector, a one-base deletion was
inadvertently introduced in the reductase gene.  In pRED-C1, the error produced a tail
of 19 frame-shifted amino acids (ATPSSFFCRSGPTSAATVA) following codon 120
which was terminated by an out-of-frame stop codon; thus, only the ferredoxin portion
of MMOR (calculated MW, 15.0 kDa) was expressed.  Expression and anion exchange
chromatography were performed exactly as described for recombinant
MMOR-Fd(1-98).34  The MMOR-Fd(1-120+tail) protein was highly purified (> 95%) by
resolution on a DEAE Sepharose CL-6B column.  The Fd fragment eluted from the
column at about 350 mM NaCl; fractions were identified by SDS-PAGE analysis and by
the characteristic plant-type ferredoxin absorbance spectrum in the 300-700 nm region.
An extinction coefficient (e458 = 9300 M-1 cm-1) was estimated for MMOR-Fd(1-120+tail)
by determining the iron content with ferrozine assays and assuming a full complement
of two iron atoms per protein molecule.
Isothermal Titration Calorimetry.  The binding affinity of the MMOH–
MMOR-Fd(1-98) complex was measured with a VP-ITC isothermal titration calorimeter
(MicroCal, Inc., Northampton, MA).  All titrations were performed at 4.2 °C in 25 mM
MOPS (pH 7.0), 2 mM tri(2-carboxyethyl)phosphine hydrochloride (TCEP; Sigma, St.
Louis, MO).  Titrant (368 µM MMOR-Fd(1-98)) was injected in 10-µL aliquots from a
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250-µL stirred titration syringe into the 1.430-mL sample cell containing 11.1 µM
MMOH.  Stirring was maintained at 310 rpm throughout the titration.  The experiment
was repeated with buffer in the sample cell in order to measure the heat of dilution for
MMOR-Fd(1-98).  Data were integrated and fit with the MicroCal Origin v. 5.0 software
package.
Kinetic Measurements of Intermolecular Electron Transfer.  Intermolecular
electron transfer in the sMMO system was examined by stopped-flow optical
spectroscopy. A Hi-Tech Scientific SF-61 DX2 double-mixing stopped-flow
spectrophotometer configured for either single-wavelength photomultiplier or multi-
wavelength diode-array collection was used for all experiments.  To make the stopped-
flow apparatus anaerobic, the syringes and flow cell were flushed first with a solution
of ca. 5 mM sodium dithionite and then with anaerobic buffer.  Proteins were
exchanged into either 25 mM MOPS (pH 7.0), 1 mM DTT (initial studies) or 25 mM
MOPS (pH 7.0) with Biogel P6 desalting columns (Bio-Rad, Hercules, CA).  A solution
of oxidized MMOR, MMOR-Fd(1-98), MMOR-Fd(1-120+tail), or MMOR(apoFAD) in a
sealed quartz cuvette was made anaerobic by 12 cycles of vacuum gas exchange with
O2-free N2.  Aliquots (5 µL) of 2-5 mM sodium dithionite were added with a gas-tight
Hamilton titrating syringe.  After each addition, optical spectra were recorded until no
further changes were observed (typically less than 2 min).  This process was repeated
until the protein was reduced completely.  Anaerobic MMOH solutions were prepared
by 10-12 cycles of vacuum gas exchange with nitrogen.  Concentrations of MMOH
were 10 µM after mixing; reductase or ferredoxin concentrations were 20 µM, except
where noted.  The reaction of reduced MMOR or MMOR-Fd with oxidized MMOH
was monitored at 470 nm (both MMOR and MMOR-Fd) and 625 nm (MMOR only) in
single-wavelength photomultiplier mode.  Data points (512 or 640) were collected on a
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logarithmic time scale (1 to 500 s, depending on the reaction).  The experiment was
repeated with the stopped-flow apparatus in multi-wavelength diode array mode.  For
each shot (2 to 800 s), 160 spectra (380-800 nm) were recorded; during data sets that
required long collection times, an anti-bleaching shutter apparatus was employed.  The
temperature was maintained at 4 °C with a constant temperature circulating water bath
for all experiments, except where noted.  The effects of MMOB and MMOD on
intermolecular electron transfer were investigated by including these proteins in the
same syringe as oxidized hydroxylase.  In some initial studies, MMOB was included
with reduced MMOR or MMOR(apoFAD).
Single-wavelength absorbance data were fit to a sum of two (MMOR-Fd and
MMOR(apoFAD)) or four (MMOR) exponentials with the program KinetAsyst (v. 2.2
or 3.04, Hi-Tech Limited, Salisbury, England).  Rate constants and intermediate spectra
were extracted from diode array data by using the global analysis routines resident in
the Specfit software suite (v. 2.10U or 3.0.16; Spectrum Software Associates, Chapel
Hill, NC).  Compositions of intermediate spectra were calculated by fitting with linear
combinations of [2Fe-2S] and FAD component spectra (Figure 4.2)34 in KaleidaGraph
(v. 3.0 or 3.6, Synergy Software, Reading, PA).
RESULTS
MMOR Domain Separation.  Fortuitously, a site-directed mutagenesis reaction
inadvertently yielded the truncated reductase, MMOR-Fd(1-120+tail), a 15-kDa protein
comprising only the [2Fe-2S] domain of full-length MMOR (Figure 4.1B).  This
serendipitous ferredoxin fragment was competent for electron transfer to MMOH,
demonstrating that the MMOR [2Fe-2S] domain can function as an independent
modular unit.  Because this truncated protein was expressed only in low yield (3 mg/L
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of E. coli culture), we cloned the MMOR-Fd(1-98) domain in part to aid characterization
of intermolecular electron transfer from MMOR to MMOH.34  FAD-depleted MMOR,
MMOR(apoFAD), was also employed to study the initial events in the MMOR–MMOH
electron transfer reaction.
Measurement of MMOH–MMOR-Fd(1-98) Binding Affinity.  The affinity of
oxidized MMOR-Fd(1-98) for oxidized MMOH was determined by isothermal titration
calorimetry.  Figure 4.3A shows the power required to compensate for the exothermic
binding reaction after each addition of titrant to the sample cell.  The incremental heat
change for each injection was calculated by integrating the heat pulses with respect to
time.  A plot of these data as a function of the MMOR-Fd(1-98)/MMOH molar ratio is
presented in Figure 4.3B.  Preliminary fitting of the enthalpy data with a non-
interacting binding sites model in the Origin software suggested that only ca. 70% of
the hydroxylase participated in binding MMOR-Fd(1-98).  The same phenomenon was
observed previously for full-length MMOR and MMOB interactions with MMOH.18
After correcting the MMOH concentration for the nonbinding fraction, a two-site
sequential (interacting sites) model was used to obtain an excellent fit to the enthalpy
data (solid line in Figure 4.3B).  Thermodynamic parameters for the binding reaction
are given in Table 4.1.
Protein Concentration Dependence of Intermolecular Electron Transfer.
Protein–protein binding and structural reorganization are prerequisites of efficient
intermolecular electron transfer reactions.  The possibility that the kinetics of protein
complex formation might affect electron transfer reactions between sMMO components
was investigated by reacting various concentrations of chemically reduced
MMOR-Fd(1-98) with oxidized MMOH in the stopped-flow instrument at 4 °C (Figure
4.4A).  The kinetic traces could not be fit well with single exponential expressions;
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using two exponential decays yielded high-quality fits to the data.  As shown in Figure
4.4B, there is no significant effect of MMOR-Fd concentration on the observed rates of
intermolecular electron transfer.  Examination of the preexponential factors returned
from data fitting showed that partitioning of electrons between the “fast” (1.0 s-1) and
“slow” (0.26 s-1) reaction phases is altered by the concentration of MMOR-Fd (Figure
4.4C).  Similar results were obtained for full-length MMOR (data not shown).
Intermolecular Electron Transfer from Ferredoxin Analogs to MMOH.
Because the [2Fe-2S] cofactor of MMOR is a one-electron carrier, the ferredoxin center
must transfer two electrons sequentially to MMOH to reduce fully each diiron(III)
hydroxylase active site.  Several MMOR analogs lacking the FAD cofactor (Figure 4.1B)
were implemented to observe the kinetics of the inaugural electron transfer from the
ferredoxin domain to MMOH uncomplicated by the flavin moiety of the full-length
reductase.  All three ferredoxin proteins transferred electrons to the hydroxylase in a
biphasic manner with varying rate constants (Table 4.2; see Discussion section for
reaction schemes).  The temperature dependence of these electron transfer reactions
was investigated for MMOR-Fd(1-98), MMOR-Fd(1-120+tail), and MMOR(apoFAD),
and activation energies were calculated with Arrhenius plots (Figures 4.5A and 4.5B,
Table 4.3).  For MMOR-Fd(1-98), the fractions of the total absorbance change associated
with the rapid and slow pathways vary slightly with temperature (Figure 4.5C).
Analysis using electron transfer theory expressions1 was performed by fitting
temperature-dependence data to eqs 2 and 3 (Figure 4.5D and Table 4.4), where h is
(2)
(3)
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Planck’s constant, R is the gas constant, T is temperature, k0 is the characteristic
frequency of the nuclei, usually assigned a value of 1013 s-1, and r0 is the close contact
distance, generally set to 3.0 Å.  HAB is the electronic coupling between redox centers, l
is the reorganizational energy, and r is the distance between the donor and acceptor
sites.  A value of 1.4 Å-1 was used for b,40 a global parameter related to the nature of the
medium between electron transfer partners.
Spectra from the global analysis of diode array data for the reaction of 20 µM
MMOR-Fd(1-98) with 10 µM MMOH at 4 °C are shown in Figure 4.6A.  Rate constants
of k1 = 1.0 ± 0.1 s-1 and k2 = 0.28 ± 0.02 s-1 were determined to give the best fit through
the biphasic data.  The composition of each intermediate was calculated by fitting the
spectra with linear combinations of the oxidized and reduced MMOR-Fd component
spectra (Figure 4.2).34  In the first electron transfer phase, the hydroxylase was reduced
by 23% (with four-electron reduced MMOH corresponding to 100%); after the second
electron transfer phase, 35% hydroxylase reduction was realized.  Since each ferredoxin
protein can transfer only one electron to MMOH, the theoretical maximum for
hydroxylase reduction in this reaction is 50%.  At the end of the electron transfer
reaction, total MMOH reduction was generally only 30-40%, however.  This result is in
accord with other binding and kinetic data that demonstrate that a significant fraction
(20-40%) of MMOH does not bind MMOB and MMOR.18  Therefore, if the nonbinding
portion of MMOH is taken into account, full reduction of the active MMOH fraction
was achieved.  This experiment was repeated for MMOR(apoFAD) (Table 4.5).
Effect of MMOB on Intermolecular Electron Transfer from Ferredoxins.
Reactions that included MMOB in the same syringe as MMOH (2 mol MMOB per mol
MMOH) exhibited the same biphasic behavior observed in the absence of MMOB.  For
MMOR-Fd(1-98), the two intermolecular electron transfer reactions occur with rate
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constants of k1 = 1.1 ± 0.2 s-1 and k2 = 0.056 ± 0.005 s-1 (Figure 4.6B).  The extent of
hydroxylase reduction after each stage of this reaction was 5% and 34%, respectively.
Thus, the majority (ca. 85%) of electrons were transferred during the slow phase.  The
effect of MMOB on this reaction is therefore twofold.  First, the rate constant for the
second electron transfer phase is decreased by a factor of about five.  Moreover, the
partitioning of electrons between the rapid and slow phases is shifted significantly
toward the slow pathway.  Adding MMOB to the experiment involving
MMOR(apoFAD) yielded similar but less pronounced results.  A fivefold reduction in
the k2 value was determined for electron transfer to MMOH, but only a slight shift in
electron partitioning was noted (Table 4.5).  Time courses of MMOH reduction
measured for three MMOR ferredoxin analogs and the effects of MMOB on two of
those reactions are illustrated in Figure 4.7A.
Kinetic traces recording intermolecular electron transfer from MMOR-Fd(1-98)
to MMOH in the presence of increasing concentrations of MMOB are presented in
Figure 4.8A.  Rate constants from parallel two-exponential fits of these data are altered
significantly as a function of MMOB concentration (Figure 4.8B).  The first equivalent
of MMOB reduces the rate constant for rapid electron transfer by 50%; adding a second
equivalent of MMOB restores this rate constant to values determined in the absence of
MMOB.  The rate constant for the slow reaction phase decreases with increasing
concentrations of MMOB such that an 8- to 10-fold reduction is observed at high
[MMOB].  The extent of the fast and slow reaction phases, as measured by the
fractional contributions of preexponential factors, is also highly dependent on MMOB
concentration (Figure 4.8C).  At high MMOB concentrations, electron transfer proceeds
almost entirely through the slow pathway.  Thus, the effective electron transfer rate
decreases steadily with increasing MMOB concentration (triangles, Figure 4.8B).  The
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effect of MMOB on electron transfer from MMOR(apoFAD) to MMOH was also
examined.  With saturating MMOB, rate constants for the rapid and slow electron
transfer phases are reduced by 15% and 200%, respectively.  In the absence of MMOB,
approximately 70% of this reaction takes place at the fast rate.  Increasing the MMOB
concentration inverts the distribution so that in the presence of saturating MMOB, only
30% of the reaction occurs via the rapid pathway.
Intermolecular Electron Transfer from MMOR3e– to MMOH.  The reaction of
20 µM reduced MMOR (MMOR3e–) with 10 µM oxidized MMOH at 4 °C was studied by
diode array stopped-flow spectroscopy.  Intermediate spectra derived from globally
fitting the data with a sequential five-component model are displayed in Figure 4.9A.
Fits converged on rate constant values of k1 = 70 ± 10 s-1, k2 = 18.5 ± 1.5 s-1, k3 = 2.5 ± 1.5
s-1, and k4 = 0.11 ± 0.09 s-1.  The oxidation state of each intermediate was determined by
fitting the spectra with linear combinations of [2Fe-2S]ox, [2Fe-2S]red, FADox, FADsq, and
FADhq component spectra (dashed lines in Figure 4.9A).  A graphical representation of
the electron distribution in each intermediate species and the extent of electron transfer
to MMOH at each stage of the reaction is given in Figure 4.9B.  In the four reaction
phases, the hydroxylase diiron sites are reduced by 30%, 25%, 11%, and 11%,
respectively, for a total of 77% reduction.  After correcting for the nonparticipating
fraction of MMOH, the extent of hydroxylase reduction after each electron transfer step
was recalculated (Table 4.6).  The first two reaction phases each account for the transfer
of about 1.5 electrons to MMOH.  The final electron is passed to MMOH in two slow
steps.
Kinetic traces for the electron transfer reaction from MMOR3e– to MMOH at
varying temperature (4-37 °C) were fit with sums of two (625 nm) or four (470 nm)
exponentials (Table 4.2).  An Arrhenius plot was constructed (Figure 4.10A), and
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activation energies for the first three electron transfer steps were determined (Table
4.3).  Inspection of the preexponential factors demonstrated that electron partitioning
through the first and second reaction phases is significantly affected by temperature
(Figure 4.10B).  Comparison to temperature-induced partitioning in the
MMOR-Fd(1-98) reaction with MMOH (Figure 4.5C) reveals nearly identical trends.
Fitting the temperature dependence data to eqs 2 and 3 generated values for the
electron transfer parameters HAB, l, and r (Figures 4.10C and 4.10D; Table 4.4).
Effects of MMOB and MMOD on Electron Transfer from MMOR3e– to
MMOH.  When two equivalents of MMOB or MMOD were added to MMOH before
mixing with MMOR3e– in the stopped-flow instrument, intermolecular electron transfer
was inhibited.  Intermediate spectra obtained from global analysis of diode array data
for the reaction of 20 µM MMOR3e– with 10 µM MMOH/20 µM MMOB at 4 °C are
shown in Figure 4.11A.  Rate constants for the four electron transfer steps are only
slightly lower than those determined in the absence of MMOB (k1 = 52 ± 7 s-1, k2 = 10.5 ±
1.5 s-1, k3 = 1.5 ± 0.5 s-1, k4 = 0.03 ± 0.01 s-1).  The inhibitory effects of MMOB on
intermolecular electron transfer instead arise primarily from a large shift in the fraction
of electrons traveling through the four reaction phases (Figure 4.11B).  The initial three
electron transfer steps combine to transmit a single electron to MMOH; the remaining
three electrons are transferred at the slowest rate (Table 4.6).  MMOD is an even more
potent inhibitor of intermolecular electron transfer in the sMMO system.  Diode array
data recorded for the reaction of 20 µM MMOR3e– with 10 µM MMOH/20 µM MMOD
were fit with a sequential four-component model to give rate constants of k1 = 3 ± 1 s-1,
k2 = 0.06 ± 0.02 s-1, and k3 = 0.009 ± 0.003 s-1 (Figure 4.12A).  These rate constants are
substantially diminished compared to those determined in the absence of MMOD.
Like MMOB, MMOD induces a change in electron partitioning between the various
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reaction phases (Figure 4.12B and Table 4.6).  During the first two steps, a total of one
electron is transferred to the two hydroxylase diiron sites.  Two more electrons are
transmitted to MMOH in the slow third step, resulting in 75% reduced hydroxylase.
Transfer of a fourth electron was not observed but may occur eventually beyond the
examined time range (400 s).  The full extent of electron transfer inhibition by MMOB
and MMOD can be appreciated by plotting percent MMOH reduction vs time (Figure
4.7B).
The MMOB concentration dependence for electron transfer from MMOR3e– to
oxidized MMOH was investigated with single wavelength stopped-flow experiments.
Kinetic traces (470 nm) for this reaction were collected at 4 °C with MMOB included in
the same syringe as MMOH (Figure 4.13A).  Rate constants extracted from parallel
four-exponential fitting are only mildly perturbed by increasing concentrations of
MMOB (Figure 4.13B).  As noted for MMOR-Fd(1-98), the extent of the fast and slow
reaction phases exhibits considerable dependence on MMOB concentration, such that
electron transfer proceeds nearly completely via slow pathways with saturating
MMOB (Figure 4.13C).  Including MMOB in the syringe with MMOR3e– produced a
similar but smaller interconversion effect.  At high MMOB concentrations, 30% of
electron transfer occurs through the rapid pathway compared to < 5% when MMOB is
pre-mixed with MMOH.
DISCUSSION
Comparison of MMOH–MMOR-Fd and MMOH–MMOR Binding
Interactions.  The ferredoxin domain of MMOR was employed in this study to model
the initial electron transfer steps from MMOR to MMOH.  To ensure that
MMOR-Fd(1-98) retains an affinity for MMOH similar to that of full-length MMOR, the
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MMOH–MMOR-Fd(1-98) binding interaction at 4.2 °C was examined by isothermal
titration calorimetry.  By fitting the calorimetric data with an interacting sites binding
model, dissociation constants of 0.6 µM and 3.2 µM were determined for the first and
second MMOR-Fd(1-98) binding interactions, respectively, with the dimeric MMOH
protein.  These values are about 1.5- to 4.5-fold greater, indicating weaker binding, than
those measured by the same method for the MMOH–MMOR interaction at 3.3 °C (0.4
µM and 0.7 µM).18  Furthermore, the MMOR-Fd protein binds to MMOH in an
exothermic reaction, whereas the MMOH–MMOR binding reaction is endothermic
(Table 4.1).  Possible reasons accounting for these differences in thermodynamic
binding parameters include different coverage of the MMOH surface owing to the
larger full-length MMOR protein, altered structural features in MMOR-Fd compared to
the [2Fe-2S] domain and adjacent peptide regions of MMOR, and more extensive
conformational changes induced by MMOH–MMOR binding.
Our previous NMR titration studies of MMOR-Fd(1-98) with MMOH revealed a
face of the ferredoxin protein, including Asp26 and Glu73, involved in binding to the
hydroxylase.35  Mutating either of these residues to alanine in full-length MMOR
resulted in decreased affinity for MMOH, demonstrating that MMOR-Fd(1-98) and
MMOR contact the hydroxylase in a similar fashion.41  Both MMOR-Fd(1-98) and
MMOR from M. capsulatus (Bath) cross-link to the MMOH alpha subunit, providing
further evidence for shared binding interactions.42  We therefore conclude that
MMOR-Fd(1-98) and MMOR minimally bind to the same sites on MMOH.  Additional
protein contacts involving the MMOH–MMOR interface and/or changes in structure
as a consequence of complex formation are probably responsible for the altered
thermodynamic properties noted in the calorimetry experiments.
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Formation of Electron Transfer Complexes.  Protein–protein binding typically
precedes intermolecular electron transfer in biological systems.  Thus, for stopped-flow
experiments in which the donor and acceptor pair is combined by mixing, rate
constants associated with protein–protein binding and orientation may contribute to
the observed rate constant for intermolecular electron transfer.  This feature was
avoided in previous studies of electron transfer from MMOR to MMOH by allowing
the pre-formed MMOH–MMOR complex to react with NADH.18  When fully reduced
MMOR-Fd(1-98) or MMOR is rapidly mixed with MMOH, the measured rate constants
for the intermolecular electron transfer reactions are independent of protein
concentration (Figure 4.4B).  This result indicates that MMOR-Fd(1-98) and MMOR
associate rapidly with MMOH to form a tight complex prior to the electron transfer
reactions.
The rate constant determined for the first electron transfer step from MMOR3e–
to MMOH at 4 °C (k = 65 ± 5 s-1) is significantly less than that observed for the initial
electron transfer from MMOR to MMOH in the NADH-initiated reaction (k = 106 ± 13
s-1).18  Since there is greater driving force for electron transfer from chemically reduced
MMOR, this smaller rate constant is somewhat surprising.  We propose that the initial
rapid association of MMOH and MMOR is followed by a slower reorganization of the
protein complex that limits the observed rate constant for intermolecular electron
transfer.  On the basis of kinetic and thermodynamic studies of MMOH complex
formation with MMOB and MMOR, a similar two-step binding process was
postulated.18  Isomerization of the initial MMOH–MMOR precomplex at 25 °C was
estimated to occur with forward and reverse rate constants of kf = 0.38 s-1 and kr = 0.057
s-1, respectively.18  Rate constants for electron transfer from MMOR3e– to MMOH at 25
°C determined in this study are k1 = 205 ± 16 s-1, k2 = 18 ± 4 s-1, k3= 4.6 ± 1.2 s-1, and k4 =
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0.28 ± 0.10 s-1.  The comparable values of k4 and the approximate MMOH–MMOR
precomplex forward isomerization rate constant suggest that the last intermolecular
electron transfer step, corresponding to the transmission of ca. 0.5 electrons to MMOH
(Table 4.6), may be controlled primarily by slow complex reorganization.  Rates for the
initial three reaction phases may not require as stringent cofactor positioning in the
MMOH–MMOR precomplex.
Modeling Intermolecular Electron Transfer in the sMMO System.  Multiple
kinetic steps are detected for electron transfer from chemically reduced MMOR or
MMOR-Fd to oxidized MMOH.  The data reported here were fit by using both parallel
(single wavelength data) and sequential (diode array data) mechanisms for the
intermolecular electron transfer reactions.  Rate constants returned from both fitting
methods were quite similar.  In addition, global fitting of diode array data with
sequential models yielded internally consistent sets of composite intermediate spectra,
which are well described by linear combinations of the previously determined oxidized
and reduced iron-sulfur and flavin component spectra.34  Multi-wavelength data sets
for the four-step reaction of MMOR3e– with MMOHox could also be fit well with various
alternative mechanisms (vide infra), but these models generally failed to converge
upon unique solutions.
For the simple case of MMOR ferredoxin analogs transferring electrons to
MMOH, a discrete hydroxylase intermediate that is 25-35% reduced and a final state
that is 50% reduced are observed.  These results are consistent with an asynchronous
mechanism (half-sites reactivity) in which a mixed-valent iron center is generated at
one hydroxylase protomer in the first reaction phase and at the other protomer in the
second reaction phase (Scheme 4.2A, upper pathway).  A concerted mechanism
(Scheme 4.2A, lower pathway), defined by simultaneous electron transfer to both
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MMOH protomers, is also possible and cannot be ruled out with certainty based on the
present data.  A third option invokes two hydroxylase populations that exhibit
intrinsically different intermolecular electron transfer rates (Scheme 4.2B).  Because
temperature or MMOR-Fd concentration variations can alter the partitioning of
electrons through the rapid and slow reaction pathways, the electron transfer steps are
interchangeable, probably by means of conformational changes in the hydroxylase
component.
The sequence of electron transfer steps and the species compositions determined
for the MMOH–MMOR reaction at 4 °C are presented graphically in Scheme 4.3.  The
first two reaction phases each correspond to the transmission of 1.5 electrons to
MMOH.  The final electron is transferred in two distinct steps.  The oxidation levels of
the MMOR cofactors were assessed throughout the electron transfer reaction by fitting
the optical spectra of intermediates with combinations of the well-established
reductase [2Fe-2S] and FAD component spectra.18,34  The oxidized, mixed-valent, and
reduced forms of MMOH are virtually silent in the visible region examined in these
stopped-flow experiments.  Although the total number of electrons transferred to
MMOH can be calculated with precision from the MMOR composition, the distribution
of electrons within the hydroxylase diiron sites cannot be ascertained.  As described for
the MMOR-Fd analogs, both asynchronous (Scheme 4.3A) and parallel (Scheme 4.3B)
electron transfer mechanisms are plausible.  Furthermore, because there are four
discrete steps, various types of half-sites reactivity can be imagined, including
differential (Scheme 4.3B, upper and center pathways) or alternating (Scheme 4.3B,
lower pathway) electron transfer to the two hydroxylase protomers.  Further
spectroscopic studies of the MMOH diiron center will be necessary to distinguish
between these mechanisms.  Since X-ray structural investigations have revealed
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substantial amino acid side chain repositioning during reduction of Hox to Hmv to Hred,43
it is likely that these conformational changes contribute to the kinetic features observed
in the present work.
Interconversion of Rapid and Slow Electron Transfer Pathways.  The binding
of MMOB to the hydroxylase induces structural changes that are coupled energetically
to the redox equilibria of the MMOH diiron centers.44-46  For the sMMO system from M.
trichosporium OB3b, the equilibrium midpoint potential of MMOH (Em = +48 mV,
relative to the normal hydrogen electrode) is decreased by 132 mV (Em = –84 mV) upon
binding MMOB.  Adding MMOR to either MMOH or an MMOH–MMOB complex
raises the hydroxylase midpoint potential to ca. +100 mV.29  Moreover, MMOR inverts
the relative values of the two MMOH redox potentials such that the transfer of two
electrons is thermodynamically favored.45  Both MMOB and MMOD alter the structure
of the MMOH diiron site, as indicated by several spectroscopic techniques.  EPR, MCD,
and EXAFS studies provide evidence for MMOB-induced changes at the hydroxylase
active site.28,30,47,48  Optical spectroscopy reveals that a small fraction (ca. 15%) of
hydroxo-bridged diiron sites is converted to (µ-oxo)diiron(III) centers when MMOD
binds to MMOH.19  Formation of the oxo-bridged species is also supported by EXAFS
spectroscopy.49  In contrast, MMOR does not alter the spectroscopic properties of the
hydroxylase diiron center.14  MMOB and MMOR profoundly affect steady-state sMMO
catalysis and efficiency, single-turnover reaction rates, and product distribution by
means of intricate interactions that are still not fully understood.18,25,28-30  By competing
with MMOB for binding to the hydroxylase, MMOD inhibits sMMO activity in steady-
state assays.19
A role for MMOB in modulating the rate of intermolecular electron transfer in
steady-state sMMO reactions has been suggested.17,21,50  Previous stopped-flow studies
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of electron transfer from MMOR to MMOH involved rapidly mixing pre-assembled
MMOR–MMOH or MMOR–MMOH–MMOB complexes with NADH and monitoring
absorbance changes associated with MMOR reduction by NADH and reoxidation as
electrons were transferred to MMOH.18  Four kinetic steps corresponding to the
transfer of two electrons into a single hydroxylase diiron site were observed.
Increasing concentrations of MMOB in the reactions increased the latter three electron
transfer rate constants to a point of saturation.  In contrast to these findings, when
chemically reduced MMOR is allowed to react with pre-mixed MMOH and MMOB,
electron transfer to the hydroxylase is substantially slower than in the absence of
MMOB (Figure 4.7B).  This inhibitory effect is produced primarily by shifting the bulk
of electron transfer from the initial, faster reaction phases to the fourth, slowest phase.
MMOB and MMOR from M. capsulatus (Bath) do not bind to each other and
have separate binding sites on MMOH.18  Therefore, the effect of MMOB on
intermolecular electron transfer must be transmitted through structural changes of the
hydroxylase component.  The fully equilibrated MMOR–MMOH–MMOB complex
exhibits relatively fast intermolecular electron transfer rates (k1 = 106 s-1, k2 = 24.5 s-1, k3
= 15.8 s-1, and k4 = 6.4 s-1) when reduced by NADH at 4 °C.18  The significantly lower
rate constants (k1 = 50 s-1, k2 = 9.4 s-1, k3 = 1.6 s-1, and k4 = 0.02 s-1) measured in the present
study for electron transfer from MMOR3e– to a pre-formed MMOH–MMOB complex
suggest that isomerization of the initial ternary complex is required for maximal
intermolecular electron transfer rates.  By extrapolation from binding data collected at
25 °C (vide supra),18 the rate constant for this isomerization reaction may correspond to
k4.  Thus, in the presence of MMOB, 75% of electron transfer from MMOR3e– to MMOH
may be gated by a slow conformational change, compared to just 14% without MMOB
(Table 4.6).  This effect can be explained by a simple model that includes two
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interconvertable populations of MMOH, Hox and Hox’, which exhibit rapid and slow
electron transfer rates, respectively (Scheme 4.3B).  Addition of MMOB to this
heterogeneous MMOH mixture would shift the equilibrium between the two species
toward Hox’, such that more electrons are transferred by the slow mechanism.  The
presence of MMOR would counteract the effect of MMOB by moving the equilibrium
toward Hox.  This intermolecular electron transfer model mimics closely the changes in
the hydroxylase redox potentials produced by MMOB and/or MMOR.29,44
The MMOB-induced structural changes in MMOH appear to block the two
fastest electron transfer routes in the ternary pre-complex, presumably by physical
disruption of the relevant pathways or thermodynamic modulation of the diiron center
redox potentials.  Neither MMOH nor MMOB affects the MMOR redox potentials.23
Although MMOB causes a large decrease in the hydroxylase midpoint potential, the
complete transfer of two electrons from MMOR3e– is still thermodynamically favorable:
FAD (E°’ = –266 mV/–176 mV) › [2Fe-2S] (E°’ = –209 mV) › MMOH–MMOB complex
(E°’ = –84 mV).23,34  Therefore, even if MMOR were to increase the MMOH redox
potentials only slowly with respect to the stopped-flow mixing and reaction times, this
effect would not wholly account for the delayed electron transfer (vide infra).  Another
possibility is that the MMOR–MMOH binding isomerization reaction comprises
multiple steps, the initial ones of which align useful electron transfer pathways.  In this
scenario, MMOB would slow these processes without drastically altering the rate of the
macroscopic conformational change.  Conversely, MMOB might serve to lock in the
structural changes induced by MMOR.  Interruption of important electron transfer
pathways in the MMOH–MMOB complex is the most reasonable explanation for
inhibition of electron transfer from MMOR3e– to pre-mixed MMOH and MMOB.  After
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MMOR binds to the MMOH–MMOB complex, a slow conformational reorganization
must occur to align the redox sites for efficient electron transfer.
A small fraction (ca. 12%) of hydroxylase reduction occurs by the two fastest
routes in the presence of two equivalents of MMOB, which suggests that a dynamic
equilibrium exists between the blocked (Hox’) and unblocked (Hox) forms of MMOH, as
presented in Scheme 4.3B.  Evidence exists for a third population of oxidized
hydroxylase, which is not involved in the equilibria between Hox and Hox’.  A nearly
constant percentage (13-17%) of intermolecular electron transfer occurs during the step
described by k3 (with and without MMOB) or k2 (with MMOD).  The magnitudes of
these rate constants are affected by MMOB (Figure 4.13B) and MMOD (Table 4.6),
demonstrating that this population of MMOH (Hox†) binds both proteins; however, the
fraction of electron transfer to Hox† is unchanged by either MMOB or MMOD.  A more
complex model that accounts for this third hydroxylase population is shown in Scheme
4.4.  Hox† may be interchangeable with the other populations of MMOH or may
represent permanently damaged protein.  By excluding the Hox† portion, relative
amounts of the equilibria-related Hox and Hox’ were calculated.  In the absence of
MMOB, 84% of intermolecular electron transfer from MMOR3e– to oxidized MMOH
takes place through the two fast pathways associated with Hox; slow reduction of Hox’
accounts for the remaining 16%.  When two equivalents of MMOB are pre-mixed with
MMOH, the partitioning of electron transfer through the fast (15%) and slow (85%)
pathways is inverted.  For a mixture of 10 µM oxidized MMOH and 20 µM MMOB (Kd
= 0.3 µM and 0.7 µM),18 MMOB is bound to about 86% of the hydroxylase protomers.
Therefore, we assign Hox’ as the hydroxylase population with structural features like
those induced by MMOB binding.  When MMOR3e– is mixed with the pre-formed
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MMOH–MMOB complex, rapid electron transfer (at k1 and k2) occurs only to those
hydroxylase protomers without bound MMOB.
There are several spectroscopic indications of heterogeneity in both oxidized
and reduced hydroxylase samples.  In freeze-quench Mössbauer studies of the reaction
of Hred/2B with dioxygen, two distinct populations of Hred were observed.25  Only the
minority species (30-40% of the iron that participated in the reaction) generated high-
valent intermediates at rates fast enough to support steady-state turnover numbers.  In
addition, a third fraction (ca. 12% of the total iron) did not react with dioxygen at all.
The occurrence of two populations of Hox from M. capsulatus (Bath) was previously
detected by EPR spectral analysis of cryoreduced samples.51  Moreover, this study
indicated that the effects of MMOB did not involve significant alterations in the
primary coordination sphere of the diiron center.  EXAFS spectroscopy of oxidized
hydroxylase from M. trichosporium OB3b revealed two populations of diiron sites with
Fe–Fe distances of 3.01 Å (60%) and 3.36 Å (40%).52  Only ca. 15% of MMOHox is
converted to the µ-oxo species by MMOD, even though two equivalents of MMOD
bind to each hydroxylase molecule.19  Therefore, the multiple populations of
hydroxylase proposed for intermolecular electron transfer reactions (Schemes 4.3B and
4.4) are not unreasonable.
When MMOR3e– and MMOB are mixed simultaneously with oxidized MMOH, a
smaller inhibitory effect on electron transfer is observed.  This result correlates well
with the proposal that MMOB produces a conformational change in MMOH that limits
electron transfer in the ternary pre-complex.  The forward rate constant for
MMOH–MMOB isomerization at 4 °C is quite small (kf = 0.0056 s-1),18 such that the full
effects of MMOB binding are not realized immediately after mixing with MMOH.  In
addition, the hydroxylase redox potentials undergo a significantly smaller shift when
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MMOH is not pre-mixed with MMOB (Scheme 4.5).  Any effect on intermolecular
electron transfer arising from decreased MMOH midpoint potentials (Em) would be
largely muted by avoiding equilibration of the MMOH–MMOB complex.
Incubating MMOH with two equivalents of MMOD inhibits electron transfer
from MMOR3e– even more severely than MMOB (Figure 4.7B).  Several possibilities
exist for inhibition of intermolecular electron transfer by MMOD:  (i) MMOD binding
to MMOH obscures the MMOR binding site; (ii) MMOD binding to MMOH induces a
conformational change in MMOH that makes MMOR binding and/or electron transfer
unfavorable; (iii) MMOD alters the MMOH redox potentials; (iv) MMOD binds to
MMOR; and (v) MMOD alters the MMOR redox potentials.  The inclusion of MMOD
in the sMMO enzyme system was established only recently;19 for this reason, its
component interactions have not been studied in as much detail as those of MMOB and
MMOR.  MMOD competes with MMOB for binding sites on the hydroxylase and
cross-links to both the MMOH alpha and beta subunits.19  There is no evidence for
binding to MMOR or MMOB, a finding that argues against proposals iv and v.  The
effect of MMOD on the hydroxylase redox potentials is currently unknown.  After
reaction with MMOR3e– in the presence of MMOD, the hydroxylase is reduced by only
75%.  Therefore, a large decrease in the midpoint potential of the MMOH–MMOD
complex that cannot be overcome by MMOR binding is possible.  One of the first two
proposals, competitive binding with MMOR or a conformational change that prevents
electron transfer, probably accounts for the majority of electron transfer inhibition
noted for MMOD.
Hysteresis in Intermolecular Electron Transfer Reactions.  In the absence of
MMOB or MMOD, MMOR3e– transmits two electrons to MMOH at 4 °C in about 31 ms,
which corresponds to a maximum turnover number of 32 s-1 for the complete reduction
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of one of the two hydroxylase diiron centers.  Pre-mixing two equivalents of MMOB
with MMOH increases the time for two-electron transfer to 11.2 s (maximum turnover
number of 0.089 s-1).  In steady-state sMMO reactions with methane, a turnover number
of ca. 0.3 s-1 is achieved with similar ratios of the MMO components at 4 °C.18  If the
effects of reductase binding to the MMOH–MMOB complex rapidly dissipated upon
dissociation of MMOR, steady-state catalysis would be limited by electron transfer to a
rate at least threefold lower than actually observed.  Therefore, either MMOR does not
dissociate from the ternary MMOH–MMOB–MMOR complex during steady-state
turnover or relaxation of the MMOH–MMOR complex to the free hydroxylase
conformational state is slow with respect to the binding and dissociation of MMOR.
Because steady-state sMMO activity can be maximized in the presence of only 0.1-0.2
equivalents of MMOR per hydroxylase,17,18,28 a single reductase molecule must service
multiple MMOH molecules during each turnover of the enzyme, a process that
requires rapid binding to and dissociation from MMOH–MMOB complexes.  We
conclude that hysteresis of the conformational changes imparted to MMOH by MMOR
is necessary for sustained rapid intermolecular electron transfer in the sMMO system.
By this mechanism, the ungated hydroxylase structure would be retained throughout
the catalytic cycle so that slow MMOH–MMOR isomerization reactions do not inhibit
turnover.  Furthermore, the equilibrated MMOHox:2MMOB complex cannot be a
catalytically relevant structure in steady-state sMMO reactions because electron
transfer to this species is too slow to support observed reaction rates.  This complex
may represent a subset of the hydroxylase population but cannot be the majority
species.  The present work was performed at 4 °C; it is possible that at higher
temperatures a step other than MMOH–MMOR isomerization becomes rate-limiting.
A comprehensive study of component interactions over a wide temperature range (4-45
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°C) suggested that the regulatory mechanism of hydroxylase activity by MMOB and
MMOR is conserved with respect to temperature, however.18  An alternative and
seemingly unlikely explanation is that a large portion of MMOH does not participate in
steady-state turnover.
Hysteresis has been invoked for several other aspects of the sMMO system.  For
example, just 0.6 equivalents of MMOB effect the full conversion of the reduced
MMOH EPR spectrum to that of the MMOHred–MMOB complex.30  Substrate
hydroxylation regioselectivity is also controlled by substoichiometric quantities of
MMOB.30  The complete effects of MMOR on the hydroxylase redox potentials, single-
turnover product yields, and MMOHred reactivity with O2 are achieved with a 0.2:1
MMOR:MMOH ratio.29  On the basis of these hysteretic changes induced by MMOR, a
mechanism in which MMOR converts MMOH to a different conformation (MMOH’’)
with distinct physical properties was proposed.29  At physiological ratios of sMMO
components (1:2:0.2 for MMOH:MMOB:MMOR),17,29 the hydroxylase would exist
primarily in the MMOH’’ form with increased and inverted redox potentials, thereby
favoring two-electron transfer.  In addition to these features of MMOH’’, we propose
that this hydroxylase conformation supports rapid intermolecular electron transfer in
the initial MMOH–MMOR or MMOH–MMOB–MMOR precomplex.
MMOR Ferredoxins as Models for Intermolecular Electron Transfer.  Several
reductase ferredoxin analogs ranging in length from a 98-residue MMOR-Fd truncate
to FAD-depleted full-length MMOR were examined as models for intermolecular
electron transfer in the sMMO system (Figure 4.1B).  These proteins, which contain
only a [2Fe-2S] cluster, facilitate interpretation of data for the inaugural interprotein
electron transfer event.  Electron transfer to MMOH from all three ferredoxin
constructs proceeds via biphasic reactions similar to the multiple phases observed for
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wild-type MMOR.  Rate constants for these electron transfer steps vary significantly
from protein to protein (Figure 4.7A and Table 4.2).  The particularly low electron
transfer rates measured for MMOR-Fd(1-98) (k1 = 1.0 s-1 and k 2 = 0.24 s-1) were
somewhat surprising; the slightly longer MMOR-Fd(1-120+tail) transfers electrons to
MMOH at 30-fold higher rates.  Spectroscopic (optical, EPR, and EXAFS) and redox
potential studies demonstrate that the [2Fe-2S] center of MMOR-Fd(1-98) is identical to
the corresponding cofactor in MMOR.34,49  The NMR structure of this short MMOR-Fd
domain reveals a fold typical of plant-type ferredoxins.35  We postulate that the
discrepancy in intermolecular electron transfer rates arises from the involvement of
MMOR residues 99-120 in complex formation with MMOH.  To test this hypothesis, we
are preparing the MMOR-Fd(1-120) construct in order to investigate intermolecular
electron transfer from this longer ferredoxin domain to MMOH.
Application of ET Theory to Intermolecular Electron Transfer in sMMO.  ET
theory may be applied to interprotein electron transfer reactions provided that the
observed rate constants are not limited by preceding adiabatic processes such as proton
transfer.  Because it is not practical to vary ∆G° systematically in most biological
systems, ET parameters can be determined instead by examining the reaction at
varying temperatures.53  There are several important caveats to this type of analysis.
Temperature-dependent changes in ∆G°, HAB, l, or the rate-limiting step can invalidate
the results of analysis by ET theory.  For most biological electron transfer reactions,
including those of the sMMO system (vide infra), –∆G° is small compared to l.
Therefore, changes in the value of ∆G° with temperature have very little effect on the
calculated ET parameters.  In addition, any uncertainty in the ∆E° value, even as large
as ±100 mV, is of little importance.53  The possibility of temperature-dependent protein
conformational changes that alter the values of HAB or l is often reduced by the limited
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range of temperatures over which biological systems can be studied.  Despite the many
stipulations, analysis of interprotein electron transfer reactions by ET theory can be a
useful diagnostic tool to distinguish between true, gated, and coupled electron
transfer.2,53
Electron transfer from MMOR to MMOH is additionally complex, with multiple
hydroxylase populations giving rise to four electron transfer rate constants.  A value
for ∆E° (+281 mV) was selected to represent the initial electron transfer from the
[2Fe-2S] cluster (E°’ = –205 mV)34 to oxidized MMOH (E1°’ = +76 mV).44  Other possible
∆E° values for the sMMO system range from +226 mV to +319 mV, corresponding to a
difference in ∆G° values of only 2.1 kJ/mol.  As discussed above, the magnitude of the
potential error in ∆G° is not significant in this analysis.  The HAB, l , and r values
determined for electron transfer from two MMOR-Fd analogs and MMOR to MMOH
are all reasonable for true electron transfer reactions (Table 4.4).  The significantly
larger values obtained for HAB and l in the MMOR-Fd(1-98) (k1 and k2) and MMOR (k4)
reactions may indicate gated or coupled electron transfer reactions.  The ET parameters
for the remaining reactions are fairly similar.  Of particular interest is r, the distance
between the reductase [2Fe-2S] and hydroxylase diiron centers in the MMOH–MMOR
complex.  For MMOR (k1 and k3) and MMOR-Fd(1-120+tail) (k1), an average r value of
11.0 ± 0.3 Å was determined.  This distance falls within the 14-Å requirement for
efficient electron transfer in biological systems.54  In addition, the shortest path from the
MMOH diiron site to the hydroxylase surface is ca. 12 Å.55  Thus, only a small
conformational change in MMOH would be required to accommodate the reductase in
a position suitable for rapid electron transfer.  If the ET theory-derived r values are
accurate, MMOR must bind in the central hydroxylase canyon region, as suggested
previously.42,56  The rather large l  values determined for intermolecular electron
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transfer (1.5-2.0 eV) suggest that considerable conformational changes accompany
hydroxylase reduction.  Oxidation of the reductase [2Fe-2S] is not expected to require
significant reorganization.  Upon formation of reduced and mixed-valent MMOH,
carboxylate shifts and severe distortion of the diiron site occur, respectively, as
observed in crystal structures of the hydroxylase in different oxidation states.43,57,58
These types of sizeable structural perturbations at the MMOH active site could account
for the large l values.  Alternatively, the observed electron transfer rate constants could
represent kinetically coupled ET reactions, in which case l would contain contributions
from both the electron transfer event and the preceding reaction step.
Concluding Remarks.  Electron transfer from chemically reduced MMOR to
oxidized MMOH occurs in four discrete kinetic phases corresponding to the transfer of
four electrons into the two dinuclear iron centers of the hydroxylase.  Both MMOB and
MMOD severely diminish intermolecular electron transfer rates by shifting the
majority of electron transfer to the slowest reaction phase, suggesting a function for
one or both of these proteins in regulating electron transfer in the sMMO system.  A
model in which MMOR-induced conformational changes to MMOH are retained
throughout the steady-state catalytic cycle is proposed to account for slow
intermolecular electron transfer observed in the ternary MMOH–MMOB–MMOR pre-
complex.  In order to distinguish between the various possible asynchronous,
concerted, and parallel electron transfer mechanisms, freeze-quench EPR, Mössbauer,
and XAS spectra are required to characterize the MMOH diiron sites throughout the
reactions.  Using flash photolysis to initiate electron transfer in pre-formed
MMOH–MMOR complexes may be valuable for determining intrinsic intermolecular
electron transfer rates in the absence of slow binding isomerization reactions.
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Table 4.1:  Thermodynamic Parameters for MMOH–MMOR-Fd and MMOH–MMOR Interactions!a
Protein
Kd1
(µM)
∆G1
(kcal mol-1)
∆H1
(kcal mol-1)
T∆S1
(kcal mol-1)
Kd2
(µM)
∆G2
(kcal mol-1)
∆H2
(kcal mol-1)
T∆S2
(kcal mol-1)
Fd(1-98)!b 0.6 –7.9 –4.4 3.5 3.2 –7.0 –5.0 2.0
MMOR!c 0.4 –8.1 4.5 12.6 0.7 –7.8 2.4 10.1
a  Isothermal titration data were fit with an interacting sites model after correcting for the nonbinding
fraction of MMOH; see text for details.  b"Measured at 4.2 °C.  c!From ref 18; measured at 3.3 °C.
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Table 4.2:  Intermolecular Electron Transfer Rate Constants for MMOR-Fd and MMOR a
Protein aa!b k1 (s-1) k2 (s-1) k3 (s-1) k4 (s-1)
MMOR-Fd(1-98) 98 1.0 ± 0.1 0.24 ± 0.04 n/a n/a
MMOR-Fd(1-120+tail)!c 139 35 ± 4 7.1 ± 1.1 n/a n/a
MMOR(apoFAD) 348 17 ± 2 2.9 ± 0.3 n/a n/a
MMOR 348 65 ± 5 12 ± 3 1.3 ± 0.2 0.032 ± 0.007
a!Measured at pH 7.0 and 4 °C in single-wavelength stopped-flow experiments.  b!aa, amino acid
residues.  c!Tail sequence:  ATPSSFFCRSGPTSAATVA.
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Table 4.3:  Activation Energies for Intermolecular Electron Transfer!a
Protein aa!b Ea1 (kcal mol-1) Ea2 (kcal mol-1) Ea3 (kcal mol-1)
MMOR-Fd(1-98) 98 11.6 12.8 n/a
MMOR-Fd(1-120+tail) 139 7.9 7.1 n/a
MMOR(apoFAD) 348 13.5 11.8 n/a
MMOR 348 8.3 9.3 10.1
a!Measured at pH 7.0 in single-wavelength stopped-flow experiments.  b!aa, amino acid residues.
181
Table 4.4:  Electron Transfer Parameters from Temperature Dependence Studies!a
Reaction Rate Constant (s-1)!b HAB (cm-1)!c l (eV)!c r (Å)!c
Fd(1-98)red + Hox k1 (1.0) 7.5 ± 3.3 2.3 ± 0.1 8.3 ± 0.6
k2 (0.24) 5.7 ± 1.3 2.4 ± 0.1 8.7 ± 0.3
Fd(1-120+tail)red + Hox k1 (35) 0.9 ± 0.5 1.6 ± 0.1 11.2 ± 0.8
k2 (7) 0.2 ± 0.1 1.5 ± 0.2 13.3 ± 0.9
MMOR3e– + Hox k1  (65) 1.1 ± 0.3 1.5 ± 0.1 11.0 ± 0.4
k2  (12) 2.5 ± 5.2 1.9 ± 0.4 9.9 ± 3.0
k3  (1.3) 1.3 ± 0.3 2.0 ± 0.1 10.7 ± 0.4
k4  (0.032) 7 ± 21 2.6 ± 0.6 8.5 ± 4.2
a!Measured at pH 7.0 in single-wavelength stopped-flow experiments.  b!Numbers in parentheses
measured at 4 °C.  c!Values of HAB, l, and r were determined by fitting rate constant vs temperature plots
with eq 2 or 3; ∆E° = +0.281 V (Fdox/red = –0.205 V, Hox/mv = +0.076 V), ∆G° = –6.48 kJ mol-1, k0 = 1013 s-1, b
= 1.4 Å-1, and r0 = 3.0 Å.  Because l >> ∆G°, altering ∆E° by ±0.1 V yields only small changes in HAB, l,
and r.
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Table 4.5:  Effect of MMOB on Intermolecular Electron Transfer for MMOR Ferredoxin Analogs!a
Protein k1 (s-1) % MMOH reduction!b k2 (s-1) % MMOH reduction
MMOR-Fd(1-98) 1.0 ± 0.1 23 (66)!c 0.28 ± 0.02 35 (34)
    + MMOB (2 eq.)!d 1.1 ± 0.2 5 (15) 0.056 ± 0.005 34 (85)
MMOR(apoFAD) 8.3 ± 0.7 19 (50) 1.2 ± 0.1 38 (50)
    + MMOB (2 eq.) 7.3 ± 0.2 20 (42) 0.25 ± 0.01 48 (58)
a!Measured at 4 °C and pH 7.0 in diode array stopped-flow experiments.  b!Percent reduction of
MMOH at the completion of each reaction phase, with four-electron reduced MMOH corresponding to
100%.  c!Numbers in parentheses represent the percentage of electrons transferred at that rate.
d!Equilibrated mixture of MMOH and two mole equivalents of MMOB.
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Table 4.6:  Distribution of Electrons in Intermolecular Electron Transfer Intermediates!a
% total Fe2S2 % total FAD!b % MMOH reduction!b
Species kf (s-1) Fdox Fdred FADox FADsq FADhq Step!c Total!c
2R3e– + Hox
  A — 6 94 0 2 98 — 4 (0)
  B 65 40 60 3 21 75 30 (39) 34 (39)
  C 20 41 59 10 57 34 25 (32) 59 (71)
  D 3 55 45 15 55 30 12 (15) 70 (86)
  E 0.2 65 35 22 53 25 11 (14) 81 (100)
2R3e– + Hox/2B d
  A — 0 100 0 0 100 — 0 (0)
  B 50 4 96 0 1 99 3 (4) 3 (4)
  C 9 4 96 0 14 86 6 (8) 9 (12)
  D 1.5 2 98 6 24 70 10 (13) 19 (25)
  E 0.04 52 48 16 63 21 54 (70) 73 (95)
2R3e– + Hox/2D e
  A — 1 99 0 0 100 — 1 (0)
  B 3 2 98 0 11 89 6 (8) 7 (8)
  C 0.08 2 98 3 31 66 13 (17) 20 (25)
  D 0.01 38 62 7 62 31 37 (48) 57 (73)
a!Measured at pH 7.0 and 4 °C in diode array stopped-flow experiments.  Intermediates are for
sequential kinetic schemes.  b!In some cases, percentages do not total 100 due to rounding.  c!Numbers
in parentheses represent percent MMOH reduction after correcting for the nonbinding hydroxylase
fraction.  d!MMOB pre-equilibrated with MMOH.  e!MMOD pre-equilibrated with MMOH.
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Figure 4.1.  (A) Examples of alternative connectivities between the one-electron carrier
and flavin/NAD(P) binding domains of flavoprotein electron transferases.  (B) MMOR
proteins examined in this study.
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Figure 4.2.  Component spectra determined for the MMOR domain proteins.  (A)
Oxidized (Fdox; solid line) and reduced (Fdred; dotted line) optical spectra for MMOR-
Fd.  (B) MMOR-FAD in the oxidized (FADox; squares), semiquinone (FADsq; triangles),
and hydroquinone (FADhq; circles) oxidation states.  From ref 34.
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Figure 4.3.  Determination of MMOH–MMOR-Fd(1-98) binding constant by isothermal
titration calorimetry.  (A) Data recorded for complex formation between MMOH (11.1
µM in the calorimeter cell) and MMOR-Fd(1-98) (368 µM in a 250-µL injection syringe)
at 4.2 °C.  Each heat pulse corresponds to a 10-µL injection into the 1.430-mL sample
cell.  (B) Integrated enthalpy data (circles) fit with an interacting sites binding model
after correction of the MMOH concentration for the nonbinding fraction of hydroxylase
(solid line).
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Figure 4.4.  Effect of MMOR-Fd concentration on electron transfer from chemically
reduced MMOR-Fd(1-98) to oxidized MMOH at 4 °C.  (A) Parallel fits through kinetic
traces recorded at 470 nm for 20 µM (squares), 40 µM (triangles), and 80 µM (circles)
MMOR-Fd(1-98) reacting with 10 µM MMOH.  Symbols are for identification purposes
only.  (B) Variation of rate constants with respect to MMOR-Fd(1-98) concentration:  k1
(circles), k2 (squares), k3 (diamonds), and k4 (triangles).  (C) Partitioning of electrons
between the rapid (k1, circles) and slow (k2, squares) reaction phases as a function of
MMOR-Fd(1-98) concentration.
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Figure 4.5.  Effect of temperature on intermolecular electron transfer from reduced
MMOR-Fd(1-98) to oxidized MMOH.  (A) Parallel fits through kinetic traces recorded
at 470 nm for the reaction of 20 µM MMOR-Fd(1-98) with 10 µM MMOH at 4 °C
(squares), 10 °C (triangles), 25 °C (circles), and 37 °C (diamonds).  (B) Arrhenius plot
for determination of activation energies:  k1 (circles) and k2 (squares).  (C) Electron
partitioning between the rapid (circles) and slow (squares) reaction phases as a
function of temperature.  (D) Analysis by electron transfer theory (see text) of the
temperature dependence of rate constants:  k1 (circles) and k2 (squares).  The solid lines
are fits to eqs 2 and 3.  Fits to the two equations are superimposable.
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Figure 4.6.  Spectra of intermediates resolved by global analysis of diode array kinetic
data for the reaction of chemically reduced MMOR-Fd(1-98) with oxidized MMOH in
the (A) absence and (B) presence of two equivalents of MMOB:  first intermediate
(squares), second intermediate (triangles), and third intermediate (circles).  Dashed
lines represent the best fitting linear combinations of component Fdox and Fdred spectra.
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Figure 4.7.  Time courses for MMOH reduction by (A) MMOR ferredoxin analogs and
(B) MMOR at 4 °C.  (A) Electron transfer reactions in the absence (solid lines) and
presence (dashed lines) of two equivalents of MMOB for MMOR-Fd(1-120+tail)
(squares), MMOR(apoFAD) (triangles), and MMOR-Fd(1-98) (circles).  (B) Progression
of electron transfer from MMOR3e– in reactions including MMOH alone (circles) and
with two equivalents of MMOB (triangles) or MMOD (squares).
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Figure 4.8.  Effect of MMOB on electron transfer from reduced MMOR-Fd(1-98) to
oxidized MMOH at 4 °C.  (A) Parallel fits through kinetic traces recorded at 470 nm for
the reaction of 20 µM MMOR-Fd(1-98) with 10 µM MMOH in the presence of no
MMOB (squares), 5 µM MMOB (triangles), 10 µM MMOB (circles), 20 µM MMOB
(diamonds), and 40 µM MMOB (inverted triangles).  (B) Variation of rate constants
with MMOB concentration:  k1 (circles), k2 (squares), and weighted average (triangles).
(C) Partitioning of electrons through the rapid (circles) and slow (squares) reaction
phases as a function of MMOB concentration.
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Figure 4.9.  (A) Spectra of intermediates resolved by global analysis of diode array
kinetic data for the reaction of MMOR3e– with oxidized MMOH:  intermediates A
(squares), B (triangles), C (circles), D (diamonds), and E (inverted triangles).  Dashed
lines are fits with linear combinations of MMOR component spectra (Fdox, Fdred, FADox,
FADsq, and FADhq).  (B) Composition of each intermediate:  Fdox (light gray), Fdred (dark
gray), FADox (diagonal lines), FADsq (narrow hatches), FADhq (wide hatches), and
MMOH reduction (black).
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Figure 4.10.  Effect of temperature on intermolecular electron transfer from MMOR3e– to
oxidized MMOH.  (A) Arrhenius plot for determination of activation energies:  k1
(circles), k2 (squares), and k3 (triangles).  (B) Electron partitioning between the fast
(circles) and slow (squares) reaction phases as a function of temperature.  (C) and (D)
Analysis by electron transfer theory (see text) of the temperature dependence of rate
constants:  k1 (C, circles), k2 (C, squares), k3 (D, triangles), and k4 (D, diamonds).  The
solid lines are fits to eqs 2 and 3.  Fits to the two equations are superimposable.
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Figure 4.11. (A) Spectra of intermediates resolved by global analysis of diode array
kinetic data for the reaction of MMOR3e– with a pre-equilibrated mixture of oxidized
MMOH and two equivalents of MMOB:  intermediates A (squares), B (triangles), C
(circles), D (diamonds), and E (inverted triangles).  Dashed lines are fits with linear
combinations of MMOR component spectra (Fdox, Fdred, FADox, FADsq, and FADhq).  (B)
Composition of each intermediate:  Fdox (light gray), Fdred (dark gray), FADox (diagonal
lines), FADsq (narrow hatches), FADhq (wide hatches), and MMOH reduction (black).
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Figure 4.12. (A) Spectra of intermediates resolved by global analysis of diode array
kinetic data for the reaction of MMOR3e– with a pre-equilibrated mixture of oxidized
MMOH and two equivalents of MMOD:  intermediates A (squares), B (triangles), C
(circles), and D (diamonds).  Dashed lines are fits with linear combinations of MMOR
component spectra (Fdox, Fdred, FADox, FADsq, and FADhq).  (B) Composition of each
intermediate:  Fdox (light gray), Fdred (dark gray), FADox (diagonal lines), FADsq (narrow
hatches), FADhq (wide hatches), and MMOH reduction (black).
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Figure 4.13.  Effect of MMOB on electron transfer from MMOR3e– to oxidized MMOH at
4 °C.  (A) Parallel fits through kinetic traces recorded at 470 nm for the reaction of 20
µM MMOR with 10 µM MMOH in the presence of no MMOB (squares), 5 µM MMOB
(triangles), 10 µM MMOB (circles), 20 µM MMOB (diamonds), and 40 µM MMOB
(inverted triangles).  (B) Variation of rate constants with MMOB concentration:  k1
(circles), k2 (squares), and k3 (triangles).  (C) Partitioning of electrons through the rapid
(circles) and slow (squares) reaction phases as a function of MMOB concentration.
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Chapter 5
Domain Engineering of the Reductase Component of Soluble Methane
Monooxygenase from Methylococcus capsulatus (Bath)*
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INTRODUCTION
The first step in the catabolic pathway of methanotrophs is the conversion of
methane to methanol by soluble or membrane-bound methane monooxygenases
(MMOs).1,2  Although the soluble MMO (sMMO) system is expressed by only a few
organisms under low-copper conditions,3 it has been characterized far more
extensively than the particulate form (pMMO) due to difficulties purifying and
stabilizing the pMMO enzymes.4-6  The sMMO proteins from two methanotrophic
bacteria, Methylococcus capsulatus (Bath)7,8 and Methylosinus trichosporium OB3b,9,10 have
been studied in great detail.11-18  Both systems comprise three components:  a dimeric
(abg)2 hydroxylase (MMOH, 251 kDa) with dinuclear, carboxylate-bridged iron centers
where dioxygen activation and methane hydroxylation occur; a regulatory protein
(MMOB, 15.9 kDa); and a reductase (MMOR, 38.5 kDa) that transfers electrons from
NADH to the MMOH diiron sites, thereby priming the hydroxylase for reaction with
dioxygen.  The N-terminal domain of MMOR, which houses a [2Fe-2S] cluster, shares
sequence,19 spectroscopic,16,20-23 and structural24 properties with ferredoxins of plants,
cyanobacteria, and archaebacteria.  A flavin adenine dinucleotide (FAD) cofactor
located in the C-terminal portion of MMOR accepts two electrons from NADH.  These
electrons are passed sequentially from the reduced FAD moiety through the MMOR
[2Fe-2S] center into the hydroxylase active sites by means of a series of intra- and
intermolecular electron transfer reactions.16,23,25,26
MMOR is a member of a class of modular flavoprotein electron transferases, also
known as the ferredoxin:NADP+ oxidoreductase (FNR) family.  These proteins contain
a flavin domain that transfers electrons between a nicotinamide dinucleotide and a
one-electron carrier domain, which may be linked or dissociable.27-29  Because the
electron carrier domain can be attached to either the N- or C-terminal end of the core
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flavin/NAD(P) unit, this domain appears to be an independent modular element.  In
support of this designation, the crystal structure of Burkholderia cepacia phthalate
dioxygenase reductase (PDR), an FNR family member with C-terminal electron carrier
connectivity, shows distinct flavin mononucleotide (FMN), NADH binding, and
[2Fe-2S] domains (Figure 5.1).29  To examine the modular nature of MMOR and
facilitate characterization of this complex protein, the ferredoxin (MMOR-Fd) and
FAD/NADH (MMOR-FAD) domains were expressed as separate polypeptides.30
NMR studies reveal that both MMOR-Fd and MMOR-FAD form well-defined
structures in solution.24,31  In nearly every respect examined, the individual MMOR
domains retain biochemical properties essentially identical to those of the
corresponding portions of full-length MMOR.  Without a covalent tether between the
domains, however, the MMOR-Fd and MMOR-FAD proteins are unable to form a
complex suitable for rapid interdomain electron transfer, since k = 1500 M-1 s-1 at 25 °C,
compared to 90 s-1 at 4 °C for internal electron transfer between cofactors in MMOR.30
In order to explore further the modularity of the sMMO reductase, MMOR
constructs were prepared in which the wild-type arrangement of [2Fe-2S] and
FAD/NADH domains is reversed to reproduce the connectivity of PDR.  The goal for
this project was to determine the extent to which the rapid interdomain electron
transfer of wild-type MMOR could be restored by connecting the domain proteins in a
non-native fashion observed in a related protein.  In this work, four linker sequences,
encompassing a variety of chemical and geometric properties, were employed to tether
the reversed domains; the spectroscopic, redox, and electron transfer properties of
these reversed-domains MMOR constructs were determined.  Through such domain
engineering, the relative effects of domain orientation, affinity, and proximity to
interdomain electron transfer may be delineated.
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MATERIALS AND METHODS
MMOR Reversed-Domains Construct Design.  To define the Fd and
FAD/NADH domain boundaries of M. capsulatus (Bath) MMOR and B. cepacia PDR,
sections of MMOR were aligned with the full-length PDR protein sequence (PDB code
2PIA) by using CLUSTAL W.32  In addition, the approximate MMOR domain sequences
(residues 1-114, Fd domain; residues 89-348, FAD/NADH domain) were compared to
and aligned with other protein sequences in the non-redundant National Center for
Biotechnology Information (NCBI) protein databases with the PSI-BLAST program.  The
final domain definition technique involved examination of the PDR secondary
structural features to ensure that the selected domain linker region was not the
terminus of an existing a-helical or b-sheet structure.  Once the domain boundaries
were set, the PDR and reversed-domains MMOR sequences were aligned.  A short
seven-amino acid linker sequence between the domains was selected based on lower
homology and lack of defined secondary structure in that region.
Four different linker sequences were designed for the reversed-domains MMOR
mutants.  The first two seven-residue linkers were chosen with the principle of minimal
perturbation.  One linker was selected as the sequence in the PDR interdomain region
and another as the MMOR sequence in that part.  A third seven-residue linker was
designed to incorporate a factor Xa protease cleavage site, which would allow the
domains to be disconnected if desired.  Finally, to investigate the importance of
domain proximity in the MMOR intramolecular electron transfer reactions, a longer
fourteen-residue linker was generated with the program LINKER.33  The primary amino
acid sequences and basic properties of the four MMOR reversed-domains constructs
(MMOR-RD) are displayed in Table 5.1.
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DNA Primer Synthesis and Purification.  All of the primers used for cloning
and DNA sequencing were designed manually and synthesized on an Applied
Biosystems Model 392 DNA/RNA synthesizer.  Each primer was purified by
polyacrylamide gel electrophoresis on a 12% denaturing polyacrylamide gel, extracted
from the gel slices by using a crush and soak method, then precipitated to remove most
of the salt added during extraction.  The DNA pellets were suspended in appropriate
quantities of deionized distilled water and stored at –20 °C.
Construction of pTrc-Fd1 and pTrc-Fd2 Plasmids.  A four-step procedure was
devised for constructing the four MMOR-RD expression vectors, as depicted in Scheme
5.1.  The mmo genes, which code for all five components of the MMO system, are
contained on a 5.5-kb section of pCH4.34  Two variations (Fd1 and Fd2) of the Fd
portion of the mmoC gene, which codes for the MMO reductase protein, were amplified
from pCH4 by polymerase chain reaction (PCR) with the primers LKFB10 (Fd1; 5’-CT-
GCGGATCCACACTATCACGGCGGTG) or LKFB20 (Fd2; 5’-AGTTGGATCCGGCC-
ATGTTAGCGGTTATTCGCGAGTTCACACTATCACGGC) and FdRH10 (5’-CCTCTC-
CAAAGCTTATGCGTCAATGGGTATAG).  The resulting 313-bp (Fd1) and 341-bp
(Fd2) fragments were flanked by BamHI and HindIII sites (bold; underlined regions are
base mismatches with template DNA), which were introduced by LKFB10/LKFB20
and FdRH10, respectively.  PCR was performed with Pfu Turbo DNA polymerase
(Stratagene, La Jolla, CA), which has 3’ ›  5’ proofreading capability, with the
following thermal cycler conditions:  45 s at 96 °C; 45 s at 96 °C, 45 s at 61 °C, and 30 s
at 72 °C for 25 cycles, followed by extension for 10 min at 72 °C.  Each mmoC-Fd PCR
product was isolated with the QIAQuick PCR purification kit (Qiagen, Inc., Valencia,
CA) and digested with BamHI (New England Biolabs, Inc., Beverly, MA) by following
the provided instructions.  After completion of the digest reaction, the restriction
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enzyme was inactivated by incubating the samples for 20 min at 80 °C.  The DNA was
isolated from the reactions (QIAQuick PCR purification kit) and then digested with
HindIII (New England Biolabs).  The high-copy-number plasmid pTrc99A (Amersham
Pharmacia, Piscataway, NJ) was digested with BamHI and HindIII by using the same
two-step procedure.  To inactivate HindIII, the Fd1, Fd2, and pTrc99A samples were
incubated for 20 min at 65 °C.  The pTrc99A digest was treated with alkaline
phosphatase (AP; Boehringer Mannheim, Indianapolis, IN) to prevent recircularization
in the subsequent ligation reaction.  After inactivating the AP by adding 20 mM
ethylene glycol-bis[b-aminoethyl ether]-N,N,N’,N’-tetraacetic acid (EGTA) and heating
at 65 °C for 10 min, DNA in the mmoC-Fd1, mmoC-Fd2, and pTrc99A digests was
purified once more (QIAQuick PCR purification kit) and ligated with T4 DNA ligase
(New England Biolabs) to yield pTrc-Fd1 (pTrc99A + Fd1) and pTrc-Fd2 (pTrc99A +
Fd2) (Scheme 5.1).  The ligase was heat-inactivated by incubation for 20 min at 65 °C,
and the ligation mixtures were transformed into supercompetent E. coli XL10-Gold
cells (Stratagene), which were selected on Luria-Bertani (LB)-ampicillin (Ap; 100
µg/mL) agar plates.  Positive clones were identified by restriction digests of DNA
isolated from plasmid minipreps.35  The sequences of the mmoC-Fd inserts were
verified by DNA sequencing (MIT Biopolymers Laboratory).
Construction of pTrc-RD1m, pTrc-RD2m, pTrc-RD3m, and pTrc-RD4 Vectors.
To introduce different linker regions into the MMOR-RD constructs, four versions
(FAD1, FAD2, FAD3, and FAD4) of the FAD/NADH region of mmoC were PCR-
amplified from pCH4 with the primers FNFE10 (5’-CGAAGACCGACCTGGAATTCT-
AAGGAGGTTATAATATGTGCCGCATCAGTTTTGGTGAG) and LKRB10 (FAD1; 5’-
GTTAGGATCCGCGCATTCGTGTTGGTTGCGCCGAATTTTTCGAAGAAGACCTG-
TTCG), LKRB20 (FAD2; 5’-GTTAGGATCCGCTGTGCGGCGCCGCTGGGCAAGA-
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ATTTTTCGAAGAAGACCTGTTCG), LKRB30 (FAD3; 5’-GTTAGGATCCGACCCTC-
AATGGTTTCATCGCCGAATTTTTCGAAGAAGACCTGTTCG), or LKRB40 (FAD4;
5’-GTTAGGATCCACCGCTACCAATGCCGAATTTTTCGAAGAAGACCTGTTCG).
The 802-bp (FAD1, FAD2, and FAD3) and 795-bp (FAD4) products were flanked by
EcoRI and BamHI sites (bold; underlined regions are base mismatches with template
DNA), which were introduced by FNFE10 and LKRB10/LKRB20/LKRB30/LKRB40,
respectively.  The double-underlined ‘A’ in LKRB10, LKRB20, and LKRB30, which was
required to incorporate the BamHI site, added a point mutation in the MMOR sequence
that was corrected by site-directed mutagenesis at a later stage in the cloning process.
PCR was performed with the thermal cycler conditions:  45 s at 96 °C; 45 s at 96 °C, 45 s
at 61 °C, and 1 min at 72 °C for 25 cycles, followed by extension for 10 min at 72 °C.
The amplified DNA was purified from the PCR reactions by using the QIAquick PCR
purification kit.  All four PCR products were digested with the restriction enzymes
EcoRI (New England Biolabs) and BamHI by following the manufacturer’s instructions.
The enzymes were heat-inactivated by incubating the samples for 20 min at 80 °C, and
the DNA was purified with the QIAquick PCR purification kit.  The plasmids pTrc-Fd1
and pTrc-Fd2 were digested with the same restriction enzymes, then treated with AP.
Following AP inactivation, the DNA was isolated with the QIAquick PCR purification
kit.  The AP-treated pTrc-Fd1, pTrc-Fd2, and mmoC-FAD digests were ligated by using
T4 DNA ligase to yield pTrc-RD1m (pTrc-Fd1 + FAD1), pTrc-RD2m (pTrc-Fd1 +
FAD2), pTrc-RD3m (pTrc-Fd1 + FAD3), and pTrc-RD4 (pTrc-Fd2 + FAD4) (Scheme
5.1).  The ligation products were transformed into supercompetent E. coli XL10-Gold
cells, and potential positive clones were identified by plating onto LB-Ap (100 µg/mL)
agar plates.  Colonies with ampicillin resistance were analyzed further by restriction
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mapping of DNA isolated from plasmid minipreps and DNA sequencing (MIT
Biopolymers Laboratory).
Site-Directed Mutagenesis to Yield pTrc-RD1, pTrc-RD2, and pTrc-RD3
Expression Vectors.  Site-directed mutagenesis (GGATCC ›  GGG TCC) was
performed to remove the point mutation required to introduce the BamHI site into the
RD1, RD2, and RD3 reversed-domains constructs.  Mutagenesis of pTrc-RD1m,
pTrc-RD2m, and pTrc-RD3m was accomplished by using the QuikChange kit
(Stratagene) and following the manufacturer’s instructions.  The primers listed in Table
5.2 were designed and purified for use in the Pfu DNA polymerase-catalyzed PCR
mutagenesis reaction.  Subsequent isolation and DNA sequencing (MIT Biopolymers
Laboratory) of pTrc-RD1, pTrc-RD2, and pTrc-RD3 (Scheme 5.1) confirmed that the
gene sequences contained only the desired mutations.
Construction of pRED-RD1, pRED-RD2, pRED-RD3, and pRED-RD4
Expression Vectors.  The final step in the reversed-domains MMOR cloning scheme
(Scheme 5.1) involved transferring the RD1, RD2, RD3, and RD4 genes from the
pTrc-RD plasmids into pKK223-3 (Amersham Pharmacia), the expression vector used
for the recombinant MMOR, MMOR-Fd, and MMOR-FAD expression systems.23,30  The
plasmids pKK223-3, pTrc-RD1, pTrc-RD2, pTrc-RD3, and pTrc-RD4 were each digested
with EcoRI and HindIII.  The mmoC-RD digests were separated from pTrc99A by
resolution on a 1% agarose-ethidium bromide gel and then extracted from the gel with
a QIAEX II kit (Qiagen).  The pKK223-3 digest was treated with AP to prevent
recircularization in the ligation reaction, the AP was inactivated as described above,
and the plasmid digest was isolated with a QIAquick PCR purification kit.  T4 DNA
ligase was used to ligate each mmoC-RD digest into the digested pKK223-3 vector.
After the ligation reactions had proceeded for 3.5 h at room temperature, the ligase was
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heat-inactivated by incubating the solutions for 20 min at 65!°C.  The resulting plasmid
solutions were transformed into supercompetent E. coli XL10-Gold cells, which were
then spread on LB-Ap (100 µg/mL) agar plates to select for pKK223-3-containing cells.
Colonies containing pRED-RD constructs were identified by restriction mapping of
DNA obtained from plasmid minipreps.
Expression Trials for the Reversed-Domains MMOR Proteins.  The pTrc99A,
pTrc-RD1, pTrc-RD2, pTrc-RD3, pTrc-RD4, pKK223-3, pRED-RD1, pRED-RD2,
pRED-RD3, and pRED-RD4 plasmids (Scheme 5.1) were transformed into E. coli JM105
cells for expression trials.  The ten clones were grown to saturation in 4-mL LB-Ap (100
µg/mL) cultures.  Aliquots (100 µL) of the saturated starter cultures were used to
inoculate 50-mL quantities of LB medium supplemented with 100 µg/mL of Ap and
500-µL quantities of 10 mM Fe(NH4)2(SO4)2·6H2O in 100 mM sodium citrate (pH 7.0),
and the cells were incubated at 37 °C with shaking (200 rpm).  When the OD660 of the
JM105/pTrc99A and JM105/pKK223-3 cultures reached ~0.6, MMOR-RD expression
was induced by adding 80 µM FeSO4 and 1.0 mM isopropyl b-D-thiogalactopyranoside
(IPTG).  Samples (1.0!mL) were collected from each culture just before induction, 15
min after induction, and then at 60-min intervals for the following 5!h.  To separate the
soluble and insoluble fractions of the MMOR-RD time-course expression samples,
BugBuster protein extraction reagent (Novagen, Inc., Madison, WI) was used according
to the manufacturer’s instructions.  In brief, each cell pellet was thawed and suspended
in 100 µL of BugBuster solution to which DNase had been added.  The samples were
gently agitated at room temperature for ca. 12 min, centrifuged for 20 min at 16,000g to
separate the soluble and insoluble cellular components, and decanted into clean tubes.
The pellets were washed with 100 µL of 25 mM potassium phosphate (pH 7.0) and then
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suspended in 100 µL of the same buffer.  The samples were analyzed by SDS-PAGE on
12% polyacrylamide gels.
Expression and Purification of MMOR-RD Proteins.  A JM105/pRED-RD1
clone was grown to saturation in 100 mL of LB-Ap (100 µg/mL) medium at 37 °C with
200 rpm shaking.  To each of six 1-L quantities of LB-Ap (100 µg/mL) medium were
added 10 mL of 10 mM Fe(NH4)2(SO4)2·6H2O in 100 mM sodium citrate (pH 7.0) and 10
mL of the saturated JM105/pRED-RD1 starter culture.  When the OD660 reached ca. 0.6,
the cultures were supplemented with 80 µM FeSO4, added as 2 mL of 40 mM
FeSO4·7H2O in 12.5 mM H2SO4 per L of cell culture, and induction was started by
adding IPTG to a final concentration of 1.0 mM.  After 4 h, the cells were collected by
centrifugation, drained briefly, and then suspended in 100 mL of cold cracking buffer
[25 mM 3-(N -morpholino)propanesulfonic acid (MOPS; pH 7.0), 1 mM 1,4-
dithiothreitol (DTT), 5 mM MgCl2, and 200 µM Fe(NH4)2(SO4)2·6H2O] containing DNase
(1.5 U/mL) and 1 mM Pefabloc SC (Boehringer Mannheim).  The cells were sonicated
on ice with three 2-min pulses at 40% output (Branson Sonifier Model 450 equipped
with a 3/4-inch horn) and then centrifuged for 40 min at 98,000g to separate the soluble
and insoluble materials.  The soluble cell extract was filtered through 0.2 µm
membranes before loading onto a DEAE Sepharose CL-6B (Amersham Pharmacia)
column (2.6 ¥ 15 cm) equilibrated in buffer A [25 mM MOPS (pH 7.0), 1 mM DTT, and
50 mM NaCl].  After a 120-mL wash with buffer A, proteins were eluted with a 740-mL
linear gradient from buffer A to buffer B [25 mM 3-(N-morpholino)propanesulfonic
acid (MOPS; pH 7.0), 1 mM DTT, and 500 mM NaCl].  Fractions containing the RD1
protein were identified by SDS-PAGE and UV-visible spectroscopy, pooled, and
concentrated by ultrafiltration.  This crude RD1 protein solution was diluted fivefold
with 25 mM MOPS (pH 7.0), 2 mM DTT and applied to a 5’-AMP Sepharose (Sigma, St.
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Louis, MO) column (2.6 ¥ 18 cm) equilibrated with buffer A.  After washing the column
with buffer A to remove protein contaminants, pure MMOR-RD1 was eluted with
buffer B containing 0.8 mM NADH.  Fractions containing the MMOR-RD1 protein
(PDR linker), as identified by color and SDS-PAGE, were pooled and exchanged into 25
mM MOPS (pH 7.0), 2 mM DTT with a Biogel P6 desalting column (Bio-Rad, Hercules,
CA).  The MMOR-RD2 (MMOR linker), MMOR-RD3 (factor Xa site), and MMOR-RD4
(long linker) proteins were expressed from JM105/pRED-RD2, JM105/pRED-RD3, and
JM105/pTrc-RD4, respectively, and purified by following the same protocol.
Purification of MMOH, MMOB, and MMOR.  MMOH was isolated from M.
capsulatus (Bath) by using a slightly modified published protocol.16  Pure hydroxylase
contained 3.9-4.0 mol Fe per mol protein, as determined by ferrozine iron assays,36,37
and exhibited a specific activity of 250-300 nmol min-1 mg-1 of MMOH for the
conversion of propylene to propylene oxide at 45 °C.  MMOB was expressed from a
recombinant E. coli system38 and purified as described in Chapter 4.  Recombinant
MMOR was expressed and purified as published,23 except that the iron additions were
performed as described above for the MMOR-RD expression systems.
Basic Characterization of MMOR-RD Constructs.  To assess the purity of the
reversed-domains proteins, SDS-PAGE and native PAGE gels were run for the four
MMOR-RD constructs with wild-type MMOR (MMOR-wt) included for comparison.
The MMOR-RD proteins in 25 mM MOPS (pH 7.0), 0.3 mM DTT were submitted to the
MIT Biopolymers Laboratory for analysis by electrospray ionization mass spectrometry
(ESI-MS).  To remove cofactors which separated from the proteins upon treatment with
formic acid, ammonium acetate, and acetonitrile, HPLC purification was necessary.
The protein component was analyzed with a Sciex model API 365 triple-stage mass
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spectrometer.  Iron assays were carried out to determine whether the MMOR-wt
extinction coefficient (e458 = 20,800 M-1 cm-1) was altered in the MMOR-RD proteins.
Optical Spectra of Oxidized and Reduced MMOR-RD Proteins.  All UV-
visible spectra were obtained with a Hewlett Packard 8453 diode array
spectrophotometer.  To examine the MMOR-RD optical spectra in various oxidation
states, anaerobic reductive titrations were performed.  A 1-mL aliquot of 40 µM MMOR
(RD1, RD2, RD3, or RD4) in 25 mM potassium phosphate (pH 7.0) was transferred to a
sealed quartz cuvette and made anaerobic by 12 cycles of vacuum gas exchange with
O2-free N2.  Aliquots of 2 mM sodium dithionite were added with a gastight Hamilton
titrating syringe.  After each addition, optical spectra (300-900 nm) were collected until
no further changes were observed (generally less than 5 min), and the final spectrum
was saved for analysis.  This process was repeated until the protein was reduced
completely.  The temperature was maintained at 25 °C with a circulating water bath.
Previous studies of the individual MMOR-FAD domain revealed that its optical
spectrum is quite sensitive to buffer composition, whereas the optical properties of
MMOR-Fd remain unchanged by varying pH or ionic strength.30  Therefore, it was
assumed that the [2Fe-2S] cofactors in the MMOR-RD constructs have optical spectra
identical to that of MMOR-Fd (Figure 5.2).  In order to determine component spectra
for the fully oxidized MMOR-RD flavin domains (FADox), a scaled oxidized MMOR-Fd
(Fdox) spectrum was subtracted from the initial titration spectrum such that the
absorbance above 550 nm was zero in each calculated spectrum.  In the same manner,
fully reduced component spectra (FADhq) were obtained by subtracting appropriately
scaled reduced MMOR-Fd (Fdred) spectra from the fully reduced MMOR-RD spectra.
Relative Redox Potential Determinations.  The differences between the three
reductase equilibrium midpoint potentials were determined for each MMOR-RD
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† 
DA(l) = SDei(l)(Dci)
construct by analyzing reductive titration data.  In addition to the FADox and FADhq
component spectra calculated for the MMOR-RD constructs (vide supra), the Fdox,
Fdred, and FADsq component spectra determined previously for the separate MMOR
domains (Figure 5.2)30 were employed.  For each redox couple (Fdox/Fdred,
FADox/FADsq, and FADsq/FADhq), a difference spectrum, ∆ei(l), was generated by
subtracting the extinction coefficients of the oxidized species from those of the reduced
species.
First, dilution corrections were applied to each spectrum in a titration data set.
A difference spectrum for each titration point was calculated by subtracting the initial
oxidized spectrum from each spectrum in the data set.  These difference spectra (350 ≤
l ≤ 800 nm) were then fit with linear combinations of component difference spectra
(KaleidaGraph, version 3.51; Synergy Software, Reading, PA), as shown in eq 1.  The
(1)
concentration differences, ∆ci, returned by fitting with eq 1 were readily converted to
species concentrations by comparison to total cofactor concentrations.  Relative
MMOR-RD redox potentials (∆E°’) were calculated with modified Nernst equations.
Average ∆E°’ values were computed by including only those data for which all four
relevant species were present at greater than 10% of the total cofactor concentrations.
Redox Potential Determinations for MMOR-RD Constructs.  Because many of
the MMOR-RD ∆E°’ values were significantly altered from those of MMOR-wt,
absolute values for the redox potentials were determined.  Anaerobic reductive
titrations of the MMOR proteins were repeated exactly as described except for the
inclusion of one or more redox-active indicator dyes with known midpoint potentials
to permit calculation of the solution potential throughout the titrations.  Dyes used for
MMOR-RD potential determination included anthraquinone-2-sulfonate (AQ2S; E°’ =
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–226 mV), phenosafranine (E°’ = –252 mV), safranine O (E°’ = –289 mV; RD3 only), and
anthraquinone-2,6-disulfonate (AQ2,6S; E°’ = –184 mV; RD2 only) in combination with
phenosafranine (15-20% relative to AQ2,6S).  Dye concentrations were ca. 40 µM for
AQ2S and AQ2,6S and ca. 10 µM for phenosafranine and safranine O.  The MMOR-RD
concentration was 30 µM in all titrations including redox dyes.
The titration data were converted to difference spectra as described and fit with
linear combinations of component difference spectra for the four redox couples
(dyeox/dyered, Fdox/Fdred, FADox/FADsq, and FADsq/FADhq).  Modified Nernst
equations were used to calculate the solution potential and MMOR-RD midpoint
potentials for each titration point.  Only those data for which the solution potential was
within 40 mV of both the indicator potential and approximate MMOR-RD potential
were included in average E°’ calculations.
Steady-State Dye Reduction Activity Assays.  The ability of the MMOR-RD
constructs to transfer electrons from NADH to redox-active dyes was investigated with
steady-state assays.  Reductase (83 nM), dichlorophenolindophenol (DCPIP, Sigma; 47
µM, E°’ = +217 mV), and 25 mM MOPS (pH 7.0) were combined in a masked cuvette.
NADH (160 µM) was introduced to initiate the reaction, and DCPIP reduction was
monitored at 600 nm (e600 = 22,000 M-1 cm-1) for 30 s with a 1-s integration time.  The
assays were repeated with K3Fe(CN)6 (92 µM, E°’ = +360 mV) in place of DCPIP.
Reduction of [Fe(CN)6]3– was observed at 420 nm (e420 = 1020 M-1 cm-1) for 60 s.
Duplicate samples were analyzed for each MMOR-RD construct as well as wild-type
MMOR.  The temperature was held constant at 15 °C with a circulating water bath for
all assays.  The absorbance vs time data were fit with lines in the spectrophotometer
software to obtain rate constants for the dye reduction reactions.
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Steady-State sMMO Activity Assays.  To determine the competence of the
MMOR-RD constructs for binding and transferring electrons to the hydroxylase,
steady-state sMMO assays were performed.  In a quartz cuvette, 1 µM MMOH, 1 µM
MMOB, 0.8 mM propylene, and 25 mM MOPS (pH 7.0) were mixed.  The reductase
concentration was varied from 0 to 3.2 µM; nine different concentrations were assayed.
NADH (160 µM) was added to initiate the propylene epoxidation reaction, and NADH
consumption was monitored at 340 nm (e340 = 6220 M-1 cm-1) for 60 s.  The temperature
was maintained at 25 °C with a circulating water bath.  Kinetic traces were fit with lines
in the spectrophotometer software.  Plots of activity vs [MMOR] were constructed and
fit with a hyperbola plus a line (MMOR-wt) or a line (MMOR-RD constructs) in
KaleidaGraph.
In addition, sMMO activity assays were carried out with nitrobenzene as the
substrate.  MMOH (1 µM), MMOB (2 µM), reductase (0.4 µM or 2 µM), and
nitrobenzene (1 mM), were combined in 25 mM MOPS (pH 7.7).  After adding NADH
(150 µM), p-nitrophenol formation was monitored at 404 nm (e404 = 15,000 M-1 cm-1) for
180 s.  The temperature was held constant at 25 °C.  Rates were determined by fitting
the kinetic traces with lines in the spectrophotometer software.  Upon complete
oxidation of NADH, a visible spectrum was collected for each reaction.
MMOR-RD Reactions with NADH.  Interdomain electron transfer rates for the
MMOR-RD constructs were determined in stopped-flow experiments.  A Hi-Tech
Scientific SF-61 DX2 double-mixing stopped-flow spectrophotometer configured in
either single-wavelength photomultiplier or multiwavelength diode array mode was
used for all data collection.  The stopped-flow apparatus was made anaerobic by
flushing the flow cell and syringes first with a solution of ca. 5 mM sodium dithionite
and then with anaerobic buffer to remove the dithionite.  Oxidized MMOR (wild-type,
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RD1, RD2, RD3, or RD4) in 25 mM MOPS (pH 7.0) was made anaerobic by 10-12 cycles
of vacuum gas exchange with O2-free N2.  Anaerobic NADH solutions were prepared
by bubbling with N2 for at least 15 min.  After mixing, concentrations of MMOR and
NADH were 20 µM and 200 µM, respectively.  The reaction of reductase with NADH
was monitored at 458, 625, and 725 nm in single-wavelength mode.  Data points (512)
were collected in 1- to 500-s shots with a logarithmic time base.  The experiment was
repeated with the stopped-flow configured for diode array mode.  For each 1.5- to 300-s
shot, 160 spectra (350-800 nm) were recorded on a log time scale.  The temperature was
maintained at 4 °C with a constant-temperature circulating water bath for all
experiments.  Single-wavelength kinetic traces were fit with a sum of three to five
exponential decays with the program KinetAsyst, version 3.04 (Hi-Tech Limited,
Salisbury, England).  Diode array data analysis was performed with Specfit, version
3.0.16 (Spectrum Software Associates, Chapel Hill, NC).
RESULTS
Expression of MMOR-RD Constructs.  Eight plasmids (pTrc-RDn  and
pRED-RDn, where n = 1-4) were prepared for expressing the engineered reversed-
domains MMOR constructs in E. coli hosts.  In each of the initial expression tests, there
was a time-dependent buildup of protein of the appropriate molecular weight in the
soluble cell extract.  The recombinant MMOR-RDn proteins represented the major
soluble protein in all of the systems.  Only in JM105/pRED-RD4 cells did a significant
amount of recombinant protein accumulate in the insoluble fraction.  Therefore, the
JM105/pTrc-RD4 expression system, for which inclusion bodies were not observed,
was used to express the MMOR-RD4 (long linker) construct.
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Initial Characterization of MMOR-RD Constructs.  All four MMOR-RD
proteins were expressed and purified in good yield (Table 5.3).  On SDS-PAGE and
native PAGE gels, the reversed-domains reductases migrated like wild-type MMOR.
The molecular weights of the apoproteins determined by ESI-MS matched closely the
expected values.  Each MMOR-RD construct contained nearly stoichiometric iron
(Table 5.3), demonstrating that the MMOR-wt extinction coefficient (e458 = 20,800 M-1
cm-1) was relatively unperturbed by domain swapping.  Only MMOR-RD2, with 1.86
mol Fe per mol protein, was slightly iron depleted.  Upon storage of samples at 4 °C,
the [2Fe-2S] clusters in the MMOR-RD proteins were significantly less stable than the
same cofactor in MMOR-wt, as revealed by accelerated loss of the pinkish-brown
ferredoxin color in the mutants.
MMOR-RD Optical Spectra.  Optical spectra recorded for the oxidized
MMOR-RD proteins could be fit reasonably well with a linear combination of the
oxidized MMOR-Fd (Fdox) and MMOR-FAD (FADox) component spectra (Figure 5.2).30
An extremely good fit to the MMOR-RD2 spectrum was obtained (Figure 5.3),
suggesting that the RD2 [2Fe-2S] and flavin cofactors are in environments essentially
identical to those of wild-type MMOR.  Small but significant deviations between the
combined component spectra and the RD1, RD3, and RD4 visible spectra were noted.
By subtracting the [2Fe-2S] contributions from the fully oxidized and fully reduced
MMOR-RD optical spectra, FADox and FADhq component spectra were generated
(Figure 5.4).  In both cases, the RD2 spectra were identical to those of wild-type
MMOR, whereas the RD1 and, to a greater extent, RD3 and RD4 spectra displayed
differences, indicating slight perturbation of the flavin site with respect to that of
MMOR-wt.
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Redox Potentials of MMOR-RD Constructs.  Relative redox potentials of each
reversed-domains reductase were determined with reductive titrations (Table 5.4).
Many of the ∆E°’ values were significantly altered compared to those measured for
MMOR23 or the individual MMOR domains.30  In particular, the FADox/sq – [2Fe-2S]ox/red
and FADox/sq – FADsq/hq difference potentials of RD1, RD3, and RD4 were considerably
lower (ca. 30 mV), suggesting decreased FADox/sq potentials in these mutants.  A key
limitation of this method is the difficulty of accurately measuring ∆E°’ values for
widely separated potentials, since there are few solution potentials at which significant
amounts of all four relevant species are present.
Therefore, a series of reductive titrations including indicator dyes was
performed to establish absolute values for the MMOR-RD redox potentials.  Figure 5.5
shows selected difference spectra obtained from a titration of MMOR-RD2 with the
indicator AQ2S.  Calculated midpoint potentials for the three redox couples of each
protein are displayed in Table 5.5.  There is generally good agreement between the
relative and absolute redox potential measurements, with a mean deviation of 6.8 mV.
The FADox/sq potentials of RD1, RD3, and RD4 are 32, 44, and 33 mV, respectively,
lower than that of MMOR-wt.23  In addition, a 27-mV decrease in the FADsq/hq potential
was measured for the RD3 construct.  All four MMOR-RD proteins have moderately
lower [2Fe-2S]ox/red potentials (9-18 mV) compared to wild-type MMOR.
Steady-State Diaphorase Activity.  The reversed-domains reductases were able
to transfer electrons from NADH to redox-active dyes at rates similar to those
measured for MMOR-wt (Table 5.6).  With DCPIP as the electron acceptor,
MMOR-RD2 was 26% less active and MMOR-RD4 was 20% more active than the wild-
type, RD1, and RD3 reductases.  Assays with ferricyanide revealed enhanced activity
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for the RD4 (86%) and RD2 (15%) constructs and substantially decreased activity for
RD3 (26% of wild-type).
Steady-State sMMO Activity.  To investigate electron transfer to MMOH,
assays were performed for the steady-state sMMO reaction with propylene at 25 °C at
various reductase concentrations.  As shown in Figure 5.6, none of the four MMOR-RD
proteins behaved like wild-type MMOR in this experiment.  For MMOR-wt, the NADH
consumption vs [MMOR] plot could be fit with a hyperbolic function representing
NADH oxidation coupled to propylene oxide formation (sMMO activity) plus a line
representing dioxygen reduction to hydrogen peroxide by excess reductase (oxidase
activity).  All four MMOR-RD NADH consumption curves could be fit extremely well
without the hyperbolic function, suggesting that electron transfer to the hydroxylase
was negligible.  The oxidase activities of the RD1, RD3, and RD4 reductases were 4-8
times higher than that measured for MMOR-wt (Table 5.6).  The RD2 construct,
however, reduced dioxygen to peroxide at only half the wild-type rate.  When
nitrobenzene was used as a substrate, p-nitrophenol formation was not observed for
any of the reactions including MMOR-RD constructs, confirming that the reversed-
domains reductases are not competent for electron transfer to the hydroxylase.
Kinetics of MMOR-RD Reduction with NADH.  The reaction of the
MMOR-RD constructs with NADH was studied by stopped-flow UV-visible
spectroscopy.  Figures 5.7A and 5.7B show typical data sets collected for the reduction
of MMOR-wt and MMOR-RD4, respectively, with NADH at pH 7.0 and 4 °C.  The
kinetic steps for this reaction, which were determined previously for wild-type
MMOR16,23 and MMOR-FAD,30 are depicted in Scheme 5.2.  Spectra corresponding to
four or five intermediates were resolved with Specfit software by using a sequential
four- (RD4) or five-component (wt, RD1, RD2, and RD3) model (Figures 5.7C and
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5.7D).  When NADH binds to MMOR, species CT1, which is characterized by a charge
transfer interaction between the NADH nicotinamide ring and the FAD isoalloxazine
moiety (lmax ≈ 575 nm), is formed.  Hydride transfer from NADH to the oxidized flavin
(FADox) yields intermediate CT2, which exhibits a lower-energy charge transfer band
(lmax ≈ 740 nm) between the reduced FAD (FADhq) and NAD+ cofactors.  Upon NAD+
release, species CT2 decays to form intermediate HQ, which has FADhq and [2Fe-2S]ox
cofactors.  Interdomain electron transfer produces the final species, SQ, with a
spectrum characteristic of FADsq and [2Fe-2S]red.  In MMOR-wt, ca. 65% of the total
electron transfer from FADhq to the oxidized [2Fe-2S] cluster occurs simultaneously
with NAD+ release.
Single-wavelength stopped-flow data were collected at 458, 625, and 725 nm for
each of the MMOR-RD proteins, as well as MMOR-wt (Figure 5.8).  The kinetic traces
were fit with sums of three to five exponential decays.  CT1 formation is observed as an
increase in A625; CT2 formation produces an increase in A725.  Subsequent decreases in
both A625 and A725 correspond to CT2 decay/HQ formation.  Intramolecular electron
transfer to form SQ yields an increase in A625 and a decrease in A725.  All four transitions
are marked by decreases in A458.  A fifth step describing a slow process, such as reaction
with excess NADH to form three-electron reduced MMOR, was required for data
fitting at long time points.  The rate constants determined for the five reductases are
summarized in Table 5.7.
DISCUSSION
MMOR-RD Constructs.  All four MMOR-RD constructs were prepared in good
yield and with nearly full cofactor occupancy.  The optical spectra of the oxidized RD1,
RD3, and RD4 reductases show changes in the flavin component with respect to the
222
MMOR-wt spectrum (Figure 5.4).  The altered MMOR-RD FADox spectra, which exhibit
increased extinction coefficients at 394 nm, resemble free flavin mononucleotide more
closely than does the wild-type FADox spectrum.  Therefore, this optical change may
correspond to an increase in solvent accessibility to the flavin cofactor in the RD1, RD3,
and RD4 constructs.  In fact, the largest optical changes are observed for RD3 (long
linker) and RD4 (negatively charged linker); the RD1 (uncharged polar linker)
spectrum is moderately perturbed.  Only RD2, with a largely hydrophobic linker,
displays an unchanged optical spectrum.  Thus, in the reversed-domains reductases,
the linker sequence appears to influence the flavin environment either by direct contact
or by structural perturbations that decrease hydrophobicity near the cofactor.
MMOR-RD Redox Potentials.  Measurements of both relative and absolute
redox potentials for the four MMOR-RD proteins revealed substantial decreases in
many of the flavin potentials compared to those of MMOR-wt23 and MMOR-FAD30
(Tables 5.4 and 5.5).  The FADox/sq redox potential in the RD1, RD3, and RD4 constructs
is lowered by 30-45 mV, a result that correlates well with the optical changes observed
for these proteins.  Like the 350-450 nm region of the FADox visible spectrum, the
FADox/sq potential seems to be modulated by the hydrophobicity of the flavin
environment.  The first residue of the linker sequence is probably the key determinant
in these shifted flavin properties.  Analysis of a preliminary MMOR-FAD NMR
structure indicates that the side chain of Leu246 (residue 343 in full-length MMOR)
packs against the FAD cofactor; residues Pro247 and Ser248 may also contact the
flavin.31  In MMOR-RD2 (MMOR linker), the Leu, Pro, and Ser residues are preserved,
and the optical and redox features of MMOR-wt are retained.  The first linker residue
in RD1, RD3, and RD4 is glycine, which cannot make hydrophobic contacts with the
isoalloxazine group.  Moreover, the conformational flexibility afforded by this amino
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acid probably increases solvent accessibility to the flavin ring.  The possibility that the
remainder of the RD2 linker/MMOR-FAD sequence (Pro247, Ser248, Gly249, Ala250,
and Ala251) affects the flavin cofactor cannot be ruled out, however.
In addition, the FADsq/hq potential of MMOR-RD3 is decreased by 26 mV relative
to MMOR-wt.  This effect is most likely due to destabilization of the anionic flavin
hydroquinone species by the presence of three carboxylate groups on the RD3 linker.
All four MMOR-RD constructs exhibit moderately lower (9-18 mV) [2Fe-2S]ox/red
potentials than wild-type MMOR.  Although these differences are small and largely
within experimental error of each other, they may reflect a slight perturbation in the
[2Fe-2S] environment.  The significantly decreased stability of the iron-sulfur clusters
in the MMOR-RD proteins lends support for this possibility.  Because the redox and
stability effects on the [2Fe-2S] cofactor are quite similar in all of the reversed-domains
reductases, a minor change in structure or orientation of the Fd domain, rather than
direct interaction with linker residues, might be expected.
Steady-State MMOR-RD Activity.  Altering the connectivity of the MMOR
domains did not seriously disrupt steady-state electron transfer from NADH to redox-
active dyes.  As indicated by increased activities in both DCPIP and K3Fe(CN)6 assays,
the long, flexible RD4 linker may afford better accessibility of substrates to the
reductase cofactors.  Conversely, the protected flavin cofactor of RD2 may prevent
efficient interaction with DCPIP, resulting in a 26% decrease in diaphorase activity
compared to MMOR-wt.  The substantial rate decrease observed for MMOR-RD3 (26%
of wild-type activity) in the ferricyanide experiment is probably the result of repulsion
between the three negatively charged residues in the RD3 linker sequence and the
negatively charged [Fe(CN)6]3– substrate.
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Although the MMOR-RD constructs were predicted to retain activity in steady-
state sMMO reactions, no evidence of productive electron transfer to MMOH was
observed in propylene or nitrobenzene assays.  Even with somewhat altered reductase
redox potentials, the normal electron transfer pathway, NADH › FAD › [2Fe-2S] ›
MMOH, is thermodynamically favored in the MMOR-RD constructs.  Therefore, either
interdomain electron transfer is blocked in MMOR-RD proteins or the reversed-
domains constructs do not make suitable complexes with MMOH.  Attaching a His6 tag
to the N-terminus of MMOR-Fd abolishes cross-linking to MMOH,39 which suggests
that the N-terminal portion of the ferredoxin domain is involved in binding MMOH.  If
so, linking the 27-kDa MMOR-FAD domain at this position, as done in this work,
would interfere with MMOH–MMOR complex formation.
In the steady-state sMMO assays, the RD1, RD3, and RD4 reductases exhibited
considerably elevated oxidase activities relative to that of wild-type MMOR (Table 5.6).
The MMOR-RD1 construct, with an uncharged polar linker, showed a fourfold increase
in dioxygen reduction.  More hydrophilic (RD3) and longer (RD4) linkers afforded
even larger (6- to 8-fold) enhancements.  Again, this behavior can be explained by
increased solvent/substrate accessibility to the reductase cofactors.  On the other hand,
the low oxidase activity measured for the MMOR-RD2 protein indicates that its
cofactors are well isolated from solvent.
Reaction of MMOR-RD Constructs with NADH.  Reduction of the MMOR-RD
constructs with NADH at pH 7.0 and 4 °C proceeds via the same kinetic steps
described previously for wild-type MMOR,16,23 except that NAD+ release and
interdomain electron transfer do not coincide (Scheme 5.2).  By analogy to MMOR23
and MMOR-FAD,30 NADH is presumed to bind rapidly to MMOR-RD, forming a
Michaelis complex, MC1, with an optical spectrum identical to that of oxidized
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reductase.  Next, a conformational rearrangement gives rise to the FAD–NADH charge
transfer interaction of species CT1.  This step occurs at 350-400 s-1 in both MMOR-wt
and MMOR-FAD, but for the FAD domain protein, relatively weak binding to NADH
(Kd = 25 µM vs 3.8 µM for MMOR) reduces the observed rate constant to 290 ± 20 s-1 in
the presence of a 10-fold excess of NADH.30  All four MMOR-RD proteins exhibit
reduced CT1 formation rates, ranging from 96 s-1 for RD3 to 229 s-1 for RD2 (Table 5.7).
Because NADH concentration dependence experiments were not performed for the
reversed-domains reductases, this decrease in the observed rate constant cannot be
assigned definitively to either reduced affinity for NADH or a slower conformational
change.  It was noted during purification, however, that the MMOR-RD proteins,
particularly the RD3 construct, did not bind well to the Sepharose 5’-AMP affinity
column.  This observation suggests that weak affinity for NADH is at least partly
responsible for the depressed CT1 formation rates.
Hydride transfer from NADH to the flavin cofactor yields intermediate CT2,
which is characterized by a charge transfer interaction between NAD+ and FADH–.
This electron transfer step proceeds at 180-190 s-1 in MMOR-wt and MMOR-FAD, as
well as MMOR-RD2.  The other MMOR-RD proteins have nearly identical CT1 and
CT2 formation rates, indicating that the rate of hydride transfer may be limited by
generation of the initial charge transfer complex.  Release of NAD+ to form
intermediate HQ, which has FADhq and [2Fe-2S]ox cofactors, occurs at 90 s-1 in MMOR
and MMOR-FAD.  Rates ranging from 75 s-1 (RD2) to 14 s-1 (RD3) were observed for the
reversed-domains constructs, reflecting varying affinities for NAD+.  In MMOR-wt, a
fraction of intramolecular electron transfer from FADhq to [2Fe-2S]ox (ca. 65% of total)
takes place upon NAD+ release; no electron transfer was detected for any of the
MMOR-RD constructs in this kinetic step.
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The final step, interdomain electron transfer to yield species SQ with cofactors
largely in the FADsq and [2Fe-2S]red oxidation states, proceeds at 25 s-1 for wild-type
MMOR, corresponding to ca. 35% of the total observed intramolecular electron
transfer.  This reaction is significantly slower in all four MMOR-RD proteins.  A rate
constant of 0.9 s-1 was measured for MMOR-RD4 (long linker), which represents a 28-
fold decrease with respect to MMOR-wt.  Participation of the histidine and tyrosine
residues of the RD4 linker in electron transfer is possible, although rather unlikely.  The
other reversed-domains reductases exhibit far slower interdomain electron transfer
rates:  0.036 s-1 for RD1 (700-fold decrease), 0.0062 s-1 for RD2 (4000-fold decrease), and
0.038 s-1 for RD3 (660-fold decrease).  Electron transfer in the three extremely slow
reactions may actually involve bimolecular processes.  If this step were to occur by a
second-order reaction in the RD1, RD2, and RD3 constructs, the sequestered flavin ring
in MMOR-RD2 may contribute to the especially low interdomain electron transfer rate
observed for this protein.
Regardless of the electron transfer pathway, none of the MMOR-RD constructs
with a short, 7-residue linker sequence is able to transfer electrons efficiently between
the flavin and [2Fe-2S] cofactors.  The short linkers apparently do not allow the
reductase domains to align properly for rapid electron transfer.  Tethering the
reductase domains with a long, flexible linker, however, afforded an engineered
protein, MMOR-RD4, with a reasonably fast interdomain electron transfer rate (0.9 s-1
at 4 °C).  This result suggests that the orientation of domains in MMOR may be
different than that in PDR.  There is precedence for such variable interdomain contacts
among FNR family proteins.  For instance, in the maize leaf ferredoxin (Fd)–FNR
complex, the Fd protein is rotated ca. 180° about the [2Fe-2S]–flavin axis with respect to
the PDR domain arrangement.40  Alternatively, a longer linker may be required in
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MMOR to accommodate the adenosine portion of FAD, which is absent from the FMN
cofactor of PDR.
Conclusions.  By reattaching the separated [2Fe-2S] and FAD domains of
MMOR in a non-native configuration, interdomain electron transfer can be restored, at
least in part, thereby demonstrating the truly modular nature of the FNR family
proteins.  The requirement of a long, flexible linker for efficient electron transfer
between MMOR-RD cofactors provides the first information about domain orientation
in full-length MMOR, the structure of which has not yet been determined.  Changing
Leu343 (MMOR numbering) to glycine in three of the MMOR-RD constructs reveals a
role for this residue in modulating the flavin optical spectrum, FADox/FADsq redox
potential, and reactivity with electron acceptors.  This work opens the road to a more
systematic investigation of MMOR-RD proteins with long linker sequences to establish
the roles of affinity, proximity, and orientation in the interdomain electron transfer
reaction.
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Table 5.1:  Primary Sequences for Reversed-Domains MMOR Constructs
Protein Linker Type N-Terminal Sequence Linker Residues C-Terminal Sequence
RD1 PDR MMOR(99-342) GATNTNA MMOR(3-98)
RD2 MMOR MMOR(99-342) LPSGAAQ a MMOR(3-98)
RD3 factor Xa site MMOR(99-342) GDETIEG MMOR(3-98)
RD4 long (14 aa) b MMOR(99-342) GIGSGGSGHVSGYS MMOR(3-98)
a!LPSGAA, MMOR residues 343-348; Q, MMOR residue 2.  b!Abbreviation:  aa, amino acid
residues.
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Table 5.2:  Primers for Site-Directed Mutagenesis of MMOR-RD Sequences
Construct Forward Primer a
RD1 5’-CCAACACGAATGCGCGGGTCCACACTATCACG
RD2 5’-CGCCGCACAGCGGGTCCACACTATCACG
RD3 5’-CCATTGAGGGTCGGGTCCACACTATCACGG
a  Forward primers are depicted; reverse primers are the reverse complements.  The
altered codon, which corresponds to Val4 of the Fd domain, is shown in bold with the
altered base underlined.
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Table 5.3:  Properties of MMOR and MMOR-RD Constructs
Reductase Linker
Yield
(mg/L)
MW (Da),
measured
Fe content
(mol/mol protein)
lmax (nm)
pH 7.0, 25 °C
A458/A394
(FADox)
MMOR n/a 15 a 38,547 ± 4 a 2.05 ± 0.05 a 337, 395, 465 1.33
RD1 PDR 25 38,413 ± 4 b 1.94 ± 0.02 337, 398, 458 1.25
RD2 MMOR 23 38,409 ± 4 c 1.86 ± 0.05 337, 397, 464 1.35
RD3 Xa site 19 38,484 ± 4 d 1.98 ± 0.11 339, 398, 463 1.11
RD4 long 13 38,985 ± 4 e 1.97 ± 0.02 339, 396, 458 1.14
a!As reported in ref 23.  b!Expected 38,415 Da for apoprotein.  c!Expected 38,410 Da for apoprotein.
d!Expected 38,487 Da for apoprotein.  e!Expected 38,989 Da for apoprotein.
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Table 5.4:  Relative Redox Potentials for MMOR-RD Constructs a
Protein FADox/sq – Fdox/red (mV) Fdox/red – FADsq/hq (mV) FADox/sq – FADsq/hq (mV)
MMOR b 33 ± 21 57 ± 29 90 ± 22
domains c 33 ± 3 61 ± 5 94 ± 6
RD1 4 ± 6 58 ± 7 62 ± 13
RD2 45 ± 2 64 ± 1 109 ± 4
RD3 9 ± 6 53 ± 8 62 ± 14
RD4 19 ± 3 48 ± 8 67 ± 11
a!Differences between MMOR redox potentials measured at pH 7.0 and 25 °C.  FADox/sq, FADox/FADsq
redox couple; Fdox/red, [2Fe-2S]ox/[2Fe-2S]red redox couple; FADsq/hq, FADsq/FADhq redox couple.  Bold
values deviate significantly from those of the MMOR domains.  b!As reported in ref 23.  c!As reported in
ref 30.
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Table 5.5:  Absolute Redox Potentials for MMOR-RD Constructs a
Protein FADox/sq (mV) b ∆ (mV) Fdox/red (mV) ∆ (mV) FADsq/hq (mV) ∆ (mV)
MMOR c –176 ± 7 n/a –209 ± 14 n/a –266 ± 15 n/a
domains d –172 ± 2 n/a –205 ± 1 n/a –266 ± 4 n/a
RD1 –208 ± 1 –32 –219 ± 2 –10 –269 ± 5 –3
RD2 –166 ± 5 +10 –218 ± 7 –9 –270 ± 7 –4
RD3 –220 ± 4 –44 –227 ± 5 –18 –293 ± 6 –27
RD4 –209 ± 4 –33 –221 ± 3 –12 –272 ± 4 –6
a!Measured at pH 7.0 and 25 °C.  b!FADox/sq, FADox/FADsq redox couple; Fdox/red, [2Fe-2S]ox/[2Fe-2S]red
redox couple; FADsq/hq, FADsq/FADhq redox couple.  Bold values deviate significantly from those of the
MMOR domains.  c!As reported in ref 23.  d!As reported in ref 30.
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Table 5.6:  Steady-State Activities for MMOR-RD Proteins a
Protein
DCPIP reduction b
(µmol min-1 mg-1)
Rel.
Act.
[Fe(CN)6]3– reduction!b
(µmol min-1 mg-1)
Rel.
Act.
oxidase activity c
(µmol min-1 mg-1)
Rel.
Act.
MMOR 8.8 ± 0.2 1.00 10.7 ± 0.6 1.00 0.095 ± 0.013 1.00
RD1 8.4 ± 0.1 0.96 10.6 ± 0.5 1.00 0.377 ± 0.004 4.00
RD2 6.5 ± 0.3 0.74 12.3 ± 0.3 1.15 0.052 ± 0.009 0.53
RD3 9.2 ± 0.3 1.04 2.8 ± 0.1 0.26 0.619 ± 0.009 6.59
RD4 10.6 ± 0.3 1.20 19.8 ± 1.1 1.86 0.710 ± 0.004 7.55
a!Bold values deviate significantly from those of MMOR-wt.  b!Measured at 15 °C.  c!Measured at 25!°C;
sMMO propylene assay in the presence of 1 µM MMOH and 1 µM MMOB.
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Table 5.7:  Rate Constants for MMOR-RD Reaction with NADH a
Protein
CT1 formation
k1 (s-1)
CT1 decay/CT2 form.
k2 (s-1)
CT2 decay
k3 (s-1)
Interdomain ET
k4 (s-1)
wild-type
comparison!b
MMOR 400 ± 50 179 ± 9 90 ± 3 c 90 ± 3 c/25 ± 2 1
RD1 160 ± 6 140 ± 5 33 ± 1 0.036 ± 0.003 0.0014
RD2 229 ± 26 177 ± 13 75 ± 3 0.0062 ± 0.0007 0.00025
RD3 96 ± 4 72 ± 2 14 ± 1 0.038 ± 0.003 0.0015
RD4 172 ± 7 169 ± 4 20 ± 1 0.9 ± 0.1 0.04
a!Measured at pH 7.0 and 4 °C.  Kinetic model depicted in Scheme 5.2.  b!Decrease in interdomain
electron transfer relative to the slow MMOR-wt rate constant (25 s-1).  c!Approximately 65% of
interdomain electron transfer coincides with CT2 decay in MMOR-wt.
238
Scheme 5.1
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Scheme 5.2
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Figure 5.1.  Reductase domain arrangement derived from the MMOR gene sequence
and homology to members of the flavoprotein electron transferase family.  The [2Fe-2S]
domain is an independent modular unit which can be linked to either the N- or C-
terminus of FNR-like proteins (top).  X-ray crystal structure of phthalate dioxygenase
reductase (bottom; ref 29).  The FMN cofactor is shown in yellow, and the [2Fe-2S]
cluster is colored green.
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Figure 5.2.  Component spectra determined for the MMOR domain proteins.  (A)
Oxidized (Fdox; solid line) and reduced (Fdred; dotted line) optical spectra for
MMOR-Fd.  (B) MMOR-FAD in the oxidized (FADox; squares), semiquinone (FADsq;
triangles), and hydroquinone (FADhq; circles) oxidation states.  From ref 30.
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Figure 5.3.  Optical spectrum of pure MMOR-RD2 fit with a linear combination of Fdox
and FADox component spectra (dashed line) determined previously for the separated
MMOR domains (ref 30).
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Figure 5.4.  Calculated flavin component spectra in the (A) fully oxidized and (B) fully
reduced oxidation states for MMOR-wt (heavy line), MMOR-RD1 (squares),
MMOR-RD2 (diamonds), MMOR-RD3 (triangles), and MMOR-RD4 (circles).
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Figure 5.5.  Difference spectra for the reductive titration of a 1-mL mixture of 30 µM
MMOR-RD2 and 40 µM anthraquinone-2-sulfonate by dithionite at pH 7.0 and 25 °C.
Spectra 1-6 correspond to the addition of 10, 15, 25, 45, 70, and 80 µL of ~2 mM
dithionite, respectively.  Fits (dashed lines) are superimposed on the difference spectra.
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Figure 5.6.  Dependence of the steady-state sMMO reaction with propylene at 25 °C on
reductase concentration.  Samples were air-saturated and contained 1 µM MMOH, 1
µM MMOB, 160 µM NADH, and 0.8 mM propylene.  Activity curves were fit with a
hyperbola plus a line (MMOR-wt, open triangles) or a line (MMOR-RD constructs).
MMOR-RD1, squares; MMOR-RD2, diamonds; MMOR-RD3, triangles; MMOR-RD4,
circles.
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Figure 5.7.  Kinetics of MMOR reduction with NADH at 4 °C and pH 7.0.  Spectra
recorded on a log time scale by diode array stopped-flow spectroscopy (A) in the first
350 ms after mixing 20 µM MMOR-wt with 200 µM NADH and (B) in the first 2.5 s
after mixing 20 µM MMOR-RD4 with 200 µM NADH.  Spectra of intermediates
resolved by global analysis of the diode array kinetic data for (C) MMOR-wt and (D)
MMOR-RD4:  MMORox (squares), CT1 (triangles; MMOR-wt only), CT2 (circles), HQ
(diamonds), and SQ (inverted triangles).
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Figure 5.8.  Kinetics of MMOR reduction with NADH at 4 °C and pH 7.0.  Time-
dependent absorbance changes at (A) 458 nm, (B) 625 nm, and (C) 725 nm for the
reaction of 20 µM MMOR with 200 µM NADH:  MMOR-wt (open squares), RD1
(closed triangles), RD2 (open triangles), RD3 (open diamonds), and RD4 (closed
circles).
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Chapter 6
Expression in Escherichia coli of the Hydroxylase Component of Soluble
Methane Monooxygenase from Methylococcus capsulatus (Bath)*
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INTRODUCTION
Methanotrophic bacteria thrive at the interface between aerobic and anaerobic
sediments. These organisms use methane as their sole source of carbon and energy,
such that only a small fraction of this greenhouse gas, which is generated by the
anaerobic degradation of organic carbon, reaches the atmosphere.1  The first step of
their primary metabolic pathway, the selective oxidation of methane to methanol (eq
1), is catalyzed by the methane monooxygenase (MMO) enzyme system.  Nearly all
CH4 + NADH + H+ + O2  ›  CH3OH + NAD+ + H2O (1)
methanotrophs express a copper-dependent membrane-bound particulate MMO
(pMMO).2,3  At low copper-to-biomass ratios, a few species of methanotrophic bacteria
produce instead a soluble form of MMO (sMMO), which contains iron.4
The sMMO complexes from two methanotrophs, Methylococcus capsulatus (Bath)
and Methylosinus trichosporium OB3b, have been characterized extensively by many
methodologies during the last twenty-five years.5-11  Maximal catalytic activity is
achieved in the presence of three protein components:  a hydroxylase (MMOH, 251
kDa), a reductase (MMOR, 38.5 kDa), and a regulatory protein (MMOB, 15.9 kDa).12-14
The hydroxylase, a dimer of three subunits5,13 in an a2b2g2 configuration (a, 60.6 kDa; b,
45.0 kDa; g, 19.8 kDa), contains two carboxylate- and hydroxo-bridged dinuclear iron
centers housed in the a subunits.  Dioxygen activation and substrate hydroxylation
occur at the diiron active sites.  MMOR is an iron-sulfur flavoprotein which shuttles
electrons from NADH through its flavin adenine dinucleotide (FAD) and [2Fe-2S]
cofactors to the hydroxylase active site.14-17  The MMOB protein, which contains no
prosthetic groups, modulates the MMO reaction by forming specific complexes with
the hydroxylase14,18 that alter the environment and therefore the spectroscopic10,13,19-21
and chemical7,14,19,22-24 properties of the diiron site.  In addition, a fourth protein
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(MMOD, 11.9 kDa), for which no function has been established, was recently identified
in the M. capsulatus (Bath) sMMO system.25
The genes encoding the sMMO proteins of M. capsulatus (Bath),26-28 M.
trichosporium OB3b,29,30 Methylocystis sp. strain M,31 Methylocystis sp. strain WI 14,32 and
Methylomonas sp. strains KSPIII and KSWIII33 have been identified and sequenced.  In
all of these organisms, the six sMMO genes, mmoX, mmoY, mmoB, mmoZ, orfY, and
mmoC, which code for MMOHa, MMOHb, MMOB, MMOHg, MMOD, and MMOR,
respectively, are clustered on a 5.5-kb segment of DNA (Figure 6.1).  Amino acid
sequences of these six sets of sMMO proteins are universally conserved as follows:
MMOHa, 73.6%; MMOHb, 46.8%; MMOB, 55.6%; MMOHg, 35.7%; MMOD, 19.4%; and
MMOR, 37.4%.11  Although the overall percent identity for the putative MMOD
products is fairly low (19.4%), there is a central region with a significantly greater
number of conserved residues (44.4%).
sMMO expression in M. capsulatus (Bath) is controlled by a single s70-dependent
copper-regulated promoter located upstream of the mmoX gene, so that the sMMO
system is produced only under conditions of low copper concentration.34  Motifs
resembling r-independent transcriptional terminators in the mmoX/mmoY (T1) and
mmoZ/orfY (T2) intercistronic regions give rise to three mRNA transcripts differing
only in their 3’ ends in the native organism.  Transcription of the homologous sMMO
genes of M. trichosporium, however, is regulated by a s54-dependent promoter upstream
from mmoX and a s70-dependent promoter located between mmoX and mmoY.35
The roles of individual amino acids in catalysis or binding can be probed by
using site-directed mutagenesis (SDM).  In order to employ this method for the MMO
system, however, the individual proteins must be expressed from controllable genes.
High-yield Escherichia coli expression systems for MMOB,28,36-38 MMOR,17 and MMOD25
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have been reported, making mutagenesis of these proteins possible.  Although the
sMMO enzymes have been studied intensively for more than two decades,
mutagenesis of the hydroxylase component, unquestionably the most interesting target
in the sMMO system, has, until very recently,39 been prevented by the lack of a useful
recombinant expression system.
Despite much effort, attempts to express active MMOH in E. coli have not yet
been successful.40-42  Reports of robust expression in E. coli of similar monooxygenases,
including toluene-4-monooxygenase,43,44 toluene-o-xylene monooxygenase,45 and
phenol hydroxylase,46 suggest that the E. coli environment is not intrinsically unsuitable
for folding and assembling multisubunit oxygenases.  Other heterologous hosts can
produce small quantities of active hydroxylase.  Trichloroethylene and chloroform
degradation was noted in a Pseudomonas putida strain expressing all of the sMMO
proteins from M. trichosporium OB3b, but expression was irregular, and the proteins
were not purified.47  After optimizing this system, plasmid stability was increased, but
no MMOH activity was detected in pseudomonad cell extracts.48  Low-level sMMO
activity was also detected in Agrobacterium tumefaciens A114,48 Rhizobium meliloti
102F34,48 Methylomicrobium album BG8,49 and Methylocystis parvus OBBP49 cells
complemented with the M. trichosporium OB3b mmo operon.
Expression of M. trichosporium OB3b MMOH in the native host has been
accomplished recently.50  The mmoX gene in the host strain was knocked out genetically
through a double-crossover recombination experiment to eliminate background
expression of the MMOH a subunit.51  By adding a plasmid carrying the mmo operon to
the sMMO-minus M. trichosporium OB3b mutant, sMMO activity was restored to wild-
type levels.50  The first site-directed MMOH mutants, expressed from a slightly
modified homologous system, were described very recently.39
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In the present work, we employed several strategies, including stringent
regulation of expression, placing all six sMMO genes on the expression vector, and
constructing artificial mmo operons, to facilitate production of active recombinant M.
capsulatus (Bath) MMOH in E. coli strains.
MATERIALS AND METHODS
sMMO Purification and Characterization.  MMOH and MMOR were isolated
from M. capsulatus (Bath) with minor modifications to a published protocol.14  The iron
content of MMOH was determined by the ferrozine method.52,53  Pure MMOR was
exchanged into distilled deionized water with a Quick Spin Sephadex G-50 column
(Boehringer Mannheim, Indianapolis, IN).  Methanol and acetic acid were added to the
desalted MMOR to yield a 15 pmol/µL solution in 50% methanol/0.1% acetic acid, and
the sample was submitted to the MIT Biopolymers Laboratory for analysis by
electrospray ionization mass spectrometry (ESI-MS).  To remove cofactors that had
separated from the reductase peptide during sample preparation, HPLC purification
was necessary.  The protein component was analyzed with a Sciex model API 365 triple
stage mass spectrometer.  Conditions for expression and purification of MMOB from a
recombinant E. coli system are described in Chapter 2.
DNA Primer Synthesis and Purification.   All of the primers used for cloning
and DNA sequencing were designed manually and synthesized on an Applied
Biosystems Model 392 DNA/RNA synthesizer.  Each primer was purified by
polyacrylamide gel electrophoresis on a 12% denaturing polyacrylamide gel, extracted
from the gel slices by using a crush and soak method, then precipitated to remove most
of the salt added during extraction.  The DNA pellets were suspended in appropriate
quantities of deionized distilled water and stored at –20 °C.
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Construction of pJLB001 for DNA Sequencing.  The mmo genes, which code for
all four components of the MMO system, are contained on a 5.5-kb section of pCH4.26,27
From the plasmid DNA the entire operon was amplified by polymerase chain reaction
(PCR) with the primers MON30 (5’-GAATGCCTTCGAATTCGGAGGAAACAAGTA-
ATGGCAC) and 40C30 (5’-CGTGCACCTTAAGCTTTCAGGCCGCCCCGGACGGCA-
G).  The resulting 5401-bp operon fragment was flanked by EcoRI and HindIII
restriction sites (boldface font), which were introduced by MON30 and 40C30,
respectively.  PCR was performed with T a q DNA polymerase (Gibco BRL,
Gaithersburg, MD) and Taq extender (Stratagene, La Jolla, CA) with the following
thermal cycler conditions:  2 min at 96 °C; 1 min at 96 °C, 1 min at 55 °C, and 6 min at
72 °C for 22 cycles, followed by extension for 15 min at 72 °C.  Because Taq DNA
polymerase lacks 3’ › 5’ proofreading capability, it produces DNA with one-base
deoxyadenosine (dA) overhangs on the 3’ ends.  This feature was exploited to ligate the
resulting mmo operon PCR product directly into the pCR2.1 vector (Invitrogen,
Carlsbad, CA) by using T4 DNA ligase (New England Biolabs, Inc., Beverly, MA or
Boehringer Mannheim).  The ligation products were transformed into competent E. coli
XL1-Blue cells and selected on Luria-Bertani (LB)-ampicillin (Ap; 100 µg/mL) followed
by LB-kanamycin (Km; 50 µg/mL) agar plates.  A positive clone was identified as
pJLB001 (Figure 6.2; Table 6.1) by restriction mapping of DNA isolated from plasmid
minipreps.54
Site-Directed Mutagenesis of pJLB001 to “Correct” mmoZ Sequence.  DNA
sequencing of pJLB001 (vide infra) revealed a base inversion at positions 63-64 in the
mmoZ  gene.  The protein expressed from this gene would have contained two
mutations in the MMOH g subunit, H21Q and V22L.  Site-directed mutagenesis was
performed to “correct” (vide infra) this error by using the QuikChange kit (Stratagene)
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and following the instructions provided by the manufacturer.  Two primers, Z63INVF
(5’-GGGTGAACAAGATCGCGCACGTCAACACCCTGG) and Z63INVR (5’-CCAGG-
GTGTTGACGTGCGCGATCTTGTTCACCC) were prepared for use in the Pfu DNA
polymerase-catalyzed PCR mutagenesis reaction.  Subsequent isolation and sequencing
(MIT Biopolymers Laboratory) of pJLB001-C showed that the mutagenesis was
successful.
Construction of Series I Vectors for MMOH Expression.  The mmo operon PCR
product (vide supra) was digested with the restriction enzymes EcoRI and HindIII by
using the conditions suggested by the supplier (New England Biolabs).  A wide-host-
range low-copy-number plasmid, pMMB190,55 was digested in the same manner.  To
inactivate the restriction enzymes, both digest reaction mixtures were incubated for 20
min at 65 °C.  The PCR product was ligated into the pMMB190 fragment by using T4
DNA ligase, and the resulting plasmid solution was transformed into E. coli XL1-Blue
cells and selected on LB-Ap (100 µg/mL) plates.  Colonies with ampicillin resistance
were analyzed further by restriction mapping of DNA isolated from plasmid
minipreps.  A plasmid with the correct insert was selected and named pJLB100 (Figure
6.3A).
To create MMO expression vectors with slightly different features, pJLB100 was
digested with EcoRI and HindIII, and the resulting operon fragment was ligated into
two similarly digested low-copy-number wide-host-range plasmids, pMMB206 and
pMMB277.55  Colonies containing plasmids were selected on LB-chloramphenicol (Cm;
10-20 µg/mL) plates.  Restriction mapping was used to identify the positive clones
pJLB200 (Figure 6.3B) and pJLB201 (Figure 6.3C), which were constructed from
pMMB206 and pMMB277, respectively.
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An expression vector containing the “corrected” mmo operon (vide supra) was
prepared by transferring the mmo genes of pJLB001-C into the multiple cloning site
(MCS) of pMMB277, exactly as described for constructing pJLB200 and pJLB201.  A
plasmid containing the desired DNA fragments, pJLB201-C, was identified by
restriction mapping.  To avoid the potential interference of lacZa peptide translation
with MMOH a subunit expression, a plasmid without the lacZa gene was constructed
from pJLB001-C and pMMB207, which differs from pMMB277 only in the absence of
this gene.55  Cloning was performed as described above, and a positive clone was
named pJLB207 (Figure 6.3D).
Construction of Series II Vectors for MMOH Expression.  The series I
expression plasmids described above included the entire mmo  operon without
alteration.  The second series of plasmids made for MMOH expression was based on
the same wide-host-range low-copy-number pMMB plasmids55 used in the first series.
Rather than the whole operon, new “artificial” operons were designed in an attempt to
improve the folding and assembly of the recombinant MMOH subunits.  Because the
first plasmid series yielded a rather high MMOB-to-MMOH ratio in the soluble fraction
and little if any MMOD or MMOR (vide infra), changes in the native gene sequence
were implemented.  The MCS present in most of the pMMB plasmids does not have
enough restriction sites compatible with the mmo operon, so it was necessary to
construct the new operon sequences in pTrc99A (Amersham Pharmacia, Piscataway,
NJ), a high-copy-number plasmid with a more useful MCS.
First, an expression vector that contains only the hydroxylase genes (mmoX,
mmoY, and mmoZ) was constructed (pJLB300, Figure 6.4C).  From the pCH4 plasmid
DNA the mmoX–mmoY segment was amplified by PCR with the primers XFE10 (5’-CA-
TAGAATGGAATTCGGAGGAAACAAGTAATGGCAC) and YRK10 (5’-CGTCATAG-
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GTACCCTATTATTTCAATCCTGCCAGAAC).  The resulting 2877-bp fragment was
flanked by EcoRI and KpnI sites (boldface font), which were introduced by XFE10 and
YRK10, respectively.  PCR was performed with Pfu DNA polymerase (Stratagene, La
Jolla, CA), which possesses 3’ › 5’ proofreading capability, with the following thermal
cycler conditions:  45 s at 96 °C; 45 s at 96 °C, 45 s at 60 °C, and 8 min at 72 °C for 25
cycles, followed by extension for 10 min at 72 °C.  The DNA was precipitated by
adding 0.1 volume of 2.5 M sodium acetate (pH 5.2) and 2.2 volumes of cold ethanol to
the PCR solution.  After incubation at –20 °C and –80 °C, the precipitated PCR product
was recovered by centrifugation for 30 min at 10,000g, 4 °C and dissolved in 10 mM
Tris (pH 8.0), 1 mM ethylenediaminetetraacetic acid (EDTA) (TE buffer).  The
mmoX–mmoY PCR product was digested with the restriction enzymes EcoRI and KpnI
(New England Biolabs) by following the provided instructions.  pTrc99A, a high-copy-
number expression vector, was digested with the same enzymes to remove the
EcoRI–KpnI fragment from its MCS.  The KpnI enzyme cannot be heat-inactivated, so
the plasmid and PCR product digests were extracted with equal volumes of
phenol:chloroform:isoamyl alcohol (25:24:1) to denature the enzymes.  The aqueous
layers were removed, and the DNA was precipitated as described above.  The pTrc99A
digest was treated with alkaline phosphatase (AP; Boehringer Mannheim) to prevent
recircularization in the subsequent ligation reaction.  After inactivating the AP by
adding 20 mM ethylene glycol-bis[b-aminoethyl ether]-N,N,N’,N’-tetraacetic acid
(EGTA) and heating at 65 °C for 10 min, the DNA was extracted again and precipitated
with ethanol.  The AP-treated pTrc99A digest and mmoX–mmoY PCR product were
ligated by using T4 DNA ligase, and the resulting plasmid solution was transformed
into competent E. coli XL1-Blue cells.  Potential positive clones were identified by
plating onto LB-agar plates containing Ap (100 µg/mL).  Colonies with ampicillin
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resistance were analyzed further by restriction mapping of DNA isolated from plasmid
minipreps.  A plasmid with the correct insert was selected and named pTXY, as
depicted in Figure 6.4A.
The mmoZ gene was PCR-amplified from pCH4 with the primers ZFK10 (5’-CT-
GGTACCCTTAAGGAGAATGACATGGCGAAACTGG) and ZRH10 (5’-AGGATGA-
AGCTTCCTCCCTTCAGTGCGGCGAC), resulting in a 558-bp segment flanked by
KpnI and HindIII sites (boldface font).  PCR was performed with the following thermal
cycler conditions:  45 s at 96 °C; 45 s at 96 °C, 45 s at 60 °C, and 1.5 min at 72 °C for 25
cycles, followed by extension for 10 min at 72 °C.  After ethanol precipitation, the PCR
product was digested with HindIII and then heated at 65 °C for 20 min to inactivate the
restriction enzyme.  The digested PCR product was isolated by ethanol precipitation,
dissolved in NEB buffer 1/BSA, and digested with KpnI.  The pTXY plasmid was
digested with K p n I and HindIII in the same two-step procedure.  The NaCl
concentration of the plasmid double digest was increased to 100 mM in order to
inactivate the KpnI.  AP was added to the plasmid digest, incubated for 60 min at 37 °C,
and then heat-inactivated as described previously.  Both the mmoZ and pTXY digests
were extracted with equal volumes of phenol:chloroform:isoamyl alcohol (25:24:1); the
DNA was recovered by ethanol precipitation and dissolved in 10 mM Tris (pH 8.0).
The mmoZ segment was ligated into pTXY as described above, and the resulting
plasmid solution was transformed into competent E. coli XL1-Blue cells.  After
performing plasmid minipreps, a vector with the correct insert was selected and named
pTXYZ, as shown in Figure 6.4B.
To construct the low-copy-number expression vector pJLB300 (Figure 6.4C),
pMMB277 and pTXYZ were digested with the restriction enzymes EcoRI and HindIII,
and the enzymes in both samples were heat-inactivated.  The pMMB277 digest was
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treated with AP, which was inactivated as described.  Both digests were extracted,
ethanol precipitated, and then dissolved in 10 mM Tris (pH 8.0).  The
mmoX–mmoY–mmoZ segment was ligated into pMMB277 with T4 DNA ligase, and the
resulting plasmid solution was transformed into competent E. coli XL1-Blue cells.
Potential positive clones were selected on LB-Cm (10 µg/mL) agar plates.  By
restriction digest analysis of plasmid DNA isolated from minipreps, seven positive
clones were identified and labeled pJLB300(En), where n = 3, 4, 6, 7, 8, 9, and 11.
A second MMOH expression vector was constructed in a similar fashion.
pJLB400 (Figure 6.5C) contains all of the genes in the mmo operon, but lacks the T2
transcription termination site located between mmoZ and orfY  in the native M .
capsulatus (Bath) DNA (Figure 6.1).  The mmoX–mmoZ segment was PCR-amplified
from pCH4 with the primers XFE10 and ZRK10 (5’-GAGCGAGACTGGTACCCTTCA-
GTGCGGCGAC) using conditions identical to those for the mmoX–mmoY PCR reaction,
resulting in a 3847-bp segment flanked by EcoRI and KpnI sites.  The PCR product was
digested with EcoRI and KpnI and inserted into pTrc99A exactly as described above to
form pTX-Z (Figure 6.5A).  Primers OFK10 (5’-CCGGTACCTTTCGTAAGGAAATCA-
CCATGGTC) and RRH10 (5’-TCACAGTACTTAAGCTTTTCAGGCCGCCCCGGAC)
were used to PCR-amplify the orfY–mmoC region from pCH4, yielding a 1415-bp
product flanked by KpnI and HindIII sites.  PCR was performed with the following
thermal cycler conditions:  45 s at 96 °C; 45 s at 96 °C, 45 s at 60 °C, and 3!min at 72 °C
for 25 cycles, followed by extension for 10 min at 72 °C.  As described for pTXYZ, the
PCR product was digested with KpnI and HindIII in a two-step procedure and ligated
into pTX-Z to yield pTX-C, as shown in Figure 6.5B.  To create pJLB400, the
mmoX–mmoC operon (no T2 site) was cut from pTX-C and ligated into pMMB277.
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Plasmid minipreps and restriction digest analysis identified three positive clones,
which were named pJLB400(Fn), where n = 3, 7, and 8.
DNA Sequencing of the mmo  Operon.  Because the low-copy-number
expression plasmid pJLB201 could not be purified adequately for DNA sequencing, the
high-copy-number pJLB001 vector constructed in parallel with the series I expression
vectors was used for sequencing the mmoX, mmoY, mmoB , and mmoZ  genes.  In
addition, the mmoB, mmoZ, orfY, and mmoC genes of pCH4 were analyzed.  Sequencing
was performed by automated fluorescent DNA sequencing on an Applied Biosystems
model 377 DNA Sequencer (MIT Biopolymers Laboratory).  Most of the sequencing
primers had been prepared previously in this laboratory.56  The DNA sequence data
were analyzed manually by comparison to previously recorded data (mmoX, mmoY,
mmoZ)28 and the published sequences (mmoC;27 region between mmoY and mmoB,
mmoB26).  All of the DNA sequencing was performed for both strands.  A discrepancy
between previously obtained data and the mmoZ sequence in pCH4 (vide supra) was
resolved by reanalyzing DNA sequencing gels.28  To ensure that the series II expression
vectors contained the correct sMMO gene sequences, pTXY (mmoX and mmoY), pTXYZ
(mmoZ), pTX-Z (mmoX, mmoY, mmoB, and mmoZ), and pTX-C (orfY and mmoC) were
submitted for sequencing.
Protein Characterization.  Denaturing polyacrylamide gel electrophoresis
(PAGE) was performed with 4-20% acrylamide precast gels (Bio-Rad, Hercules, CA) or
hand-cast 12% polyacrylamide gels (Bio-Rad) using a Tris/glycine, sodium dodecyl
sulfate (SDS) buffer system.  Electrophoresis samples were prepared by incubation for
5 min at 100 °C in denaturing buffer [62.5 mM Tris (pH 6.8), 10% (v/v) glycerol, 0.2%
SDS, 5% (v/v) b-mercaptoethanol, and 0.025% bromophenol blue].  The molecular
weight markers used as standards for SDS-PAGE (Bio-Rad) were (substance, kDa):
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phosphorylase B, 97.4; serum albumin, 66.2; ovalbumin, 45.0; carbonic anhydrase, 31.0;
trypsin inhibitor, 21.5; and lysozyme, 14.4.
A Tris/glycine buffer system and non-denaturing sample buffer [62.5 mM Tris
(pH 6.8), 10% (v/v) glycerol, and 0.025% bromophenol blue] were employed for native
PAGE analyses.  In order to prevent protein denaturation, samples were incubated on
ice prior to loading onto 4-20% acrylamide precast gels (Bio-Rad).  Since all native
PAGE gels were run for analysis by Western blotting, native MMOH was included as
the standard.
For both SDS-PAGE and native PAGE gels, blotting onto nitrocellulose was
performed with a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad).  Polyclonal
MMOH antibodies41 were used in combination with horseradish peroxidase (HRP)-
linked goat anti-rabbit antibodies in the standard development of Western blots.  The
Immun-Blot HRP Assay Kit (Bio-Rad), in which HRP converts 4-chloro-1-naphthol to a
purple solid, afforded detection of proteins binding MMOH antigens.
Indirect ELISA quantification of recombinant MMOH was performed according
to standard protocols.  Protein A–alkaline phosphatase conjugate was added to
antigen-bound MMOH antibodies, and color development was achieved by incubation
with p-nitrophenyl phosphate (Sigma, St. Louis, MO) for about 17 h.  Absorbance
values were determined with a Titertek Multiskan microtiter plate reader (Labsystems,
Helsinki, Finland) configured with a 405 nm filter.
MMOH Expression in E. coli Hosts:  Series I Plasmids.  The series I plasmid
constructs pJLB100, pJLB200, and pJLB201, were transformed into competent E. coli
JM105 cells and electroporated into electrocompetent E. coli BL21(DE3) cells for
expression tests.  For initial expression of sMMO proteins from pJLB100, the E. coli
JM105 expression host was grown to saturation in a 5-mL LB-Ap (100 µg/mL) culture.
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A 1-mL aliquot of this culture was used to inoculate 100 mL of LB supplemented with
100 µg/mL of ampicillin.  After incubation at 37 °C for 3.25 h with shaking (200 rpm),
isopropyl b-D-galactopyranoside (IPTG, 0.4 mM) was added to induce expression of
the MMO proteins.  Beginning 20 min after induction, 1-mL samples were collected at
ca. 60-minute intervals for the following 16 h.  The bacteria were pelleted in 1.5-mL
Eppendorf tubes by centrifugation for 5 min at 4 °C, frozen in liquid nitrogen, and
stored at –80 °C until completion of the time course experiment.  The cells collected at
each time point were suspended in SDS loading buffer, boiled for 5 min, and analyzed
by SDS-PAGE.
Expression from pJLB100, pJLB200, and pJLB201 in E. coli JM105 was performed
in a similar manner.  Since pJLB200 and pJLB201 contain a gene for chloramphenicol
resistance rather than ampicillin resistance, media for these expression systems were
supplemented with 10 µg/mL of chloramphenicol.  LB-antibiotic media (100 mL) were
inoculated with 1 mL of saturated 5-mL cultures and incubated for 3 h at 37 °C with
shaking.  Immediately prior to induction, 200 µL of an iron solution (0.56 g of
FeSO4⋅7H2O dissolved in 47.5 mL of deionized water acidified with 2.5 mL of 0.25 M
H2SO4) was added to the growth medium.  Expression was induced by adding IPTG
(0.05 mM), and the temperature was reduced to 25 °C.  Bacteria were collected after 10
min or 7 h and pelleted by centrifugation.  The harvested cells from each 100-mL
culture were suspended in 50 mL of 25 mM 3-(N-morpholino)propanesulfonic acid
(MOPS; pH 7.0) containing 5 mM MgCl2, DNase (2 units/mL), and 1 mM Pefabloc SC
(Boehringer Mannheim) and transferred to 50-mL glass beakers in an ice bath.  The cell
suspensions were sonicated at 40% maximum output (Branson Sonifier model 450
equipped with a 3/4-inch horn) with three two-minute pulses, which were separated
by several minutes to prevent overheating.  The lysed cells were centrifuged at 98,000g
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for 30 min in order to separate the soluble and insoluble materials.  The supernatants
were transferred to 50-mL Falcon tubes and stored at 4 °C.  To denature insoluble
proteins, about 5 mL of 6 M urea in 10 mM MOPS (pH 7.0) was added to each extract
pellet, and the tubes were rotated overnight at 4 °C.  SDS-PAGE gels and Western blots
using polyclonal antibodies for MMOH were performed by following standard
protocols.  In addition, the amounts of hydroxylase produced in both the soluble and
insoluble fractions were quantitated by indirect ELISA.
Similar expression experiments were carried out with the protease-deficient E.
coli BL21(DE3) strain.  Several variables, including induction time, IPTG concentration,
temperature, growth medium (LB and M9 media), and collection time, were altered in
subsequent expressions in both JM105 and BL21(DE3) hosts.  To examine the subunit
assembly of the recombinant hydroxylase, native PAGE Western blots using MMOH
antibodies were carried out according to standard protocols.
MMOH Expression in E. coli Hosts:  Series II Plasmids.  The following
plasmids were transformed into competent E. coli JM105 and BL21(DE3) cells:
pJLB300(E3), pJLB300(E6), pJLB400(F3), pJLB400(F7), and pMMB277.  For initial
expression of the recombinant proteins, the E. coli JM105 expression hosts containing
pMMB277, pJLB300(E3), and pJLB400(F3) were grown to saturation in 4-mL LB-Cm (10
µg/mL) cultures.  Aliquots (1 mL) of these cultures were used to inoculate 100-mL
quantities of LB-Cm (10 µg/mL) medium, which were transferred to a 37 °C incubator
set to rotate at 200 rpm.  Protein expression was induced with 0.5 mM IPTG and 80 µM
FeSO4 (vide supra) at OD600 ~0.6.  Beginning 15 min after induction, 1-mL samples were
collected at ca. 60-min intervals for the following 5 h.  In addition, samples were
collected immediately prior to starting induction.  The bacteria were pelleted in 1.5-mL
Eppendorf tubes by centrifugation for 5 min at 4 °C, frozen in liquid nitrogen, and
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stored at –80 °C until completion of the time course experiment.  The whole-cell time
course samples were analyzed by SDS-PAGE.
Expression from pJLB400 in JM105 and BL21(DE3) Hosts.  Expression from
pJLB400(F3) and pJLB400(F7) in both E. coli JM105 and BL21(DE3) was performed
under conditions more suitable for MMOH expression and assembly.  LB-Cm (10
µg/mL) cultures (100 mL) were inoculated with 100-µL aliquots of saturated 4-mL
cultures and incubated at 37 °C with shaking.  When the OD600 of the two BL21(DE3)
cultures reached ~0.8 (3.5 h after inoculation), expression of sMMO proteins was
induced by adding 0.05 mM IPTG, 80 µM FeSO4, and reducing the temperature to 25
°C.  Induction was started in the two JM105 cultures in the same manner when the
OD600 was ~0.7 (4.75 h after inoculation).  The bacteria were collected 4 h (JM105
cultures) or 5.25 h (BL21(DE3) cultures) after starting induction and pelleted by
centrifugation.  The harvested cells from each 100-mL culture were suspended in 25-
mL quantities of cracking buffer [25 mM MOPS (pH 7.0), 8 mM sodium thioglycolate
(NaTG), 5 mM MgCl2, and 200 µM Fe(NH4)2(SO4)2·6H2O] containing DNase (1.5
units/mL) and 1 mM Pefabloc SC and transferred to 125-mL stainless steel beakers.
The cell suspensions were sonicated at 40% maximum output (Branson Sonifier model
450 equipped with a 3/4-inch horn) with three 2-min pulses, which were separated by
5 min to prevent overheating.  The lysed cells were centrifuged at 120,000g for 30 min
in order to separate the soluble and insoluble materials.  The supernatants were filtered
through 0.2 µm membranes, drop-frozen in liquid nitrogen, and stored at –80 °C.  The
pelleted material was washed with buffer and transferred to clean ultracentrifuge
tubes.  To each tube 15 mL of 6 M urea in 25 mM MOPS (pH 7.0) was added, and the
tubes were rotated overnight at 4 °C.  SDS-PAGE and native PAGE Western blots using
polyclonal antibodies to MMOH were performed by following standard protocols.
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Expression from JM105/pJLB300+pRED and JM105/pJLB400+pRED.  In the
initial time course study for JM105/pJLB400(F3), there appeared to be little to no
MMOD or MMOR production, even at relatively high IPTG levels.  To investigate
whether MMOR is necessary for proper folding and/or assembly of MMOH,
competent E. coli JM105 cells were transformed with the high-copy-number pRED-K2
(MMOR expression plasmid)17 and either pJLB300(E3) or pJLB400(F3) and plated on
LB-Ap (75 µg/mL)-Cm (10 µg/mL) agar plates.  Duplicate 100-mL LB-Ap-Cm cultures
were inoculated with 100-µL aliquots of saturated JM105/pJLB300(E3)+pRED-K2 or
JM105/pJLB400(F3)+pRED-K2 starter cultures.  The expression cultures were
supplemented with 100 µM Fe2+ added as 1.0 mL of 10 mM Fe(NH4)2(SO4)2·6H2O in 100
mM sodium citrate (pH 7.0).  When the OD660 was ~0.6, sMMO protein expression was
induced by adding 0.5 mM or 0.05 mM IPTG and 200 µL of the FeSO4 solution
described above (80 µM final [Fe2+] addition).  The cultures induced with 0.5 mM IPTG
were used for a time course study in which samples were collected at approximately
60-min intervals after induction as described above.  SDS-PAGE gels were run to
examine protein production over the 5-h time course.  About 5 h after induction, cells
in the low-IPTG cultures were collected by centrifugation and then frozen with liquid
nitrogen.  The JM105/pJLB300(E3)+pRED-K2 and JM105/pJLB400(F3)+ pRED-K2 cells
were sonicated and ultracentrifuged exactly as described above to isolate the soluble
cell extracts, which were drop-frozen in liquid nitrogen and stored at –80 °C.  Urea (6
M) was added to the pelleted materials to solubilize denatured proteins.  After
overnight rotation at 4 °C, the samples were centrifuged to remove insoluble lipids and
other solids.  SDS-PAGE and native PAGE Western blots were performed according to
standard protocols.
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Expression from pJLB300 in JM105 and BL21(DE3) Hosts.  Expression from
pJLB300(E3) and pJLB300(E6) was performed in the E. coli strains JM105 and
BL21(DE3).  Cultures (100 mL) of LB-Cm (10 µg/mL) were inoculated with 100-µL
aliquots of 4-mL saturated overnight cultures.  The cells were grown at 37 °C with
shaking at 200 rpm until the OD600 reached ~0.7.  At this time, MMOH production was
induced by the addition of 0.05 mM IPTG and 80 µM FeSO4, and the temperature was
reduced to 30 °C.  The cells were collected by centrifugation 5 h after starting induction
and suspended in cracking buffer [25 mM MOPS (pH 7.0), 8 mM NaTG, 2 mM cysteine,
5 mM MgCl2, and 200 µM Fe(NH4)2(SO4)2·6H2O] containing DNase (1.5 units/mL) and
1 mM Pefabloc SC.  The soluble and insoluble components were isolated as described
above.  MMOH production in the expression cells was analyzed with SDS-PAGE and
native PAGE Western blots.
Large-scale expressions of BL21(DE3)/pJLB300(E3) were performed to produce
protein for purification trials.  A 100-mL LB-Cm (10 µg/mL) culture was inoculated
with 100 µL of a saturated 4-mL BL21(DE3)/pJLB300(E3) culture and incubated
overnight at 37 °C.  Six 1-L quantities of LB-Cm (10 µg/mL) were inoculated with 1-mL
aliquots of the saturated starter culture and transferred to a 37 °C incubator set to
rotate at 200 rpm.  When the OD600 was ~0.7, induction was started with 0.05 mM IPTG
and 80 µM FeSO4.  The temperature was reduced to 30 °C approximately 4 h later.
About 7.5 h after starting induction, the cells were collected by centrifugation, frozen
with liquid nitrogen, and stored at –80 °C.  The cells were thawed and suspended in
100 mL of cracking buffer (described above), transferred to a large stainless steel
beaker, and sonicated on ice with three 2-min pulses at 40% output (Branson Sonifier
model 450 equipped with a 3/4-inch horn).  The lysed cells were centrifuged for 40 min
at 98,000g to separate the soluble cell extract, which was then filtered through 0.2 µm
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membranes to remove any remaining particulate matter.  A 12-L expression was
performed in nearly the same manner, except that 5 min before induction the
temperature was reduced to ca. 27 °C and the FeSO4 solution was added.  In addition,
the cells were sonicated immediately after collection.
Purification of Recombinant MMOH from JM105/pJLB201.  The pJLB201
expression vector was selected for further study, since it yielded more soluble MMOH
than the other series I plasmids.  In addition, proteolysis was not as significant a
problem with this system.  Four 500-mL cultures of JM105/pJLB201 were grown to
saturation, then induced as described previously.  The cells were harvested, frozen in
liquid nitrogen, and stored at –80 °C.  The frozen expression cells were suspended in
100 mL of cracking buffer and sonicated for a total of 6 min.  After centrifugation at
98,000g  for 45 min, the soluble cell-free extract was filtered through a 0.2 µm
membrane.  This solution was loaded onto a Q-Sepharose Fast Flow (Amersham
Pharmacia) column (2.5 ¥ 11 cm) equilibrated with 25 mM MOPS (pH 7.0) containing
50 mM NaCl.  The column was washed with 150 mL of the equilibration buffer, and a
500-mL linear gradient from 50 to 300 mM NaCl was applied.  Fractions were pooled
and analyzed for MMOH by SDS-PAGE, native PAGE, and Western blotting
techniques.  Purification was also attempted with the more complex buffer [25 mM
MOPS (pH 7.0), 5 mM MgCl2, 2 mM cysteine, 8 mM NaTG, and 200 µM
Fe(NH4)2(SO4)2·6H2O] used for purifying native MMOH, a shallower elution gradient,
and a shorter column (2.5 ¥ 8 cm).
Purification of Recombinant MMOH from BL21(DE3)/pJLB300.  In the small-
scale BL21(DE3)/pJLB300 expression trials, a very small band of properly assembled
MMOH was detected by native PAGE Western blotting.  A partial purification was
attempted for a 6-L expression of BL21(DE3)/pJLB300(E3).  The cells were grown,
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induced, collected, and sonicated as described above.  The soluble cell extract was
loaded onto a DEAE Sepharose CL-6B (Amersham Pharmacia) column (2.6 ¥ 15 cm)
equilibrated with buffer A [25 mM MOPS (pH 7.0), 8 mM NaTG, 2 mM cysteine, and
200 µM Fe(NH4)2(SO4)2·6H2O], and the column was washed with 120 mL of buffer A to
remove unbound proteins.  A 740-mL linear gradient from 0 to 300 mM NaCl was run,
followed by a 160-mL wash with buffer B [buffer A plus 300 mM NaCl].  Fraction
samples were pooled into fourteen groups, labeled A-N.  SDS-PAGE and native PAGE
gels and Western blots were run to examine the elution pattern for the recombinant
MMOH.
A 12-L expression of BL21(DE3)/pJLB300(E3) was employed to purify the
recombinant MMOH further.  The soluble cell extract was resolved on a CL-6B column
as described.  Fractions eluting at 135-180 mM NaCl were pooled based on the elution
profile of assembled MMOH determined in the previous 6-L purification.  The pool of
MMOH-containing fractions was concentrated to about 5 mL by ultrafiltration over a
YM100 membrane.  The sample was passed through a 0.2 µm filter and loaded onto a
Superdex 200 (Amersham Pharmacia) size-exclusion column (2.6 ¥ 80 cm).  A 750-mL
wash with 25 mM MOPS (pH 7.0), 120 mM NaCl, 1 mM DTT, and 5% glycerol was
performed with the fraction collector set to high sensitivity.  The concentrator and
superloop were washed thoroughly before using to avoid contamination by native
MMOH.  In addition, a new YM100 membrane was used for concentrating the crude
recombinant MMOH (rMMOH) sample.  Fraction pools were analyzed for assembled
MMOH with SDS-PAGE and native PAGE gels and Western blots.  As a control, the
cell extract from a 12-L BL21(DE3)/pMMB277 growth was resolved by column
chromatography in exactly the same manner.  Gels and Western blots were run to
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determine whether contamination from native MMOH was introduced during
purification.
Assays for Recombinant MMOH Activity.  Several assays for recombinant
MMO hydroxylase activity were performed.  Conversion of propylene to propylene
oxide by the MMO system was monitored by gas chromatography (GC).  To soluble
cell-free extracts, the following reagents were added (final concentration):  MMOR (0.2
µM), NADH (1.0 mM), propylene (0.5 mM), and NaTG (8.0 mM).  A Western blot for
MMOB showed that it was present at a significantly higher concentration than
MMOH,57 so no additional MMOB was included in the assay mixture.  The samples
were incubated for 3 h at 25 °C in small glass vials.  Chloroform extraction separated
the nonpolar propylene and potential propylene oxide product from the reaction
components, and 5.0-µL aliquots of the organic layers were analyzed by using a
Hewlett Packard Model 5890A gas chromatograph with a Porapak Q column.
Propylene activity assays were also carried out for partially purified rMMOH
from a BL21(DE3)/pJLB300 expression (vide supra).  Because the total amount of
assembled MMOH was estimated to be only 10 µg, the seven fractions containing
MMOH were each concentrated to ca. 30 µL in Centricon 30 concentration devices
(Amicon, Beverly, MA).  The fractions were combined to make a single 210-µL sample,
which was analyzed by a propylene steady-state kinetics assay and by product
analysis.  Assaying an unknown amount of MMOH for activity is inherently difficult,
since activity varies dramatically with the relative concentrations of MMOH, MMOB,
and MMOR.14  A total of 10 µg of MMOH yields a concentration of 0.1 µM in a 400-µL
volume, which was deemed enough to monitor NADH consumption in a propylene
steady-state assay.  The following reagents were added (final concentration) for 400-µL
standard samples:  MMOH (100 nM), MMOB (100 nM), MMOR (100 nM), propylene
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(0.8 mM), and buffer [25 mM MOPS (pH 7.0) and 1 mM DTT].  These components were
added to a 1-mL masked cuvette and mixed thoroughly by inverting.  NADH (0.16
mM) was added to initiate the reaction, and NADH consumption was monitored at 340
nm (e340 = 6220 M-1 cm-1) over a period of 6 min with a Hewlett Packard Model 8452A
diode array spectrophotometer.  Blank samples were prepared in the same manner,
except that MMOH was excluded from the reaction contents.  To the 210-µL
recombinant MMOH sample, MMOB (100 nM), propylene (0.8 mM), and buffer were
added (initially no MMOR).  NADH (0.16 mM) was introduced, and the reaction was
monitored for 3 min.  MMOR (100 nM) was added to initiate MMO activity; at three
points during the 18-min reaction, supplemental NADH was added to assure
availability for the MMO system.  Each 400-µL sample was extracted with 80 µL of
chloroform to remove the propylene and potential propylene oxide product and
centrifuged for 5 min at 10,000g  to separate the organic and aqueous layers.
Identification of the propylene oxide product was performed by GC, as described
above.
Nitrobenzene assays were used to identify column fractions containing active
MMOH from a JM105/pJLB201 expression.  Reaction mixtures (700 µL) containing 200
µL of sample and 1.0 µM MMOB, 0.2 µM MMOR, 1.0 mM nitrobenzene, and 2 mM
NaTG in 25 mM MOPS (pH 7.7) were prepared.  A 600-µL aliquot was transferred to a
cuvette, NADH (1.0 mM) was added to initiate the reaction, and formation of
p-nitrophenol (lmax = 404 nm) was monitored.
A colorimetric assay to detect naphthalene oxidation58,59 was employed to
examine MMO activity in colonies on agar plates, whole cells grown in liquid culture,
and cell-free extracts.  In addition, since copper has been reported to inhibit MMOR
irreversibly,4,60 some expression cells were transferred to M9 minimal medium54 before
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induction.  In brief, solid naphthalene was added to 1.0-mL samples, which were
incubated at room temperature for ca. 45 min.  A 100-µL aliquot of 1% (w/v) Fast Blue
BN dye (tetrazotized o-dianisidine; Sigma), which reacts with naphthol to form purple
diazo dyes, was added to each sample.  The dye products were stabilized by addition
of glacial acetic acid (300 µL) after 15 s.
Indole assays were also attempted, although initial studies showed that indole is
at best a poor substrate for the M. capsulatus (Bath) sMMO enzyme system.61  Bacteria
containing pJLB expression vectors were spread on LB-agar plates which contained Cm
(10 µg/mL), IPTG (20 µg/mL), and indole (100 µg/mL).  The plates were incubated
overnight at 37 °C.
Search for ORFs Surrounding the mmo Operon.  In an effort to identify key
components for proper folding and assembly of MMOH, open reading frames in the
DNA region encompassing the mmo operon were located.  Preliminary sequence data
for the entire M. capsulatus (Bath) genome (4600 kb) was obtained from The Institute for
Genomic Research (TIGR) website (http://www.tigr.org).  At the time this analysis
was performed (August 2002), the TIGR search program provided a maximum of 1000
nt on either side of a search sequence.  Therefore, starting with the published sMMO
genes,26-28 a bootstrapping method was employed to reconstruct the DNA surrounding
the mmo operon.  A 1340-nt sequence that disrupted the mmo operon was also repeated
multiple times throughout the genome, presumably an artifact of the incomplete stage
of the sequencing.  These repeats were removed to yield a 27.4-kb contiguous sequence
including 4.1 kb upstream and 18 kb downstream of the sMMO genes.  Putative open
reading frames (ORFs) were identified on both DNA strands by using the ORF Finder
function on the National Center for Biotechnology Information (NCBI) website
(http://www.ncbi.nlm.nih.gov).  For each ORF, protein BLAST and conserved domain
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searches were performed against all available non-redundant databases on the NCBI
site.  Those gene-translated proteins with significant homology to other proteins were
accepted as possible M. capsulatus (Bath) proteins.  In some cases, the start site for the
gene was unclear.  To help resolve these discrepancies, the DNA was also analyzed for
bacterial promoter regions with the Neural Network Promoter Prediction tool available
at the Berkeley Drosophila Genome Project website (http://www.fruitfly.org/
seq_tools/promoter.html).
RESULTS
Corrections to the M. capsulatus (Bath) sMMO Gene Sequences.  Six errors
were identified in the published DNA sequences of the M. capsulatus (Bath) sMMO
genes,26,27 including four in the hydroxylase genes.  Each of the changes could be
verified by at least one method.  The first error is a two-base inversion in codon 84 of
mmoX, GTA › GAT, where the former is from the published gene sequence and the
latter from the present work.  This inversion results in a change in the a-subunit
protein sequence from Q78FGSLQVALTR to Q78FGSLQDALTR.  A double frame shift
in mmoY (CGG ACG AGT TCA TGC AAC › CGG GAC GAG TTC ATC AAC) yields a
R141TSSCN ›  R141DEFIN change in the hydroxylase b subunit.  This frame-shift
sequencing error at the end of m m o Y  was observed previously by X-ray
crystallography.62  Finally, the g subunit has two altered residues, I19AHVNT ›
I19AQLNT, resulting from a two-base inversion at codons 21 and 22 of mmoZ (CAC
GTC › CAG CTC).  Therefore, site-directed mutagenesis to correct the mmoZ “error”
in pJLB001 actually introduced a base inversion (vide supra).  The alterations in the a
and b subunits were used in refinements of the crystallographically determined M.
capsulatus (Bath) sMMO hydroxylase structure.  Reanalysis of the hydroxylase crystal
272
structure solved to 1.7 Å resolution63 revealed that the g-subunit residues Gln21 and
Leu22 identified here better fit the electron density than the His and Val residues
deduced from the published gene sequence.26
N-terminal sequencing of MMOB isolated from M. capsulatus (Bath) indicated
that residue 12 is Ile rather than Phe.28  Subsequent sequencing of the cDNA showed a
one-base error in codon 12 (TTC › ATC), which would produce the observed change
in the protein sequence.  Mass spectrometric investigations also support this sequence
change.38,64  The remainder of the gene sequence is correct as published.26  A two-base
inversion in codon 254 of mmoC (CAC ›  ACC) corresponds to a change from
V252NHEP to V252NTEP in the protein sequence.27  A reductase mass of 38,545.6 Da was
obtained by ESI-MS, which is consistent with the sequence change.  With the N-
terminal methionine intact and the H254T sequence correction, the expected mass is
38,542.6 Da, less than a 0.01% difference from the observed value and within the
accuracy range of the mass spectrometer.  On the other hand, the published sequence
would yield a mass of 38,578.7 Da, a difference of 33 Da (0.09%), which is well outside
the expected accuracy of the instrument.  No discrepancies were found between the
published DNA sequence for orfY27 and the sequencing reported here.
Expression of sMMO Proteins in E. coli:  Series I Vectors.   Cultures of E. coli
JM105/pJLB100 expressed proteins with molecular weights corresponding to those of
the a, b, and g subunits of MMOH, as well as MMOB and MMOR (Figure 6.6).  In
addition, a faint ~12-kDa band on the SDS-PAGE time-course gel may be MMOD.
Maximal expression of the MMO proteins occurred 5-7 h after IPTG addition.  Because
they appeared in a time-dependent fashion, it is highly likely that these proteins were
expressed from the MMO operon insert.  A significant number of inclusion bodies were
formed in cells containing the pJLB100 expression vector, as indicated by a distinct
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color change from yellow to fairly white soon after induction began.  Therefore, even
the low-copy-number expression system produced misfolded or misassembled MMO
proteins when induced with 0.4 mM IPTG.
Reducing the IPTG concentration to 0.05 mM decreased visible inclusion body
formation dramatically.  Since so little recombinant protein was produced in samples
expressed with low IPTG levels, however, identification of the MMOH proteins on
SDS-PAGE gels was not possible.  Western blots using antibodies to MMOH showed
that all three subunits of the hydroxylase were clearly present in both the soluble and
insoluble, misfolded fractions in each of the three initial JM105/pJLBxxx expression
systems, where xxx = 100, 200, or 201 (Figure 6.7).  Lack of hydroxylase in control
cultures containing the pMMB plasmids without the MMO operon inserts showed that
the hydroxylase antibodies do not cross-react with native E. coli proteins.  Proteolysis
which yielded specific cleavage products appeared to be a significant problem in this
experiment.  Because the SDS-PAGE gels used for this and similar Western blots had a
4-20% polyacrylamide gradient, estimation of the molecular weight of the cleavage
fragments based on gel mobility was imprecise, making fragment identification
difficult.
Apart from antibiotic resistance, the major difference in the pJLB100, pJLB200,
and pJLB201 vectors is the strength of their inducible promoters.  Both pJLB100 and
pJLB200 have the taclac (tac–lac UV5 in tandem) promoter, which reaches only ~5% of
the expression level of the tac promoter contained in pJLB201.55  Both Western blot and
ELISA studies indicated that the JM105/pJLB201 system yielded somewhat greater
quantities of soluble hydroxylase than the other two systems.  ELISA analysis of both
the soluble and urea-denatured expression proteins showed that the maximum
concentration of MMOH in the soluble JM105/pJLB201 fraction was 0.2 µM, which
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corresponds to 1 mg per 100-mL culture.  Expression from pJLB100 and pJLB200
yielded 35% and 54% as much total MMOH (both soluble and insoluble) and 30% and
59% as much soluble MMOH, respectively, as the less tightly controlled pJLB201
system.  In comparison, a semi-quantitative Western blot indicated that the
concentration of MMOB in the JM105/pJLB201 soluble fraction was ~8 µM, about 40
times greater than the MMOH concentration.57
As shown in Figure 6.8A, the protease-deficient E. coli BL21(DE3) host yielded
recombinant MMOH which was far less proteolyzed than that recovered from JM105
cells (Figure 6.7).  A native PAGE Western blot of the same BL21(DE3) and JM105
expression samples (Figure 6.8B) showed that no significant portion of the recombinant
hydroxylase was present in the native a2b2g2 form, however, which suggests that
factors other than proteolysis are involved in the misfolding or misassembly of the
MMOH subunits.  Variation of several growth conditions, including induction time,
growth medium, and collection time, made little difference in the quality of soluble
hydroxylase expressed by the E. coli host.  Either lowering the temperature or IPTG
concentration slowed the rate of expression, thereby decreasing the total amount of
insoluble protein produced.  These strategies, however, failed to yield a significant
increase in the amount of soluble recombinant MMOH.
Purification of rMMOH from JM105/pJLB201.  Proteins in the JM105/pJLB201
cell-free extract were resolved by anion exchange chromatography.  Western blots of
pooled fractions indicated that although the MMOH subunits were expressed, the
entire a2b2g2 holoenzyme did not elute at a single salt concentration (Figure 6.9).
Instead, the g subunit eluted from the column throughout the entire 50-300 mM NaCl
gradient, while much of the a subunit did not bind strongly to the column and eluted
in the column flowthrough and wash fractions.  That which remained bound eluted in
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a rather non-specific manner over the entire first half of the ionic gradient.  Only the b
subunit displayed an elution profile similar to that of native MMOH, which elutes at
150 mM NaCl under similar chromatographic conditions.  The results of this
experiment were reproduced, and native PAGE Western blot analysis of the fractions
gave further proof that no significant portion of rMMOH was present in the native
form.  Varying the column size and elution profile did not improve recombinant
hydroxylase recovery.
Assays for rMMOH Activity:  Series I Vectors.  None of the assays detected
recombinant hydroxylase activity for the series I expression systems.  Since the
propylene oxide GC assay is quite sensitive, it is unlikely that the lack of activity in
cell-free extracts and whole-cell assays can be attributed to extremely low
concentrations of hydroxylase.  A distinct possibility is that MMOH, which is inhibited
by MMOB at molar ratios greater than 2:1,14 was completely inactivated by the high
levels of MMOB in the extract (> 40:1).  Hydroxylase activity was unaffected by
attempts to remove excess protein B by buffer exchange.  In the nitrobenzene assays,
some of the Q-Sepharose column fractions yielded an initial increase in A440 followed
by a net decrease in the absorbance at this wavelength.  Whereas it is possible that the
nitrophenol product was degraded by other components of the E. coli extracts,
subsequent studies indicated that nitrophenol consumption is negligible.  Although
reported to be a substrate for MMO,58,59 naphthalene was not converted to naphthol
under any of the assay conditions or by the native sMMO proteins.  It is probable that
very little naphthalene dissolved in the aqueous buffer, thus preventing its oxidation
by MMO.  Detergent solubilization of naphthalene59 was unsuccessful.  Finally, none of
the MMO expression colonies grown on LB-Cm-IPTG-indole agar plates converted
indole to indigo.
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Expression of sMMO Proteins in E. coli:  Series II Vectors.  Cultures of E. coli
JM105/pJLB300(E3) and JM105/pJLB400(F3) induced with 0.5 mM IPTG produced
large quantities of proteins with molecular weights corresponding to those of the a, b,
and g subunits of MMOH (Figure 6.10).  In addition, MMOB was expressed in the
JM105/pJLB400(F3) culture.  Expression from pJLB400, which lacks the transcription
terminator region between mmoZ and orfY, yielded little to no MMOR or MMOD,
however.  Therefore, another factor, possibly the unusual mmoC ribosome binding site
(RBS), appears to prevent reductase synthesis in E. coli.
By coexpressing from the pJLBxxx and pRED-K2 plasmids, the requirement for
MMOR in MMOH folding and/or assembly was investigated.  SDS-PAGE analysis of
time course samples for the JM105/pJLB300+pRED-K2 and JM105/pJLB400+pRED-K2
expressions (0.5 mM IPTG) revealed production of large quantities of MMOR and
smaller amounts of the MMOH a and b subunits.  Very small bands for the MMOH g
subunits could be identified in the pJLB400+pRED gel.  No assembled hydroxylase was
apparent in native PAGE Western blots, which suggests that a lack of MMOR is not the
primary difficulty in assembling MMOH in non-native hosts.
As observed for the series I expression vectors, reducing the IPTG concentration
to 0.05 mM significantly decreased inclusion body formation, so this inducer
concentration was used for all subsequent expression experiments.  Western blots
demonstrated that all three hydroxylase subunits were present in both the soluble and
insoluble fractions in both the JM105/pJLB400 and BL21(DE3)/pJLB400 expression
systems.  Proteolysis appeared to be a considerable problem, although the proteolytic
patterns were different in the two E. coli hosts.  Native PAGE Western blots
demonstrated that no significant portion of the recombinant hydroxylase expressed
from pJLB400 was present in the native a2b2g2 form.  SDS-PAGE Western blot analysis
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of the JM105/pJLB300 and BL21(DE3)/pJLB300 samples revealed that all three MMOH
subunits were present in both the soluble and insoluble fractions of each expression
culture (Figure 6.11A).  Very small a2b2g2 bands were present in the
BL21(DE3)/pJLB300 cell extracts, as determined by native PAGE Western blot analysis
(Figure 6.11B).
Purification of rMMOH from BL21(DE3)/pJLB300.  The soluble cell extract
from a 6-L BL21(DE3)/pJLB300(E3) expression culture was resolved on a Sepharose
CL-6B column by FPLC.  The fractions were combined into 13 pools, which were
labeled A-N.  These pools were analyzed by SDS-PAGE and native PAGE gels and
Western blots (Figure 6.12).  The a2b2g2 MMOH holoenzyme eluted from the column in
pools G and H, which corresponded to a NaCl concentration of about 150 mM.  Thus,
the recombinant MMOH behaved much like native MMOH in this purification.  The
amount of assembled MMOH was quite small compared to the relatively large portion
of misfolded or misassembled hydroxylase.  In addition, the amount of gamma subunit
in these fractions seemed rather low.
A second 12-L BL21(DE3)/pJLB300(E3) expression was performed to provide
enough material for purification of the recombinant MMOH.  The cells were expressed,
collected, and resolved on a Sepharose CL-6B column in exactly the same manner
described for the 6-L culture.  Fractions that eluted between 135 and 180 mM NaCl
were pooled without further analysis, concentrated, and resolved on a Superdex 200
column.  The initial 26 5-mL fractions (elution volumes between 130 and 240 mL) were
divided into 9 pools labeled A-I.  The pooled samples were analyzed by SDS-PAGE
and native PAGE gels and Western blots (Figure 6.13).  From the native Western blot, it
was apparent that the assembled MMOH eluted mainly in pools D, E, and F (170-200
mL).  This elution profile matched that of native MMOH quite closely.
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GC Assays for rMMOH Activity:  Series II Vectors.  Steady-state propylene
assays were performed for two blanks (no MMOH), two standards, and the sample of
recombinant MMOH purified from BL21(DE3)/pJLB300.  The blanks and standards
exhibited linear degradation of NADH with respect to time.  For the rMMOH sample,
however, NADH consumption was fast and non-linear, even before MMOR was added
to initiate the propylene epoxidation reaction.  Therefore, the recombinant sample
contained other enzymes capable of oxidizing NADH.  Three extra additions of NADH
were made throughout the 18-min reaction time to ensure that NADH would be
available for putative MMO activity.  Spectra taken during the rMMOH assay showed
the presence of a cytochrome (lmax = 420 nm), rapid consumption of NADH (decrease
in A340), and a general increase in the absorbance between 380 and 700 nm, which was
not readily explicable.  Each propylene assay was extracted with chloroform, and the
organic layers were analyzed by GC (Figure 6.14).  In the positive control reaction
containing 100 nM MMOH, propylene and the MMO oxidation product, propylene
oxide, eluted at 2.13 and 6.37 min, respectively.  The blank (no MMOH) exhibited a
propylene peak (2.27 min) but no propylene oxide peak.  In the recombinant MMOH
assay, peaks for both propylene (2.20 min) and propylene oxide (6.44 min) were
observed.  The small propylene peak in the rMMOH sample was probably due to
longer sample handling rather than degradation since propylene was shown
previously to be stable in E. coli cell extracts.
Mock Purification of rMMOH from BL21(DE3)/pMMB277.  The possibility
that the MMOH observed in the BL21(DE3)/pJLB300 Superdex fractions and
responsible for sMMO activity was not derived from the recombinant expression
culture but from contamination by native MMOH-containing materials was noted.  In
order to investigate this scenario, a mock purification was performed for a 12-L
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BL21(DE3)/pMMB277 expression.  The cells were expressed, collected, and resolved on
DEAE Sepharose CL-6B and Superdex 200 columns exactly as described for the
BL21(DE3)/pJLB300(E3) expression cells.  The initial 26 fractions from the size-
exclusion column were grouped into nine pools labeled A-I and examined by SDS-
PAGE and native PAGE gels and Western blots.  Unfortunately, a small amount of
assembled MMOH was detected in pools D-G, presumably introduced during the
purification.
Identification of Genes Flanking the mmo Operon of M. capsulatus (Bath).
Nine genes encoding proteins with conserved domain sequences were identified in the
18-kb region of M. capsulatus (Bath) DNA downstream of the mmo operon (Figure 6.15).
In the 4.1-kb DNA segment immediately upstream of mmoX, no ORFs with conserved
domains were found.  The putative proteins include a GroEL-like chaperonin, two
proteins of a two-component sensory transduction system, a transcriptional regulator
(s54 activator), the three subunits of formate dehydrogenase, a protein L-isoaspartate
carboxymethyltransferase (PCMT), and an RNA 3’-terminal phosphate cyclase (RTC)
(Table 6.2).  For formate dehydrogenase, PCMT, and RTC, extremely high homology to
other known proteins indicates an unambiguous function.  The larger protein of the
sensory transduction system (129 kDa) exhibits nine conserved domains, including
histidine kinase-related sequences in the C-terminal region (residues 500-1160).  The
smaller component (67 kDa) has three domains related to signal transduction and
regulation of cGMP turnover.
A BLAST search revealed that the M. capsulatus (Bath) chaperonin has high
sequence homology to many prokaryotic GroEL and heat shock proteins.  The most
similar database entry is a GroEL homolog from M. trichosporium OB3b (encoded by
mmoG; NCBI accession number X55394),65 which exhibits 43% identity to the M .
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capsulatus (Bath) protein (Figure 6.16).  Unlike bacterial GroEL,66 there is no
cochaperone (GroES) gene near the M. capsulatus (Bath) mmoG gene.  In fact, there is a
more highly conserved GroEL gene elsewhere in the M. capsulatus (Bath) genome (79%
identity, 5% dissimilarity to E. coli GroEL) with an associated GroES gene.  By
comparison, the M. capsulatus (Bath) GroEL homolog has just 37% identity (27%
dissimilarity) to E. coli GroEL.  Aligning the M. capsulatus (Bath) mmoG product, GroEL
from M. capsulatus (Bath), and GroEL from E. coli K12 (NCBI accession number
NC_000913) demonstrates clearly this difference in sequence homology (Figure 6.17).
DISCUSSION
Corrections to the M. capsulatus (Bath) sMMO gene sequences.  All six
changes in the sMMO gene sequences are consistent with independent
crystallographic, mass spectrometric, and N-terminal sequencing experiments.  The
four alterations in the MMOH protein sequences increase the masses of the a, b, and g
subunits by 16, 126, and 5 Da, respectively.  A study of the M. capsulatus (Bath) sMMO
hydroxylase by ESI-MS revealed precisely these mass differences.67  Based on the ESI-
MS data obtained, the authors correctly deduced the actual sequences of the b and g
subunits, although they could not distinguish between isoleucine and leucine in the
R141T S S C N ›  R141DEFIN correction to the b  subunit.  Because of apparent
misinterpretation of MS/MS sequencing of the a-subunit peptides (data not shown in
the published MS work), however, they misidentified L82 as T82 and Q83 as R83 and
failed to correct V84 to D84.  Although these suggested sequence changes
(Q78FGSTRVALTR) yield the observed peptide mass, they cannot be explained by
simple DNA sequencing errors.  In contrast, the two-base inversion found in mmoX
codon 84 in the present work, which results in a Q78FGSLQVALTR ›
281
Q78FGSLQDALTR sequence change, produces the same 16-Da increase in mass with
only a minor DNA sequence change.  In addition, the “corrected” residues identified67
do not fit the MMOH crystal structure electron density as well as the Q78FGSLQDALTR
sequence (Figure 6.18).  Although MS is a useful tool, it is best used in conjunction with
other complementary techniques in order to minimize errors.
MMOH Expression in Heterologous Hosts.  Prior to this work, it was
established that large quantities of misfolded, insoluble hydroxylase subunit proteins
could be produced in E. coli hosts.41  This ample protein synthesis suggested that the
failure to express active MMOH was a post-translational problem, perhaps a result of
expressing too much protein too quickly or in inappropriate ratios.  The expression
vectors used in these previous experiments were all high-copy-number plasmids with
strong promoters.  Therefore, in an effort to regulate MMOH expression more
stringently, the M. capsulatus (Bath) sMMO genes were cloned into low-copy-number
vectors with more tightly controlled promoters.  In addition, the entire mmo operon
was included, a technique that has been successful for robust expression of similar
monooxygenases in E. coli.43-46
By using this approach of limiting the rate of MMOH expression, the amounts of
insoluble inclusion bodies were indeed dramatically reduced in the series I
JM105/pJLBxxx and BL21(DE3)/pJLBxxx systems (xxx = 100, 200, or 201).  For the first
time, all three hydroxylase subunits were expressed, albeit at low levels, in the soluble
fraction of E. coli hosts (Figure 6.7).  Complex component interactions14 make
measuring sMMO activity of unpurified material inherently difficult.  Thus, the
assembly of recombinant hydroxylase was assessed directly with native Western blots.
For E. coli systems using the first series of expression plasmids, neither folded MMOH
nor sMMO activity was detected.
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A second generation of plasmids (pJLB300 and pJLB400) was prepared in an
effort to address unequal expression levels of the sMMO components.  Small quantities
of hydroxylase with the native a2b2g2 form were observed in protease-deficient
BL21(DE3)/pJLB300 (mmoX–mmoY–mmoZ insert) but not JM105/pJLB300 cell extracts
(Figure 6.11).  This finding represents the first report of E. coli expressing MMOH with
native assembly, although only a very small fraction of the total soluble hydroxylase
was folded correctly.  After a two-step purification procedure, sMMO activity was
detected in the rMMOH sample.  Unfortunately, MMOH was also noted in a control
purification, demonstrating that contamination from native MMOH was unavoidable
on equipment routinely used with relatively enormous quantities of native MMOH.
The partially purified rMMOH may indeed have been active, but the possibility of
native MMOH introduction during purification precludes any claim of recombinant
hydroxylase activity.  These sMMO hydroxylase expression systems, although perhaps
slightly better than many previous attempts, suffer from the same intractable problems
encountered repeatedly in E. coli hosts.  Too little rMMOH is expressed in a soluble
form and of that, only a tiny fraction is assembled properly.  Moreover, purifying or
assaying activity of such minute amounts of material is extremely challenging.
Improving the yield of soluble, folded recombinant hydroxylase is vital for generating
a convenient system for producing site-directed mutants of MMOH.
A recent report states that knocking out a groEL gene (mmoG) located upstream
of mmoX in M. trichosporium OB3b abolished sMMO activity in the mutant.68  Therefore,
it appears that a special chaperonin is essential for proper folding and assembly of the
sMMO proteins.  That M. capsulatus (Bath) also has a groEL-like gene adjacent to its
mmo operon, although on the 3’ side (Figure 6.15), strengthens the notion that this
protein is part of the sMMO system.  Because MMOB, MMOR, and MMOD can be
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expressed in soluble form in E. coli, they are likely unaffected by the absence of the
GroEL homolog in the knockout strain.  On the other hand, without mmoG, as is the
case for nearly every previous heterologous expression system, the hydroxylase does
not assemble properly to any great extent.  In particular, E. coli does not seem to have a
hospitable environment for MMOH folding and assembly.  Despite exhaustive efforts
to develop a recombinant E. coli system for active MMOH expression, this goal has not
yet been achieved.36,41,42,51  Low levels of sMMO activity were measured in several
heterologous hosts, including Pseudomonas putida F1,47,48 Agrobacterium tumefaciens
A114,48 and Rhizobium meliloti 102F34,48 that had been complemented with the M .
trichosporium OB3b mmo operon (mmoX–mmoC).  These species may contain a more
suitable, but not ideal, chaperone for MMOH assembly, which affords small quantities
of active MMOH.  Heterologous expression of M. trichosporium OB3b sMMO in two
methanotrophs, Methylomicrobium album BG8 and Methylocystis parvus OBBP, yielded
low-level production of active sMMO, but difficulty isolating and maintaining these
transconjugate strains was also reported.49  Although the putative mmoG chaperonin
may not be the only factor required for assembling MMOH, its absence likely
contributed to the low or nonexistent activities noted for non-native hosts.
Homologous Expression of MMOH in M. trichosporium OB3b.  The only
published high-yield hydroxylase expression system employs a sMMO-minus mutant
of M. trichosporium OB3b in which the mmoX gene was disrupted by marker-exchange
mutagenesis.51  Complementing this strain with a plasmid carrying the M. trichosporium
OB3b mmo operon and native promoter sequences yielded transconjugates that
expressed sMMO at wild-type levels and activities.50  In this homologous host, innate
factors necessary for correct MMOH folding and assembly were apparently present.
The decreased copper sensitivity of these systems was attributed to a higher
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concentration of active regulator protein, presumably encoded by the expression
plasmid, or a larger sMMO promoter copy number.50  A recent report of the first
MMOH site-directed mutants demonstrated the usefulness of this homologous
expression system.39  Of the four a subunit mutants prepared (C151E, C151Y, T213A,
and T213S), only MMOH(T213S), which was expressed in good yield, could be
purified.  Low-level expression was noted for the remaining three mutants; upon cell
lysis, sMMO activity observed in whole-cell assays (C151E and T213A) was abolished.
The homologous expression systems for recombinant M. trichosporium OB3b
MMOH represent an important step toward probing the roles of individual
hydroxylase residues in sMMO catalysis.  As observed in the initial mutagenesis
experiments, preparing strains for MMOH mutant expression is a time-consuming,
low-efficiency process.39  More importantly, a major limitation is the requirement for
high-level sMMO activity for growth of the host on methane under copper-limited
conditions.  For the three MMOH mutant-expressing strains that grew poorly without
added copper (0.4 µM), instability or inactivity prevented in vitro characterization of
the hydroxylase mutants.39  Although whole-cell assays are of some utility, a more
robust method for obtaining large quantities of purified MMOH mutants will be
necessary for comprehensive mechanistic studies.
Future Directions.  During the last decade, systems for producing recombinant
sMMO hydroxylase have improved dramatically, but high-yield MMOH expression in
a heterologous host remains elusive.  Hosts such as E. coli or Pseudomonas would afford
much simpler construction of mutants as well as eliminate the requirement for sMMO
activity that hampers the current homologous expression systems.  Although many
different heterologous hosts have been investigated already,47-49 broad-host-range
expression plasmids facilitate screening additional species.  The fact that only low-level
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sMMO expression was observed in heterologous methanotroph systems49 suggests that
MMOH may need a special environment for proper folding and assembly.  An
intriguing possibility is the inclusion of a GroEL homolog in the sMMO system.68
Identifying and coexpressing the protein(s) associated with assembling MMOH in the
native hosts may afford heterologous systems for ample production of recombinant
hydroxylase.
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Table 6.1:  Descriptions of Plasmids Used for Constructing sMMO Expression Vectors
Plasmid Characteristics a
pMMB190
pMMB206
pMMB207
pMMB277
pCR2.1
pTrc99A
pKK223-3
pJLB001
pJLB001-C
pJLB100
pJLB200
pJLB201
pJLB201-C
pJLB207
pJLB300
pJLB400
pTXY
pTXYZ
pTX-Z
pTX-C
pRED
IncQ lacIq bla(ApR) Ptaclac lacZa rrnB
pMMB190 Dbla Wcat from pUC8CM
pMMB206 D(Ptaclac, polylinker, and lacZa) W(Ptac and polylinker from pMMB66EH)
pMMB206 DPlac UV5
ApR, KmR, multi-copy insertion vector for PCR products (Invitrogen)
ApR, lacIq/Ptrc-based multi-copy expression plasmid, MCS (Amersham Pharmacia)
ApR, lacIq/Ptac-based multi-copy expression plasmid, MCS (Amersham Pharmacia)
pCR2.1 Wmmo operon PCR product
pJLB001, base inversion in mmoZ “corrected” by SDM
pMMB190 Wmmo operon PCR product
pMMB206 Wmmo operon from pJLB100
pMMB277 Wmmo operon from pJLB100
pMMB277 Wmmo operon from pJLB001-C
pMMB207 Wmmo operon from pJLB001-C; no lacZa
pMMB277 W(mmoX, mmoY, mmoZ from pTXYZ)
pMMB277 Wmmo operon from pTX-C; no T2 transcription termination site
pTrc99A WmmoX–mmoY PCR product
pTXY WmmoZ PCR product
pTrc99A WmmoX–mmoZ PCR product
pTX-Z WorfY–mmoC PCR product
pKK223-3 WmmoC PCR product
a  Abbreviations:  Ap, ampicillin; bla, gene encoding b-lactamase; cat, gene encoding Cm
acetyltransferase; Cm, chloramphenicol; D, deletion; lacZa, sequence coding for the a-peptide of
b-galactosidase; Km, kanamycin; MCS, multiple cloning site (polylinker); W, insertion; PCR,
polymerase chain reaction; Plac UV5, promoter; Ptac, trp-lac hybrid promoter; Ptaclac, Ptac and
Plac UV5 in tandem; R, resistance; SDM, site-directed mutagenesis.
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Table 6.2:  Open Reading Frames Located Near the M. capsulatus (Bath) mmo Operon
Gene Length (nt) Strand a MW (kDa) Putative function/homology
mmoG 1680 + 59.5 chaperonin with homology to GroEL/Hsp60
regB 1836 – 67.4 response regulator (sensory transduction system)
regA 3534 – 128.6 response regulator/hybrid sensory histidine kinase
mmoR 1746 + 63.4 transcriptional regulator, s54-dependent activator
fdoI 636 – 24.3 formate dehydrogenase, g subunit
fdoH 873 – 31.6 formate dehydrogenase, b subunit
fdoG 3201 – 118.7 formate dehydrogenase, a subunit
pcm 678 + 24.5 protein-L-isoaspartate carboxymethyltransferase
rtcA 1086 + 37.8 RNA 3’-terminal phosphate cyclase
a DNA strand containing mmo genes defined as + strand.
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Figure 6.1.  Schematic of the mmo operon of M. capsulatus (Bath).  The six ORFs are
clustered on a 5.5-kb section of DNA under the control of a single s70-dependent
copper-controlled promoter located upstream of mmoX .  The two r-independent
transcription termination sites are labeled T1 and T2.
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Figure 6.2.  Plasmid map for the pJLB001 sequencing plasmid, which was constructed
by ligating the mmo operon PCR product directly into the pCR2.1 vector.
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Figure 6.3.  Series I expression vectors.  Plasmid maps for (A) pJLB100 (taclac promoter,
ApR), (B) pJLB200 (taclac promoter, CmR), (C) pJLB201 (tac promoter, CmR), and (D)
pJLB207 (tac promoter, CmR, no lacZa; two-base inversion in mmoZ introduced by site-
directed mutagenesis).  The disrupted lacZa gene in pJLB100, pJLB200, and pJLB201 is
shaded gray.  Abbreviations:  bla, gene encoding b-lactamase; cat, gene encoding Cm
acetyltransferase; ApR, ampicillin resistance; CmR, chloramphenicol resistance.
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Figure 6.4.  Construction of pJLB300.  The M. capsulatus (Bath) mmoX–mmoY genes were
ligated into pTrc99A to produce pTXY (A).  Insertion of mmoZ into pTXY yielded
pTXYZ (B).  To make pJLB300 (C), the mmoX–mmoY–mmoZ fragment of pTXYZ was
transferred into the MCS of pMMB277.  Abbreviations:  bla, gene encoding b-lactamase;
cat, gene encoding chloramphenicol acetyltransferase.
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Figure 6.5.  Construction of pJLB400.  The M. capsulatus (Bath) mmoX–mmoZ genes were
ligated into pTrc99A to produce pTX-Z (A).  Insertion of the orfY–mmoC fragment into
pTX-Z yielded pTX-C (B).  To make pJLB400 (C), the mmoX–mmoC operon of pTX-C
was transferred into the MCS of pMMB277.  Abbreviations:  bla, gene encoding b-
lactamase; cat, gene encoding chloramphenicol acetyltransferase.
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Figure 6.6.  Denaturing polyacrylamide gel electrophoretic analysis of proteins
produced by the JM105/pJLB100 system.  Lanes 1 and 11, molecular weight standards;
lanes 2 and 12, MMOH from M. capsulatus (Bath); lane 3, control pMMB190 system
without mmo operon insert, 20 min after induction; lanes 4-10, time points collected 20
min to 5 h after induction with 0.4 mM IPTG; lanes 13-19, continued time points
collected 6 to 16 h after induction; lane 20, control pMMB190 system 16 h after
induction.  The protein molecular weight markers (Bio-Rad) used for SDS-PAGE were
(protein, kDa):  phosphorylase B, 97.4; serum albumin, 66.2; ovalbumin, 45.0; carbonic
anhydrase, 31.0; trypsin inhibitor, 21.5; and lysozyme, 14.4.
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Figure 6.7.  Western blot analysis of MMO hydroxylase produced by three series I
expression plasmids.  Lane 1, MMOH from M. capsulatus (Bath); lanes 2-5, soluble
protein isolated from E. coli JM105 cells containing pMMB206, pJLB100, pJLB200, and
pJLB201, respectively.  Lanes 6-9, denatured insoluble protein expressed from plasmids
pMMB206, pJLB100, pJLB200, and pJLB201, respectively.  MMOH expression was
induced with 0.05 mM IPTG, and cells were collected 5 h after induction.
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Figure 6.8.  SDS-PAGE (A) and native PAGE (B) Western blot analyses of MMOH
expressed from pJLB201 with 0.05 mM IPTG in either E. coli BL21(DE3) or JM105 cells.
Lanes 1 and 10, MMOH from M. capsulatus (Bath); lanes 2-4, decreasing amounts of
soluble protein from BL21(DE3)/pJLB201 expression cells, collected 3 h after induction;
lanes 5-7, decreasing amounts of soluble protein isolated from BL21(DE3)/pJLB201
expression cells, collected 8 h after induction; lane 8, soluble protein from
JM105/pJLB201 cells induced for 5 h; lane 9, soluble protein from BL21(DE3)/pJLB201
cells induced for 5 h.
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Figure 6.9.  Western blot analysis of MMO hydroxylase in fractions of soluble protein
expressed by E. coli JM105/pJLB201 resolved on a Q-Sepharose Fast Flow column.
Lanes 1 and 11, MMOH from M. capsulatus (Bath); lanes 2 and 3, unfiltered and filtered
samples, respectively, before column separation; lane 4, flowthrough and wash
fractions; lanes 5-16, fraction pools for NaCl gradient (0.05 to 0.30 M); lane 17, final
column wash (2 M NaCl); lanes 18 and 19, fraction pools for the 115-150 mM NaCl
region where native MMOH elutes under similar conditions; lane 20, insoluble proteins
denatured in urea.
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Figure 6.10.  SDS-PAGE analysis of proteins produced in E. coli JM105/pJLB300 (A) or
JM105/pJLB400 (B) induced with 0.5 mM IPTG over a period of 5 h at 37 °C.  (A) Lane
1, molecular weight standards; lane 2, MMOH from M. capsulatus (Bath); lane 3,
JM105/pMMB277 before induction; lane 4, JM105/pJLB300 before induction; lanes 5-9,
JM105/pJLB300 expression time points between 15 min and 5 h after induction; lane
10, JM105/pMMB277 5 h after induction.  (B) JM105/pJLB400 time-point samples
identical to those in (A) except for the inclusion of MMOB and MMOR in lane 2.
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Figure 6.11.  SDS-PAGE (A) and native PAGE (B) Western blot analyses of MMOH
expressed from pJLB300 with 0.05 mM IPTG in either E. coli JM105 or BL21(DE3) cells.
(A) Lanes 1 and 10, MMOH from M. capsulatus (Bath); lanes 2 and 3, soluble protein
from JM105/pJLB300 cells; lanes 4 and 5, soluble protein from BL21(DE3)/pJLB300
cells; lanes 6-9, denatured insoluble protein expressed from JM105 (lanes 6 and 7) or
BL21(DE3) (lanes 8 and 9).  (B) Lanes 1 and 8, MMOH; lanes 2-5, as in (A); lanes 6 and
7, soluble protein from JM105/pJLB300+pRED-K2 and JM105/pJLB400+pRED-K2
expressions, respectively; lane 9, soluble protein from JM105/pJLB300 (lane 2) spiked
with native MMOH; lane 10, soluble protein from JM105/pJLB300+pRED-K2 (lane 6)
spiked with native MMOH.  The arrow is pointing to the faint band of assembled
MMOH in the BL21(DE3)/pJLB300 samples.  The high molecular weight band in the
standards is a degradation product of the native MMOH protein.
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Figure 6.12.  (A) and (B), SDS-PAGE Western blots of MMOH in fractions of soluble
protein expressed by E. coli BL21(DE3)/pJLB300 resolved on a Sepharose CL-6B
column.  Lanes 1 and 10, MMOH from M. capsulatus (Bath).  (A) Lane 2, soluble cell
extract; lane 3, column flowthrough; lanes 4-9, column fractions containing increasing
NaCl concentrations.  (B) Lanes 2-9, continuation of NaCl gradient in Western blot A.
(C) and (D), native Western blots exactly as corresponding blots A and B, respectively.
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Figure 6.13.  SDS-PAGE gel (A), native PAGE gel (B), SDS-PAGE Western blot (C), and
native PAGE Western blot (D) of MMOH in fractions of soluble protein expressed by E.
coli BL21(DE3)/pJLB300 resolved on a Superdex 200 size-exclusion column.  Lane S,
MMOH from M. capsulatus (Bath); lanes A-I, pools of column fractions.
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Figure 6.14.  Gas chromatography (GC) traces for detection of propylene oxide in
steady-state sMMO propylene assays.  Each assay was performed in a 400-µL volume
containing 100 nM MMOB, 100 nM MMOR, 0.8 mM propylene, 0.16 mM NADH, and
buffer [25 mM MOPS (pH 7.0) and 1 mM DTT].  After incubation at ambient
temperature for 5-20 min, samples were extracted with chloroform, and 5-µL aliquots
of the organic material were analyzed by GC.  Traces are shown for (A) a blank
containing no MMOH, (B) the partially purified rMMOH sample, and (C) a standard
containing 100 nM MMOH.  The sensitivity between 3.0 and 7.4 min was increased for
trials A and B compared to trial C.
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Figure 6.15.  Open reading frames located downstream of the M. capsulatus (Bath) mmo
operon.  Possible functions, based on sequence homology to other proteins, are
indicated for some of the putative gene products.
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Figure 6.16.  Sequence alignment of GroEL homologs from M. capsulatus (Bath)
(Mcapsulatus) and M. trichosporium OB3b (Mtrichosporium).  Identical residues are
depicted in reverse, and conservative substitutions are shown with a gray background.
The proteins are 43% identical and 26% dissimilar.
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Figure 6.17.  Sequence alignment of chaperone proteins from M. capsulatus (Bath) and
E. coli K12.  Residues that are identical in at least two sequences are depicted in reverse.
Conservative substitutions are shown with a gray background.  The two GroEL
proteins are more highly conserved than the M. capsulatus (Bath) GroEL homolog.
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Figure 6.18.  Comparison of a-subunit protein sequences with the M. capsulatus (Bath)
MMO hydroxylase X-ray crystal structure electron density.  Comparison of fits for the
a-subunit sequences (A) S81LQDAL reported in this work and (B) S81TRVAL reported
in ref 67 with the electron density map for the M. capsulatus (Bath) MMOH crystal
structure.
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